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ABSTRACT 
Patients with type 2 diabetes mellitus have a greatly increased risk of coronary 
artery disease and heart failure due to a number of factors such as insulin 
resistance, hyperglycaemia, arterial hypertension, and obesity. To study the 
changes seen in hearts of diabetic patients the aim of this project was to 
generate a clinically relevant diet-induced obese mouse model which could 
mimic these changes.  
Male C57BL/6 mice were fed a 45% high fat diet for 8, 11, and 14 weeks. 
Metabolic and histological changes in animals that responded to the high fat diet 
(diet-induced obese, DIO) were investigated and the most appropriate feeding 
period was determined for further studies.  
DIO animals showed significantly increased body weight gain, elevated fasting 
serum insulin levels and over time animals developed impaired glucose 
tolerance. Histological analysis of DIO hearts after 14 weeks of high fat diet 
showed significantly increased interstitial fibrosis and after all three time points a 
previously unrecognised coronary microvascular remodelling was observed in 
DIO mice. Molecular mechanisms involved in insulin resistance and coronary 
microvascular remodelling were investigated in DIO mice after 11 weeks of high 
fat diet. Animals showed alterations in coronary flow, endothelial dysfunction 
and myocardial gene expression analysis revealed differentially expressed 
genes involved in lipid and carbohydrate metabolism. Validation experiments 
showed that one of these genes, regulator of G-protein signalling (RGS2), had a 
significant reduction at both RNA and protein level in total heart lysates. 
Additionally, RGS2 expression in vascular smooth muscle cells of small vessels 
in the heart was significantly reduced in DIO mice. After a shift from high fat to a 
normal rodent chow a reversal of microvascular remodelling as well as a return 
of RGS2 expression levels back to baseline were observed. 
In conclusion, this diet-induced mouse model shows features of cardiomyopathy 
and coronary microvascular remodelling which is closer to the phenotype seen 
in patients with arterial hypertension or hypertrophic cardiomyopathy compared 
to other mouse or rat models. 
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1.1 Diabetes mellitus  
Diabetes mellitus is a chronic condition comprising a group of metabolic 
diseases, of which raised blood glucose (hyperglycaemia) is the most evident 
sign. The most common types of diabetes are type 1 diabetes mellitus (T1DM) 
and type 2 diabetes mellitus (T2DM). The prevalence of diabetes mellitus has 
increased worldwide over the last 20 years. The World Health Organisation 
estimates that around 366 million people worldwide will be suffering from 
diabetes mellitus by the year 2030 due to population growth, aging, obesity and 
a lack of physical activity [1].  
 
T1DM, also known as insulin-dependent diabetes mellitus, generally develops in 
children and adolescents. It is a disease, in which the pancreas fails to produce 
insulin due to an autoimmune-mediated destruction of pancreatic ß-cells [2]. 
Patients with T1DM rely on exogenous insulin for survival and to prevent the 
development of diabetic coma.  
 
Of the diabetic patients 90-95% suffer from T2DM, also known as non-insulin 
dependent diabetes mellitus [3]. Although T2DM is most common in middle age 
and later life, an increase in cases in adolescents and young adults has been 
reported in recent years due to an increase in child obesity and physical 
inactivity [4]. T2DM is a complex, multifactorial disease caused by environmental 
and genetic factors [5] complicated by microvascular and macrovascular 
disease [6]. Macrovascular complications such as heart attack and stroke 
constitute the primary cause of mortality in T2DM [7]. Risk factors for T2DM 
include genetic predisposition, age, obesity, lack of physical activity and 
cardiovascular disease (CVD) [8]. Phenotypically, it is characterised by impaired 
pancreatic ß-cell function, reduced ß-cell mass, glucagon hypersecretion, 
hyperglycaemia, insulin resistance and is associated with obesity in more than 
80% of cases [9].  
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1.2 Physiological actions of insulin 
Glucose is an important source of energy in the body. In the fasting state, 
glucose is produced endogenously via gluconeogenesis (formation of glucose 
primarily from lactate and amino acids) and glycogenolysis (breakdown of 
glycogen) through the conversion of glucose-6-phosphate to glucose by the 
enzyme glucose-6-phosphatase and released from the liver into the blood 
stream [10, 11]. Glucoregulatory hormones such as glucagon, insulin, amylin, 
cortisol, epinephrine and glucagon-like peptide-1 maintain circulating glucose 
concentrations in a relatively narrow range and both gluconeogenesis and 
glycogenolysis are partly under the control of glucagon, a hormone produced in 
the α-cells of the pancreas [10]. After a meal, glucose enters the circulation via 
intestinal absorption. Under normal physiological conditions, circulating glucose 
levels peak after food intake (postprandial stage), slowly decrease over the next 
several hours and return to fasting levels.  
 
Insulin plays a central role in regulating carbohydrate and fat metabolism. It is 
produced by the pancreatic β-cells in response to increases in blood glucose 
levels and amino acids following the ingestion of a meal [10]. In order to control 
glucose concentrations after a meal, insulin firstly stimulates glucose uptake in 
insulin-sensitive tissues like heart, skeletal muscle, liver and adipose tissue 
through binding to specific receptors present on insulin-sensitive cells. This 
binding initiates a signalling cascade leading to the translocation of insulin-
responsive glucose transporters to the cell membrane and thereby facilitating 
glucose uptake [10, 12]. Skeletal muscle represents the main target tissue with 
about 70% of blood glucose being taken up, whereas the heart is only a minor 
site of whole body glucose disposal [13] (Figure 1.1). Secondly, insulin 
suppresses the endogenous production of glucose by stimulating the synthesis 
of glycogen from glucose and inhibiting glycogenolysis in skeletal muscle and 
liver [10] and also decreases hepatic gluconeogenesis, thus preventing the 
influx of more glucose into the bloodstream (Figure 1.1). The net effect of all of 
these changes is to increase glucose uptake, reduce circulating glucose levels 
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and increase the conversion of glucose into the storage molecules, glycogen 
and fat [14] (Figure 1.1). In the kidneys insulin also stimulates several important 
physiological processes including sodium reabsorption, plasma volume, and 
reabsorption of phosphate and glucose [12, 15]. 
 
In the cardiovascular system insulin has many important roles. Among the most 
important cardiovascular actions of insulin is the modulation of blood flow via 
opposing effects of vasodilation and vasoconstriction of the vasculature. The 
arterial wall is composed of three layers: the intima containing the endothelium, 
the media, and the adventitia [16]. Each of these layers has individual roles like 
the regulation of vascular tone, haemostasis, and/or vascular permeability by 
vascular endothelium or regulation of blood delivery and generation of 
continuous blood flow by the media [17]. Insulin stimulates the increased 
production of the potent vasodilator nitric oxide (NO) from vascular endothelium 
[18] which relaxes the underlying vascular smooth muscle cells (VSMC) [19]. On 
the other hand, insulin can activate the sympathetic nervous system and 
stimulate the secretion of the vasoconstrictor endothelin-1 (ET-1) from vascular 
endothelium [12], which opposes the vasodilator actions of NO [20]. For 
example, in the postprandial state insulin stimulates dilation of terminal arterioles 
which increases the number of perfused capillaries (capillary recruitment) and 
elevates total blood flow by relaxation of larger resistance vessels leading to an 
increase in glucose uptake into insulin-sensitive tissues [21] (Figure 1.1). 
 
In the heart, insulin plays a role in cardiac metabolism by modulating glucose 
uptake, glycolysis, lipid metabolism, protein synthesis, growth and apoptosis 
[22]. Additionally, insulin not only modulates cardiac contractility which results in 
increased myocardial work and oxygen consumption [23] but also augments 
myocardial perfusion by its vasodilatory action [12] (Figure 1.1). The above 
described biological functions of insulin which are related to the regulation of 
cardiovascular homeostasis are regulated by two major branches of the insulin 
signalling transduction pathway. The metabolic actions of insulin are generally 
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mediated via the phosphatidylinositol-3 kinase (PI3K)-dependent pathway 
whereas the non-metabolic, mitogenic and growth promoting effects of insulin 
are mediated via the mitogen-activated protein kinase (MAPK)-dependent 
pathway [14] (Figure 1.2). 
 
 
 
 
Figure 1.1: Physiological actions of insulin. 
 
Insulin secretion promotes glucose uptake in insulin-sensitive tissues like 
skeletal muscle, heart and adipose tissue. Additionally, insulin regulates blood 
flow in the vasculature, heart rate and contractility of the heart but also sodium 
reabsorption and plasma volume in the kidney. At the same time insulin 
attenuates lipolysis in adipose tissue and glucose production in the liver. 
Adapted from [24]. Figure was produced using Servier Medical Art 
(www.servier.com). 
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1.3 Insulin signalling transduction pathway 
1.3.1 General features of insulin signalling 
Insulin elicits its biological actions by binding to the insulin receptor (IR) which is 
composed of an extracellular α-subunit and an intracellular β-subunit [25, 26]. 
As briefly mentioned before, this leads to the activation of  two major branches 
of the insulin signalling transduction pathway, a PI3K-dependent pathway which 
is associated with the metabolic actions of insulin and a MAPK-dependent 
pathway which is associated with the regulation of mitogenesis, growth, and 
differentiation [12] (Figure 1.2).  
 
Binding of insulin to IR results in tyrosine kinase activity of its β-subunit [27] 
leading to autoposphorylation as well as tyrosine phosphorylation of insulin 
receptor substrates 1 and 2 (IRS-1 and IRS-2) in the PI3K-dependent branch 
and the Src homology 2 (SH2)-domain and a collagen-homologous region 
containing (Shc) substrate in the MAPK-dependent branch [28-30].  
Phosphorylated insulin receptor substrates interact with IRS-bound PI3K which 
is composed of a regulatory p85 subunit and a catalytic p110 subunit [31]. SH2-
domains of the regulatory p85 subunit bind to tyrosine-phosphorylated motifs on 
IRS-1 which allosterically activates the p110 subunit to generate the lipid 
product phosphatidylinositol-(3,4,5)-triphosphate (PIP3) from the 
phosphatidylinositol-(4,5)-bisphosphate (PIP2) substrate [32]. PIP3 binds to and 
phosphorylates 3-phosphoinositide-dependent kinase-1 (PDK-1) which in turn 
activates downstream protein serine-threonine kinases like protein kinase B 
(PKB, Akt) and atypical protein kinase C (aPKC) isoforms by phosphorylation 
[12] (Figure 1.2). This PI3K-dependent activation of the protein serine-threonine 
kinases leads to the phosphorylation of various downstream targets like 
endothelial NO synthase (eNOS), glycogen synthase kinase 1 (GSK1) or 
forkhead box O (FOXO) transcription factor that account for the metabolic 
effects of insulin such as glycogen synthesis, glucose uptake, or suppression of 
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gluconeogenesis in insulin-sensitive tissues like skeletal muscle, adipose tissue, 
liver or heart [12] (Figure 1.2).  
 
In addition to the PI3K-dependent branch of insulin signalling pathways, tyrosine 
phosphorylation of IRS-1 or Shc also leads to the activation of the MAPK-
dependent signalling branch leading to the binding of Shc to Grb-2 and thus 
activation of Sos, a guanosine triphosphate (GTP) exchange factor [33, 34] 
which in turn activates the small GTP binding protein Ras. This will initiate a 
kinase phosphorylation cascade which ultimately leads to phosphorylation of 
MAPK and thus to the activation of a variety of transcription factors that regulate 
gene transcription, to protein synthesis as well as cell growth and differentiation 
[12] (Figure 1.2 left). 
 
1.3.2 Insulin signalling in the cardiovascular system 
As described above, insulin plays an important physiological role in vascular 
endothelium by stimulating the production of NO [35]. NO is produced in 
vascular endothelium by activation of eNOS which catalyzes the conversion of 
the substrate L-arginine to NO and L-citrulline [36]. eNOS activity is regulated in 
a calcium-dependent and -independent manner as well as by other post-
translational modifications like acylation and S-nitrosylation [37]. Calcium-
dependent increases in enzymatic activity result through the activation of G 
protein-coupled receptors by vasodilators such as acetylcholine leading to a rise 
in intracellular calcium levels and thus interaction of calcium/calmodulin with the 
calmodulin binding site on eNOS [35]. The calcium-independent increase in 
eNOS activity occurs via the PI3K-dependent branch of the insulin signalling 
transduction pathway leading to the phosphorylation of eNOS by Akt and 
consequently to NO production in endothelial cells [37]. Subsequently, NO 
diffuses into VSMC leading to the activation of guanylate cyclase, an increase in 
cyclic guanosine monophosphate (cGMP) levels and thus to vasorelaxation [38]. 
Besides its role in vasorelaxation, NO also plays an important role in the 
inhibition of platelet adherence, leukocyte adhesion to endothelial cells and 
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smooth muscle cell proliferation and migration as well as the promotion of 
endothelial re-growth [39, 40].  
 
In the heart, insulin is responsible for the regulation of cardiac metabolism by 
modulating glucose uptake, lipid metabolism, protein synthesis, growth, and 
contractility [41, 42]. Physiological growth of the heart is regulated through PI3K-
dependent insulin signalling. Downstream targets of Akt are responsible for the 
promotion of cardiac growth (e.g. activation of mammalian target of rapamycin 
[mTor]) [43] or the regulation of cardiomyocyte size (e.g. suppression of GSK3β 
or FOXO) [12]. Additionally, glucose uptake is modulated by insulin. Glucose is 
the major carbohydrate utilised by the heart and heart muscle glucose transport 
shares many similarities with that in skeletal muscle [44]. At the cellular level, 
insulin-mediated glucose uptake is dependent on the transmembrane glucose 
gradient as well as the recruitment of glucose transporters to the sarcolemma 
and transverse-tubule system via the PI3K-dependent insulin signalling branch 
[13, 45]. The glucose transporter GLUT1 is responsible for basal cardiac 
glucose uptake whereas GLUT4 is the dominant transporter in response to 
insulin stimulation in the adult heart, skeletal muscle and adipose tissue [46]. 
GLUT4 is stored in intracellular storage membrane vesicles from which it is 
recruited to the sarcolemma and t-tubules during insulin stimulation or exercise 
[47, 48] (Figure 1.2). In the fasting state, about 15% of total skeletal GLUT4 is 
located at the sarcolemma but within 30 min of insulin administration, about 80% 
will translocate to the sarcolemma [13]. 
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Figure 1.2: Insulin signalling transduction pathway.  
 
Binding of insulin to the insulin receptors leads to the activation of  two major 
branches of the insulin signalling transduction pathway, a PI3K-dependent 
pathway (right) which is associated with metabolic actions of insulin and a 
MAPK-dependent pathway (left) which is associated with the regulation of 
mitogenesis, growth, and differentiation. Adapted from [12]. Figure was 
produced using Servier Medical Art (www.servier.com). 
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1.4 Insulin resistance  
Insulin resistance occurs when normal levels of insulin are less effective at 
lowering blood glucose concentrations as a maximal occupancy of the insulin 
receptor will not induce maximal stimulation of glucose uptake and utilisation in 
insulin-sensitive tissues [49]. Insulin resistant states are characterised by 
hyperinsulinaemia, hyperglycaemia and inappropriately high circulating levels of 
free fatty acids (FFA) and therefore constitute a major risk factor for the 
development of T2DM [50-52]. Studies have shown that insulin resistance is 
already present 10-20 years before the onset of T2DM [53, 54] and that insulin 
resistance is a consistent finding with T2DM [53, 55-57]. Thus, insulin resistance 
provides the necessary background predisposition to develop T2DM [58]. In 
people who develop T2DM, an increase in insulin secretion by the pancreas 
occurs to compensate for the insulin resistance and lower blood glucose levels 
[3]. A failure of this compensatory mechanism leads to attenuated glucose 
uptake and oxidation in skeletal muscle and adipose tissue and an increase in 
gluconeogenesis and glycogenolysis as well as a reduction in glycogen 
synthesis in the liver [59]. This will result in an increased release of glucose into 
the blood stream (hyperglycaemia) in the fasting state (impaired fasting glucose) 
[59] which is the basis of an impaired glucose tolerance in the postprandial 
stage. Although insulin resistance provides the necessary background 
predisposition, the progressive β-cell failure is responsible for the progression 
from insulin resistance to diabetes and its further worsening [58]. 
 
In adipose tissues, insulin resistance will lead to an increase in lipase activity 
resulting in increased breakdown of triglycerides and a reduction of FFA 
esterification and utilisation [59]. This will result in an increase in the FFA flux 
into the blood stream, an increase in blood triglyceride levels and thus reduce 
insulin secretion by the pancreatic β-cells and insulin sensitivity (Figure 1.3). 
Lipid deposition in liver or muscle will increase and result in ectopic fat 
accumulation which adds significantly to insulin resistance, atherogenic 
dyslipidaemia and hyperinsulinaemia [59] and thus promote the progression of 
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CVD and diseases like non-alcoholic fatty liver disease (NAFLD) [24, 59, 60]. 
Additionally, insulin resistance also promotes excessive adipogenesis leading to 
an increase in adipose tissue mass and obesity. Adipose tissue secretes a 
number of peptide hormones like leptin, adiponectin, tumor necrosis factor α 
(TNFα), interleukin-6 (IL-6) or plasminogen-activator inhibitor 1 (PAI1) that play 
an important role in metabolic and vascular homeostasis [12]. An increase in 
adipose tissue will stimulate the production of pro-inflammatory cytokines like 
TNFα or IL-6 and adipokines like leptin or PAI1 [61]. Also, low levels of the 
circulating anti-inflammatory adipokine adiponectin are associated with insulin 
resistance [62]. This will promote a pro-inflammatory and pro-thrombotic state 
which accelerates the development of endothelial dysfunction either indirectly 
through the metabolic risk factors or by direct action on the arterial wall leading 
to the development of atherosclerosis (Figure 1.3) [63]. 
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Figure 1.3: Role of insulin resistance in the development of metabolic 
abnormalities.  
 
Insulin resistant states are characterised by hyperinsulinaemia and 
hyperglycaemia which affect cardiovascular function. Additionally, an increase in 
adipose tissue mass will lead to increased production of adipokines and excess 
release of free fatty acids (FFA). The excess release of FFA will lead to lipid 
accumulation in muscle, liver and the pancreas which adds to insulin resistance, 
atherogenic dyslipidaemia, and hyperinsulinaemia. The production of 
inflammatory cytokines like TNFα or IL-6 promotes a pro-thrombotic and pro-
inflammatory state which is associated with vascular dysfunction and 
atherogenesis. BP, blood pressure; TNFα, tumor necrosis factor α; IL-6, 
interleukin 6; ↑, increase. Adapted from [63]. Figure was produced using Servier 
Medical Art (www.servier.com). 
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The exposure of organs and the vasculature to high levels of FFA as well as to 
hyperglycaemia will lead to the formation of advanced glycation end products 
(AGEs), increased production of reactive oxygen species (ROS), diacylglycerol 
(DAG), and oxidative stress [64]. This will result in modulation of cellular 
processes in skeletal muscle, the myocardium, and vasculature and thus further 
promote an impairment of the insulin signalling transduction pathway (Figure 
1.4), the development of endothelial dysfunction and atherosclerosis as well as 
structural and cellular damage in metabolic organs [13]. Insulin resistance has 
been proposed to be the result of disturbed insulin receptor binding, receptor 
defects or a disruption of insulin signalling transduction [24]. Impaired insulin 
signalling will lead to reduced GLUT4 translocation to the sarcolemma and thus 
to reduced glucose uptake and metabolism (Figure 1.4). Dysregulation of 
muscle-mediated glucose removal from the circulation is central to insulin 
resistance and T2DM [65]. In skeletal muscle, studies have shown that 
abnormalities already as early as at the level of IRS-1 tyrosine phosphorylation 
as well as IRS-1-associated PI3K activity and activation of PKC contribute to 
insulin resistance [13, 66]. The deficit of IRS-1 tyrosine phosphorylation in 
skeletal muscle might contribute significantly to the prognostically important, 
whole-body insulin resistance seen in diabetic patients [67, 68].  
 
Although the myocardium is not a major site of glucose disposal, recent studies 
have revealed that reduced insulin sensitivity is a risk factor for mortality in 
individuals with ischaemic heart failure [68, 69]. Additionally, studies have shown 
that myocardial glucose utilisation during hyperinsulinaemia is reduced in 
diabetic patients [70, 71], which suggests that the diabetic heart is insulin 
resistant. At the molecular level, Cook et al. have demonstrated an increase in 
IRS1-PI3K activity and diminished levels of GLUT4 at the sarcolemma despite 
normal GLUT4 content in hearts of diabetic patients [72]. The reduced levels of 
GLUT4 at the sarcolemma due to decreased translocation is hypothesised to be 
a major mechanism for impaired glucose uptake in the diabetic heart [72]. 
Results from animal studies on the mechanisms of impaired myocardial GLUT4 
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translocation in insulin-resistant states vary depending on the model used. 
Mazumder et al. observed a complete failure of insulin to increase glucose 
uptake in isolated cardiomyocytes of ob/ob mice [73]. At the molecular level, an 
increase in basal tyrosine phosphorylation of the insulin receptor and a blunted 
response after insulin stimulation and lower levels of Akt phosphorylation were 
observed in these hearts. However, no changes in GLUT4 content were seen 
[73]. On the other hand, Cook et al. confirmed their findings of normal GLUT4 
content but reduced GLUT4 at the sarcolemma in humans also using the ob/ob 
mouse [72]. Although both groups used the same model, Mazumder et al. used 
a working heart model whereas Cook et al. used non-stimulated baseline hearts 
[72, 73]. This might have contributed to the differences observed. Interestingly, 
another study has shown that a short duration of high-fat feeding as a model of 
T2DM causes an early reduction in glucose utilisation on the basis of reduced 
GLUT4 content and translocation [74] and a further study showed reduced total 
GLUT4 expression as well as Akt phosphorylation in the heart of C57BL/6 mice 
after 10 days of high-fat diet feeding [75]. 
 
In the vasculature, NOS is activated in a PI3K-dependent manner. Impaired 
insulin signalling transduction will lead to a reduction of eNOS activity and 
impairment of NO production (Figure 1.4). Additionally, enhanced ROS 
production in the vasculature via activation of nicotinamide-adenine dinucleotide 
phosphate (NADPH) will lead to an inactivation of NO and consequently to a 
reduction of NO bioavailability [35, 76]. All this will not only result in impaired 
insulin-mediated vasodilation but also to an enhanced production of pro-
inflammatory cytokines, increased VSMC proliferation and increased platelet 
aggregation [77] and eventually contribute to endothelial dysfunction and the 
development of atherosclerosis.  
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Figure 1.4: Impaired insulin signalling transduction pathway in 
compensatory hyperinsulinaemia. 
 
Left: PI3K-dependent insulin signalling transduction pathway. Right: Impairment 
of PI3K-dependent insulin signalling pathway under pathological conditions 
contributes to insulin resistance and endothelial dysfunction. AGE, advanced 
glycated end products; DAG, diacylglycerol; ROS, reactive oxygen species; 
PKCs, protein kinase C isoforms; ↓, reduced. Adapted from [12]. Figure was 
produced using Servier Medical Art (www.servier.com). 
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1.5 The metabolic syndrome 
Insulin resistance along with visceral adiposity, atherogenic dyslipidaemia, 
elevated blood pressure and a chronic subclinical inflammatory state were first 
clustered together into a group of metabolic abnormalities and disorders in 1988 
and termed “Syndrome X” by Reaven et al. [50]. Later this cluster was termed 
“insulin-resistance syndrome” and now it is generally known as metabolic 
syndrome [78].  
 
The metabolic syndrome is highly prevalent and is expected to rise due to the 
increase of obesity in the population. About 20-25% of healthy subjects and 80% 
of diabetic patients have the metabolic syndrome [79, 80] and patients with the 
metabolic syndrome have a 3-4 fold increased risk of developing T2DM [81, 82]. 
The metabolic syndrome allows identification of patients who are at high risk of 
developing T2DM, CVD and cardiovascular death [78] and helps to better 
understand the pathophysiological mechanisms that link the individual 
components with each other and with the increased risk of CVD [83].  
 
Although there are variations in the definitions and criteria of the metabolic 
syndrome, the central features are insulin resistance, visceral obesity, 
atherogenic dyslipidaemia and endothelial dysfunction [83]. In an attempt to 
develop standardised criteria for the diagnosis, the current clinical approach 
focuses on waist circumference/obesity, dyslipidaemia and hypertension [83, 
84]. A summary of the criteria of the metabolic syndrome defined by the 
International Diabetes Federation (IDF) can be found in Table 1.1 [84]. 
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Table 1.1: Definition of the metabolic syndrome by the IDF 
 
Obesity* Waist circumference: ≥94 cm (male), 
≥80 cm (female) 
Hyperglycaemia Fasting glucose ≥5.6 mmol/L and/or medication 
Dyslipidaemia Triglyceride levels ≥1.7 mmol/L or specific treatment 
Dyslipidaemia (second, 
separate criteria) 
HDL cholesterol: <1.03 mmol/L (male), 
<1.2 mmol/L female or 
specific treatment 
Hypertension >130/85 mmHg and/or medication 
 
* ≥3 of the above criteria necessary. Adapted from [84]. 
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1.6 Diabetic complications  
The sustained hyperglycaemia in T2DM causes damage to blood vessels and 
the organs they supply leading to the development of diabetes specific 
microvascular complications in the retina, renal glomerulus and peripheral nerve 
[85, 86]. Hyperglycaemia-induced pathophysiological changes include initial 
abnormalities in blood flow and increased vascular permeability but also 
microvascular cell loss, progressive capillary occlusion, or decreased production 
of trophic factors for endothelial and neuronal cells [86]. On the molecular level, 
increased AGE formation, the activation of PKC isoforms, as well as an increase 
in the polyol and hexosamine pathway flux have been implicated in these 
microvascular changes [86-89]. Eventually, these changes lead to oedema, 
ischaemia and hypoxia-induced neovascularisation in the retina, proteinuria, 
mesangial matrix expansion and glomerulosclerosis in the kidney, and multifocal 
axonal degeneration in peripheral nerves [86]. Thus, diabetes is a leading cause 
of blindness, end-stage renal disease and a variety of debilitating neuropathies, 
which all represent the main cause of morbidity in T2DM [86, 90]. 
 
Moreover, individuals with T2DM are also at a significantly higher risk of 
macrovascular diseases such as peripheral arterial disease, ischaemic stroke or 
coronary artery disease (CAD) [85] and have a greater likelyhood of having 
hypertension, dyslipidaemia, and obesity [91]. The increased prevalence of CAD 
in diabetes may be accounted for by the presence of diabetes-associated risk 
factors like obesity, hypertension and dyslipidaemia although a substantial 
proportion remains unexplained [13, 92]. Diabetic patients suffer from a 2-4 fold 
increased risk of incident coronary heart disease or fatal CVD compared with 
patients without diabetes with heart attacks and stroke accounting for about 80% 
of all deaths [90].  
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1.6.1 Microvascular dysfunction 
Dysregulation of vascular function and structure is common in patients with 
diabetes [93]. With complications such as stroke or acute coronary syndromes 
much attention has focused on diabetic macrovascular disease [94]. However, 
microvascular disease significantly contributes to morbidity associated with 
T2DM [90]. Microvascular dysfunction (in vessels smaller than 150 µm in 
diameter) may affect both peripheral vascular resistance and insulin-mediated 
glucose disposal, thereby contributing to hypertension and insulin resistance, 
respectively [95]. Additionally, disturbances in microvascular function may arise 
before overt hyperglycaemia and pathologic changes in large vessels are 
observed [96, 97]. It has been shown that the most consistent structural change 
in the microvasculature is thickening/remodelling of the vascular wall in 
arterioles in the glomeruli, retina, skin, muscle, and myocardium, resulting in the 
classic diabetic microangiopathy [94]. There are two types of vascular 
remodelling: eutrophic and hypertrophic remodelling. Eutrophic remodelling is 
the rearrangement of otherwise normal material around a narrow lumen and 
occurs in essential hypertension [98]. In contrast, hypertrophic remodelling is 
characterised by vascular smooth muscle hypertrophy or hyperplasia and occurs 
in renovascular hypertension [99]. Clinical and experimental studies of 
hypertension and diabetes have reported alterations in subcutaneous vessel 
morphology with an increase in the media-to-lumen diameter ratio in small 
arteries attributed to remodelling and hypertrophy of the vessel wall [93, 100]. 
Rizzoni et al. have shown that the effects of diabetes and hypertension on 
subcutaneous small artery morphology are quantitatively similar (despite the 
presence of different hemodynamic load), but qualitatively different, i.e. 
hypertrophic remodelling in diabetes vs. eutrophic remodelling in hypertension 
[100]. Moreover, they have shown that the addition of hypertension in diabetic 
patients has little additive effect on small artery remodelling [100]. Although the 
mechanisms of vascular remodelling are not fully understood, it has been 
suggested that neurohumoral factors, insulin and insulin-like growth factor 1 as 
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well as increased collagen deposition might play a role in vascular structural 
alterations, smooth muscle cell hypertrophy and cell growth [101]. 
 
In the heart, coronary microvascular dysfunction has been described in different 
diseases such as hypertrophic cardiomyopathy (HCM) [102] and arterial 
hypertension [103-105]. Similar to other vascular beds, coronary microvascular 
dysfunction is due to remodelling of intramural coronary arterioles (Figure 1.6). 
Pathogenic mechanisms of coronary microvascular dysfunction can be divided 
into structural, functional and extravascular [92]. Structural alterations are for 
example luminal obstruction, vascular remodelling or perivascular fibrosis 
whereas functional alterations include endothelial, smooth muscle, and 
autonomic dysfunction. A detailed description of the pathogenic mechanisms 
and their causes is summarised in Table 1.2.  
 
 
 
Figure 1.5: Coronary arteriolar remodelling in hypertrophic 
cardiomyopathy (HCM) and hypertension. 
 
Histological sections of transmural vessels of healthy subjects (A), and patients 
with HCM (B) or hypertension (C). Trichrome staining showing fibrosis in blue. 
Myocardium is shown in shades of red. Pathogenic alterations of coronary 
microvascular remodelling like thickening of the vessel wall (indicated by white 
bars), perivascular fibrosis (blue), or decreased luminal size are observed in 
HCM (B) and hypertension (C). Images provided by Prof P.G. Camici. 
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Table 1.2: Pathogenic mechanisms of coronary microvascular dysfunction 
 
Alterations Causes 
 
Structural  
Luminal obstruction Microembolisation in acute coronary 
syndromes or after recanalisation 
Vascular-wall infiltration Infiltrative heart disease (e.g. Anderson-
Fabry cardiomyopathy) 
Vascular remodelling HCM, arterial hypertension 
Vascular rarefaction Aortic stenosis, arterial hypertension 
Perivascular fibrosis Aortic stenosis, arterial hypertension 
 
Functional 
 
Endothelial dysfunction Smoking, hyperlipidaemia, diabetes 
Dysfunction of smooth muscle cells HCM, arterial hypertension 
Autonomic dysfunction Coronary recanalisation 
 
Extravascular 
 
Extramural compression Aortic stenosis, HCM, arterial 
hypertension 
Reduction in diastolic perfusion 
time 
 
Aortic stenosis 
 
HCM: hypertrophic cardiomyopathy. Adapted from [92]. 
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Coronary microvascular dysfunction may also cause an impairment of coronary 
flow and coronary flow reserve thus contributing to myocardial ischaemia and 
fibrosis. Coronary flow reserve is a measurement of the ability of the coronary 
microvasculature to respond to a stimulus and is expressed as a ratio of peak 
(i.e. maximal hyperaemia) to baseline coronary flow [92]. Impaired coronary flow 
has not only been shown in patients with hypertension or HCM but also in 
diabetic patients [106]. Studies have shown that hyperaemic myocardial flow in 
patients with T2DM and macrovascular disease was decreased by 28% and 
even further reduced in diabetic patients with evidence of coronary 
microangiopathy [107, 108].  
 
In the absence of CAD or myocardial disease, coronary microvascular 
dysfunction can be the functional counterpart of traditional coronary risk factors 
like smoking, hypertension, hyperlipidaemia, diabetes, or insulin-resistant states 
[109-111]. At this stage structural and functional alterations are, at least in part, 
reversible by lifestyle intervention or medical treatment [92]. In the presence of 
myocardial disease coronary microvascular dysfunction is sustained in most 
instances by adverse remodelling of intramural coronary arterioles [92]. This 
type of coronary microvascular dysfunction is found in primary (genetic) 
cardiomyopathies like HCM [102, 112, 113]  or dilated cardiomyopathy [114-116] 
or secondary cardiomyopathies such as those due to arterial hypertension [117] 
or aortic stenosis [118, 119]. It may be severe enough to cause myocardial 
ischaemia and it is unclear whether medical treatment may reverse some cases 
[92]. 
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1.6.2 Diabetic cardiomyopathy 
Under normal physiological conditions, the heart utilises fatty acids (FA), 
carbohydrates, amino acids, ketones, and lactate. FFA and carbohydrates 
(especially glucose) are the major source from which the heart derives most of 
its energy [46]. In normal hearts, 60% to 90% of the energy is derived from FFA 
oxidation [120]. Depending on the physiological and pathophysiological 
conditions, the heart can rapidly switch substrate selection. The increase in 
circulating levels of insulin, glucose, and FFA in T2DM have been shown to 
affect myocardial energy metabolism leading to functional, biochemical and 
morphological abnormalities and increased vulnerability in the presence of 
stressors such as ischaemia and cardiac hypertrophy [121, 122]. Using 
euglycaemic clamps and positron emission tomography Iozzo et al. have shown 
that the hearts of diabetic patients demonstrate reduced insulin-stimulated 
glucose uptake indicating that the diabetic heart is insulin resistant [70]. 
Myocardial insulin resistance leads to an increase in FFA uptake and the heart 
consequently adapts to using FA exclusively for adenosine triphosphate (ATP) 
generation [13]. High FFA uptake and metabolism augment the accumulation of 
FA intermediates and triglycerides [123] and increase oxygen demand and 
generation of ROS leading to cardiac damage [46]. Patients with diabetes also 
exhibit changes in cardiac structure and cardiomyocyte ultrastructure. This can 
be attributed to the diabetic milieu of hyperglycaemia, hyperinsulinaemia, 
increased cellular FFA uptake or hyperglycaemia-induced oxidative stress [13, 
124]. At the macroscopic level left ventricular hypertrophy and increased heart 
mass with mildly reduced left ventricular systolic performance has been 
observed [125]. At the microscopic level morphological abnormalities like 
myocyte hypertrophy, perivascular fibrosis, increased quantities of matrix 
collagen, cellular triglyceride and cell membrane lipid have been demonstrated 
[126, 127]. Figure 1.5 summarises mechanisms that may lead to the 
development of diabetic cardiomyopathy.  
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Figure 1.6: Summary of mechanisms that may lead to the development of diabetic cardiomyopathy. 
 
EC: excitation-contraction; ROS: reactive oxygen species; FA: fatty acid; PKC: protein kinase C; AGE: advanced 
glycated end products; RAAS: renin-angiotensin-aldosterone system; Adapted from [128].
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1.7 Animal models of insulin resistance and diabetic 
cardiomyopathy 
It is important to understand the pathogenesis and underlying molecular 
mechanisms of insulin resistance and diabetic cardiomyopathy. However, 
research in humans is limited due to ethical considerations [8] and therefore 
appropriate models with a phenotype and pathogenesis resembling the human 
disease are crucial. Animal models are useful and advantageous in biomedical 
studies because they offer the promise of new insight into human disease. Both 
rodent and non-rodent (e.g. pig, dog, non-human primates) models have been 
developed, but most models are still based on rodents due to the 
expensiveness, practical difficulties, extreme care and ethical considerations of 
non-rodent models [8]. Mouse models have been a preferred model due to their 
easy maintenance, short generation time, and the ease of generating transgenic 
and knock-out models [128], but recently advances in generating rat knock-out 
models offer the possibility to complement existing transgenic mouse models 
[129]. Generally, rodent models have many traits in common with human 
diabetic cardiomyopathy and thus, several models of diabetes and insulin 
resistance have been extensively studied [130]. A selection of rodent models of 
diabetes is shown in Table 1.3.  
 
A good model of diabetic cardiomyopathy should firstly show evidence of left 
ventricular (LV) dysfunction such as decreased ejection fraction and/or evidence 
of diastolic dysfunction [128]. Secondly, it should show evidence of myocardial 
injury such as interstitial or replacement fibrosis, and thirdly, LV hypertrophy. 
Several studies on rodent models of obesity, insulin resistance and T2DM have 
demonstrated LV hypertrophy, diastolic dysfunction, increased cardiac FFA 
uptake and utilisation, decreased cardiac efficiency, impaired mitochondrial 
energetics, increased myocardial lipid storage, and impaired Ca2+ handling [46, 
128] which mirror similar observations that have been made in humans.  
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There are three main ways of creating animal models of insulin resistance, 
diabetic cardiomyopathy and either type 1- or type 2-like diabetes: (1) 
spontaneously diabetic, (2) genetically engineered and (3) artificially induced 
(Table 1.3). Models for both T1DM and T2DM have been used interchangeably 
due to a significant overlap in their cardiac phenotype characterised by 
increased FFA utilisation, decreased glucose utilisation and impaired calcium 
handling [128]. But despite this overlap, the overall physiology as well as the 
pathophysiological mechanisms of T1DM and T2DM are different and therefore 
the relative models should be considered separately.  
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Table 1.3: Selected Rodent Models of Diabetes 
 Phenotypic alterations 
Spontaneously Diabetic Rodents  
 
Otsuka Long-Evans Tokushima Fatty 
Rats (OLETF) 
 
Late onset hyperglycaemia (18 weeks of age), mild obesity, clinical onset of 
diabetes (mostly in males), hypertriglyceridaemia 
Goto-Kakizaki Rats (GK) Mild type 2 diabetes, hyperglycaemia, hyperinsulinaemia, insulin resistance 
Zucker Diabetic Fatty Rats (ZDF) Obesity, hyperinsulinaemia, hyperglycaemia, hyperleptinaemia, increased serum 
fatty acids and triglyceride levels 
ob/ob mice Transient hyperglycaemia, glucose intolerance, hyperinsulinaemia 
db/db mice Hyperglycaemia, impaired insulin response to glucose 
  
 
Genetically Engineered Diabetic Mice 
 
 
GLUT2-/- 
 
Moderate insulin resistance, glucose intolerance, decreased adipose mass 
GLUT4-/- Insulin resistance, diabetic hypertension, diabetic ketoacidosis, early postnatal death 
IR-/- Growth retardation, mild insulin resistance, beta cell hyperplasia, hyperinsulinaemia 
IRS-/- Severe insulin resistance, beta cell hyperplasia, diabetes in 50% of adult mice 
  
 
Artificially Induced Diabetic Rodents 
 
 
Neonatal STZ-induced Diabetes 
 
Hyperglycaemia, impairment of glucose-stimulated insulin release 
STZ-Spontaneously Hypertensive Rat  Insulin resistance, hypertension 
Fat-fed/STZ-induced Diabetic Rodents Hyperglycaemia, hyperinsulinaemia, increased free fatty acid and triglyceride levels 
High fat diet-fed Diabetic Rodents Hyperinsulinaemia, insulin resistance, glucose intolerance 
 
GLUT: glucose transporter, IR: insulin receptor; IRS: insulin receptor substrate; STZ: Streptozotocin.  
Adapted from [130].
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1.7.1 Spontaneously diabetic models 
The advantage of using spontaneously diabetic mice is that the development of 
T2DM is natural involving genetic factors and that animals develop characteristic 
features resembling human T2DM. However, although their homogeneous 
background keeps variability to a minimum and reduces sample size it also 
implies that the development of T2DM is highly genetically determined unlike the 
heterogeneity seen in humans. Furthermore, inbred animals are generally more 
expensive and their availability is limited.  
 
1.7.1.1 Leptin and the leptin receptor 
Examples of spontaneously diabetic mouse models are the obese, leptin-
deficient ob/ob mouse and the diabetic, leptin receptor-deficient db/db mouse. 
Leptin is a key regulator of appetite, body weight, and energy balance in the 
central nervous system [12]. It is encoded by the obesity (ob) gene and 
expressed predominantly in adipose tissue and, at lower levels, in gastric 
epithelium and placenta [131]. Leptin interacts with the leptin receptor (Ob-R), 
which has six isoforms (Ob-Ra – Ob-Rf) [132] (Figure 1.7). Ob-Rb is the only 
isoform with a long cytoplasmic region containing all motifs required for 
activation of the major signalling pathway used by leptin, the Janus kinase/ 
signal transducer and activator of transcription (JAK/STAT) signal transduction 
pathway [131, 132]. Besides the JAK/STAT signalling pathway, it has been 
shown that other signalling pathways like MAPK and 5’-AMP-activated protein 
kinase (AMPK) are also involved in leptin signalling [132] and that leptin 
interacts with insulin signalling [133]. Similarly to insulin, leptin acts on the 
vasculature by inducing endothelium-dependent vasodilation [134, 135] via a 
PI3K-Akt-eNOS pathway [136]. 
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Figure 1.7: Leptin receptor (Ob-R) isoforms.  
Ob-R isoforms share identical extracellular, ligand-binding domains but differ at 
the C terminus. Five isoforms have transmembrane domains but Ob-Rb is the 
only isoform that encodes all protein motifs for capable for activating the 
JAK/STAT signal transduction pathway. Ob-Re is truncated and secreted. The 
blue lines show the WSXWS motif, which indicates members of the cytokine 
receptor family and the red lines indicate JAK/STAT box motifs. Adapted from 
[131]. 
 
 
1.7.1.2 The leptin-deficient ob/ob mouse 
Of the various mouse models available the leptin-deficient ob/ob mouse is one 
of the best characterised. Obese ob/ob mice are homozygous for the obese 
spontaneous mutation Lepob which originally occurred in an outbred multiple 
recessive stock prior to 1950 [137]. Animals with this mutation exhibit a 
significantly altered feeding behaviour, metabolism, and endocrine function due 
to the leptin-deficiency leading to reduced energy expenditure and increased 
food intake (hyperphagia) with body weights reaching up to three times the 
weight of normal animals. Additionally, ob/ob mice show a diabetes-like 
syndrome of hyperglycaemia, mild impaired glucose tolerance, and severe 
hyperinsulinaemia [138]. It is important to note that depending on the strain, 
ob/ob mice show phenotypic differences like transient hyperglycaemia 
(subsiding at around 14 to 16 weeks of age) on the C57BL/6 background and 
severe diabetes with regression of pancreatic islets and early death on the 
Extracellular
Intracellular
Ob-Ra Ob-Rb Ob-Rc Ob-Rd Ob-Re Ob-Rf
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C57BL/KS background [8]. At the myocardial level, dysfunction is associated 
with myocardial lipid accumulation, altered substrate utilisation (increased FFA 
oxidation, reduced glucose oxidation and increased myocardial oxygen 
consumption) and impaired myocardial insulin signalling [73]. Although the ob/ob 
mouse has many features of human T2DM, it has to be noted that severe 
obesity due to leptin-deficiency is extremely rare in humans. Congenital leptin 
deficiency with loss-of-function mutations in the leptin gene has been identified 
in only twelve subjects worldwide [139-141]. Furthermore, it has been shown 
that upon injection of leptin the phenotype of increased body weight, 
hyperphagia, reduced energy expenditure and insulin resistance is reversible 
[142, 143].  
 
1.7.1.3 The leptin receptor-deficient db/db mouse 
Mice homozygous for the spontaneous mutation in the leptin receptor (Leprdb) 
were first identified in 1966 at the Jackson Laboratory in the C57BL/KsJ strain. 
The diabetic (db) gene in these animals encodes for a point mutation of the 
leptin receptor, leading to abnormal splicing and defective signalling of leptin 
[144]. The lack in leptin signalling results in hyperphagia, excessive thirst and 
excessive urine production as well as obesity which is identifiable after three to 
four weeks of age [145]. Depending on the background strain (C57BL/KsJ or 
C57BL/6) mice have differing levels of hyperglycaemia (less in C57BL/6) despite 
similar degrees of hyperphagia and weight gain which might be explained by the 
pancreatic islet cell hypertrophy in the C57BL/6 background [146]. With 
increasing age, progressive impairment of insulin response to glucose is 
observable in db/db mice [130]. Mice also exhibit ketosis and progressive body 
weight loss and do not survive longer than 8 to 10 months. In addition to the 
metabolic phenotype, db/db mice show abnormal cardiac muscle morphology, 
decreased cardiac muscle contractility and increased left ventricular diastolic 
pressure [124]. Unlike in the ob/ob mice, exogenous leptin administration in 
db/db mice fails to reverse the metabolic alterations due to the defect in the 
leptin receptor [8]. Similarly to leptin-deficient subjects with mutations in the 
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leptin gene, only one mutation in the leptin-receptor gene has been reported in 
three severely obese adults [147]. 
 
1.7.2 Genetically engineered diabetic mice 
Genetic manipulations targeting members of the insulin signalling pathway (IR, 
IRS-1, PI3K, and GLUT4) have been developed to study the effect of single 
gene mutations on the development of insulin resistance and T2DM in vivo. 
These models are valuable in dissecting this complex disease on the genetic 
level [8] as they exhibit various phenotypic characteristics of T2DM. It is 
important to mention however, that the production of genetically modified 
animals requires specific knowledge for the generation and maintenance and 
thus make these models not suitable for high-throughput studies like drug 
testing. 
 
1.7.2.1 Cardiac-specific insulin receptor knockout (CIRKO) 
One way of ablating insulin signalling in the heart is the generation of mice with 
a cardiomyocyte-specific knockout of the insulin receptor via a cardiac-specific 
alpha-myosin heavy chain promoter. Compared to controls, hearts of these 
animals are up to 30% smaller in size due to reduced cardiomyocyte size [148]. 
Like the ob/ob and db/db mice, cardiac dysfunction in CIRKO mice is associated 
with impaired insulin signalling, altered substrate utilisation (increased FA 
oxidation, reduced glucose oxidation and increased myocardial oxygen 
consumption) and mitochondrial dysfunction [149]. Additionally, CIRKO hearts 
are more susceptible to ischaemic injury and increased premature mortality 
following coronary artery ligation was observed [148]. This is in line with human 
findings which have shown that adaptations of the diabetic heart to ischaemia 
are impaired and that sudden death after myocardial infarction is more likely in 
diabetic subjects [150, 151]. 
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1.7.2.2 IRS-1 knockout 
The IRS family is composed of four members (IRS-1 to 4) with distinctive 
patterns of tissue expression [152]. To clarify the physiological role of IRS-1 in 
vivo and its effects on peripheral insulin action, an IRS-1 knockout mouse model 
was constructed in 1994 [153]. Animals homozygous for this targeted disruption 
of the IRS-1 gene have lower birth weights than wild-type litter mates and 
maintain lower body weight proportional to their smaller size [154]. Additionally, 
these animals are insulin resistant and show abnormal glucose tolerance 
whereas no histological abnormalities in the heart, liver, spleen and kidney were 
found [153]. Together with knockout studies of other members of the IRS family, 
it appears that IRS-1 is the main mediator of insulin signalling in skeletal muscle, 
adipose tissue, and β-cell secretory function [152]. 
 
1.7.2.3 Cardiomyocyte-specific GLUT4 knockout 
Mice with a cardiomyocyte-specific knockout of the glucose transporter GLUT4 
via a cre-loxP system are normotensive, non-obese, and don’t show any 
differences in their metabolic profile compared to wild-type mice [155]. GLUT4 
deficiency in the heart leads to mild cardiac hypertrophy and under basal 
conditions GLUT4 deficient hearts are capable of maintaining normal function 
[155]. However, cardiac dysfunction occurs when the hearts are stressed with 
decreased contractile recovery following ischaemia/reperfusion [155, 156] and 
alterations in excitation-contraction coupling in isolated cardiomyocytes [157]. 
 
A detailed phenotypic description of mouse models of cardiomyopathy is shown 
in Table 1.4. 
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Table 1.4: Mouse models of cardiomyopathy 
 
Cardiomyopathy Mouse Model Type of Diabetes Relevant Phenotype 
 
ob/ob 
 
Type 2 
 
LVH, cardiac dysfunction, lipotoxicity, abnormal substrate metabolism, decreased 
cardiac efficiency, mitochondrial dysfunction, impaired insulin signalling, altered 
gene expression, oxidative stress 
 
db/db 
 
Type 2 
 
Cardiac dysfunction, lipotoxicity, abnormal substrate metabolism, decreased 
cardiac efficiency, mitochondrial dysfunction, impaired insulin signalling, altered 
gene expression, oxidative stress 
 
High-fat feeding 
 
Type 2 
 
Cardiac dysfunction, abnormal metabolism, impaired insulin signalling, decreased 
cardiac efficiency 
 
CIRKO mouse (cardiomyocyte 
insulin receptor KO) 
 
Type 2 
 
Cardiac dysfunction, altered substrate metabolism, increased injury and dysfunction 
following LVH 
 
IRS-1 KO mouse 
 
Type 2 
 
LVH, cardiac dysfunction and increased fibrosis following pressure overload 
hypertrophy 
 
Cardiomyocyte GLUT4 KO 
 
not 
defined 
 
Cardiac hypertrophy, decreased cardiac glucose utilisation, decreased recovery 
from ischaemia 
 
IRS-1: Insulin receptor substrate-1; GLUT4: Glucose transporter 4; KO: knockout; LVH: left ventricular hypertrophy. 
Adapted from [124]. 
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1.7.3 Artificially induced diabetic rodents 
1.7.3.1 Chemical manipulation 
Chemical manipulation with streptozotocin for example will result in pancreatic 
β-cells toxicity causing DNA damage and ultimately leads to insulin deficiency 
[158]. Animals will develop hyperglycaemia within 7 to 14 days after the first 
injection [128] and also show increased serum FFA, cholesterol and triglyceride 
levels. However, animals treated with streptozotocin present progressively 
decreasing insulin levels with the duration of diabetes [159] and are generally 
used as models for T1DM.  
 
1.7.3.2 Surgical manipulation 
Surgical manipulation involves either a complete or partial pancreatectomy and 
is used for the induction of T1DM and T2DM. It has been reported mostly in 
dogs, pigs, rabbits but also been performed on rats and mice. A pancreatectomy 
of 70-90% does not cause a severe form of diabetes and is characterised by 
moderate hyperglycaemia [8]. Due to the reduced islet β-cell mass it resembles 
human T2DM; however removal of the pancreas also leads to dissection of 
glucagon-secreting α-cells which may lead to problems in counter regulatory 
response to hypoglycaemia [8].  
 
1.7.3.3 Dietary manipulation 
Many animal models of insulin resistance and diabetic cardiomyopathy have 
little clinical relevance for human diabetes as they are based on monogenic 
disorders or chemical destruction of pancreatic β-cells [160]. With changes in 
dietary habits in Western countries, diets rich in carbohydrates such as sucrose 
and fructose, as well as saturated fats [161-163] have been associated with 
many diet-induced complications including metabolic syndrome, CVD, and 
NAFLD [163, 164]. Mouse Western-style diets that mimic these risk factors in 
human Western populations have been used for many decades [163]. In 1988 
Surwit et al. introduced the high-fat diet-fed C57BL/6 mouse model as a more 
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relevant model of early human diabetes [165]. High fat diets typically have 40-
60% of their energy derived from fat with 60% diets often used for obesity 
studies, whereas diets with 45% of their calories derived from fat are considered 
to represent more the Western-style diet [161]. In general, animals fed a high-fat 
diet ad libitum gradually increase body weight and are characterised by 
hyperinsulinaemia, insulin resistance and glucose intolerance [165]. It is 
important to note that a number of different fat sources are available. Depending 
on the fat source (lard, soybean oil, milk fat, cocoa butter) and therefore also the 
fatty acid profile (saturated and unsaturated fatty acids) the metabolic outcome 
will be different. Animals fed a lard-derived high fat diet develop hyperglycaemia, 
hyperinsulinaemia and over time hypertension whereas a cocoa-derived high fat 
diet does not affect plasma glucose and insulin levels [166]. 
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1.8 Aim 
Insulin resistance plays an important role in the development of micro- and 
macrovascular complications in diabetic patients. Many rodent models have 
been extensively used to study the molecular mechanisms involved in the 
development and the effects of insulin resistance but drug-induced or genetically 
modified models do not fully mimic the pathophysiological changes seen in 
humans. Previous work in our group has shown decreased levels of GLUT4 at 
the sarcolemma in the heart of diabetic patients but not in patients with left 
ventricular dysfunction [72]. The results seen in T2DM were also confirmed in 
hearts of the leptin-deficient ob/ob mouse, one of the best studied mouse 
models of insulin resistance and diabetic cardiomyopathy [72]. Although these 
results mimic our findings in humans, the ob/ob mouse model is an extreme 
model with only a few cases occurring in the human population. Due to its 
extreme phenotype with leptin deficiency and overt obesity, results should be 
interpreted with care and questions whether this model is the most appropriate 
and representative for human diabetes should be asked. Therefore, the aim of 
this thesis was to characterise a diet-induced mouse model of insulin resistance 
which avoids the extreme features of ob/ob mice and mimics more closely 
human disease. 
 
Chapter 3 describes the generation of a diet-induced obesity (DIO) mouse 
model of insulin resistance and T2DM which circumvents the problem of leptin 
deficiency and thus represents an alternative model to the ob/ob mouse. The 
characterisation of this model will be described by looking at whole body 
composition, metabolic parameters and histological analysis of target organs of 
insulin resistance, the liver and kidney. In addition, potential structural changes 
of the heart associated with insulin resistance will be investigated by histological 
analysis. Finally, we determine whether this model fulfils the general criteria 
necessary for an animal model of insulin resistance, and which length of feeding 
is most suitable to further investigate cardiovascular and molecular changes in 
the heart.  
 56 
 
In Chapter 4 the cardiovascular and metabolic changes seen in the heart will be 
further investigated. In particular we look at coronary microvascular dysfunction, 
mechanical properties of DIO hearts as well as potential effects on insulin 
signalling and cardiac gene expression in DIO hearts and compare the model to 
the leptin-deficient ob/ob mouse. 
 
Finally, in Chapter 5 the role of a potential novel candidate gene involved in 
coronary microvascular remodelling will be investigated by looking at its 
expression in vascular smooth muscle cells of control and DIO mice. 
Additionally, we describe the effects of a shift in diet from high fat diet to normal 
rodent chow on metabolic markers, coronary microvascular remodelling and the 
expression of this potential candidate. 
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Chapter Two: Materials & Methods 
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2.1 Experimental animals 
Male C57BL/6 and ob/ob (B6.V-Lepob/OlaHsd) mice were obtained at 4-5 weeks 
of age from Harlan Laboratories, Inc (UK). Mice had access to a standard rodent 
chow and water ad libitum and were housed in temperature-controlled facilities 
with a 12 h light and 12 h dark cycle (5 animals per cage). C57BL/6 mice were 
randomised and put either on standard rodent chow (control group) or on a 45% 
high-fat, Western-style diet (SDS Diets, UK) for 8, 11 and 14 weeks (Table 2.1).  
 
Body weight was measured weekly. After 6 weeks, animals were divided into 
two groups. Animals with the highest body weight gain were defined as “diet-
induced obese” (DIO) mice. Animals with body weights ranging between the 
average ± 3 standard deviations of the control group were defined as “diet-
induced obese resistant” (DIO-R) as described by Enriori et al. [167]. Only DIO 
mice were used in further experiments. Animal care and all experimental 
procedures were performed in accordance with the regulations of the UK Home 
Office. 
 
Table 2.1: Composition of diets 
 Normal rodent chow High fat diet 
Protein 27.3% 20% 
Carbohydrate 61.2% 35% 
Fat 11.5% 45% 
     % of calories consumed 
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2.2 Stock solutions and buffers 
All chemicals were purchased from Sigma Aldrich, UK or VWR International Ltd, 
UK unless otherwise stated. Solutions were made from laboratory grade 
reagents and sterile water (dH2O) and stored at room temperature unless 
otherwise stated. TAE buffer was purchased from the MRC CSC Media Kitchen. 
A detailed description of buffers and stock solutions used are listed in the 
Appendix (Appendix A – Buffers and stock solutions). 
 
2.3 Tissue harvesting 
2.3.1 Blood sampling 
After terminal anaesthesia with isoflurane, blood was collected from the left 
carotid artery for serum and plasma preparation. Blood samples for serum 
preparation were incubated for 30 min at room temperature to allow clotting and 
centrifuged at 5,000 rpm for 10 min in a microcentrifuge. For plasma 
preparation, blood was collected in microcentrifuge tubes containing heparin 
(1000 IU/mL) and centrifuged immediately after collection. Serum and plasma 
samples were stored at -20 ºC until further use. 
 
2.3.2 Tissue harvesting for molecular studies 
After sacrificing the animals by cervical dislocation, organs were quickly 
removed, rinsed in ice-cold sterile PBS and snap frozen in liquid nitrogen. For 
insulin stimulation intra-peritoneal injection of 0.5 U/kg human insulin or an equal 
volume of saline for controls was given and animals were sacrificed 30 min after 
injection. Organ weights and visceral fat pad weights as well as tibia length were 
recorded for each animal. For the preparation of RNA or protein, snap frozen 
tissue was placed in a custom made metal mortar which was cooled in liquid 
nitrogen. The pre-cooled custom made pestle was inserted and pushed with 
force to crush the tissue. The resulting powder was quickly transferred to a 
cryotube and stored at -80 ºC until further use. 
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2.3.3 Tissue harvesting for histological studies 
For histological studies, mice were sacrificed by cervical dislocation. Organs 
were excised, rinsed in ice-cold sterile PBS and fixed in 10% neutral buffered 
formalin solution (Sigma Aldrich, UK) for 24-48 h and embedded in paraffin.  
 
2.4 Blood biochemistry 
2.4.1 Oral glucose tolerance test 
For the glucose tolerance test, mice were fasted over night for 12 h and a 
glucose dose of 4 g D-glucose/kg body weight, in a 50% aqueous solution, was 
administered by oral gavage. Glucose levels were measured in blood drops from 
the tail taken before and at 15, 30, 60 and 120 min after the administration using 
a commercially available blood glucose monitor (Boots, UK) with blood glucose 
test strips from Abbot Diabetes Care Ltd. 
 
2.4.2 Determination of mouse serum insulin concentrations 
Serum insulin concentrations in C57BL/6 and ob/ob mice were measured by 
enzyme-linked immunosorbent assay (ELISA) using the Rat/mouse Insulin 
ELISA kit (Linco Research, UK) according to manufacturer’s instructions. Briefly, 
serum samples were applied to microtiter plate wells pre-coated with pre-titered 
amounts of monoclonal mouse anti-rat insulin antibodies to allow capture of 
insulin molecules present in the samples. After bindin of biotinylated polyclonal 
antibodies to the captured insulin, streptavidin conjugated horseradish 
peroxidise enzyme was applied which allows the binding with the immobilized 
biotinylated immunocomplex. Quantification of the immobilised antibody-enzyme 
conjugates was performed by monitoring horseradish peroxidise activities in the 
presence of the substrate 3,3’,5,5’ tetramethylbenzidine. After acidification of 
formed products, the enzyme activity is measured spectrophotometrically by the 
increased absorbancy at 450 nm, corrected for the absorbancy at 590 nm to 
correct for optical imperfections in the plate. Rat insulin standards (0 – 10 
ng/mL) were provided as well as two quality controls (one in the lower and the 
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other in the higher range of insulin concentration) as an estimate of the accuracy 
of the test. Unknown serum samples (10 µL sample volume) were used in 
duplicates and absorbance was read in an Anthos 2001 plate reader within 5 
min of adding the stop solution. To determine insulin concentrations, average 
absorbance of duplicates (Abs450nm-590nm) was plotted on the y-axis and 
concentrations of insulin standards on the x-axis on a log scale graph. The 
concentrations of the unknown samples were derived from the standard curve 
by solving the equation of the standard curve trend line for “x” and entering the 
average absorbance values of unknown samples as “y”. 
 
2.4.3 Determination of mouse serum leptin concentrations 
Serum leptin concentrations were quantified using the Mouse Leptin ELISA kit 
from Millipore (Millipore Corporation, UK) according to manufacturer’s 
instructions with the same principles of the procedure as described in Section 
2.4.2. Mouse leptin standards (0.2 – 30 ng/mL) were provided as well as two 
quality controls as an estimate of the accuracy of the test. Unknown serum 
samples (5 µL sample volume for DIO mice and 10 µL for control and ob/ob 
mice) were used in duplicates. To compensate the volume deficit of DIO 
samples, assay buffer was used to have a final sample volume of 10 µL. 
Absorbance was read at 450 nm in an Anthos 2001 plate reader within 5 min of 
adding the stop solution. Absorbance at 590 nm was used as the reference 
wavelength to correct for optical imperfections in the plate. For the standard 
curve, average absorbance (Abs450nm-590nm) of mouse leptin standards were 
plotted on the y-axis against the concentrations of mouse leptin standards on 
the x-axis on a log scale graph. Concentrations of unknown samples were 
derived from the standard curve by solving the equation of the standard curve 
trend line for “x” and entering the average absorbance values of unknown 
samples as “y”. For DIO samples, calculated data were multiplied by 2 to 
accommodate for the dilution factor. 
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2.4.4 Determination of mouse serum free fatty acid 
concentrations 
Serum free fatty acid concentrations were quantified using the Free Fatty Acid 
kit by Abcam according to manufacturer’s instructions. Palmitic Acid (0 – 10 
nmol) was used as standards and Acyl-CoA synthetase used to convert fatty 
acids to their CoA derivatives, which were subsequently oxidized with the 
concomitant generation of colour. For testing serum samples of DIO and control 
mice, 10 µL serum was directly added to each well and sample volume adjusted 
with assay buffer for a final volume of 50 µL/well. Standards and test samples 
were run in duplicates. Optical density was measured at 570 nm on an Anthos 
2001 plate reader and fatty acid concentration was calculated by subtracting the 
background value (the 0 Control) from all readings and then plotting the 
standard curve nmol/well vs. OD 570 nm. Sample readings were applied to the 
standard curve to obtain fatty acid amount in the sample wells. Fatty acid 
concentrations were calculated with the following equation: 
 
Fatty acid concentration = Fa/Sv (nmol/µL or mM) 
 
Fa is the fatty acid amount (nmol) in the well obtained from standard curve 
Sv is the sample volume (µL) added to the sample well 
 
 
2.4.5 Determination of plasma asymmetric dimethylarginine 
(ADMA) 
Plasma ADMA levels of DIO and control mice were determined using liquid 
chromatography/mass spectrometry by Dr James Leiper, MRC CSC Nitric Oxide 
Signalling Group as previously described [168].  
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2.5 Histological analysis and histomorphometry 
Tissues for histological analysis were harvested as described in Section 2.3.3. 
Following paraffin embedding, multiple 4 μm thick sections were cut from each 
organ and stained with haematoxylin and eosin and picro-sirius red. Preparation 
of sections and staining was performed by Ms Martina Leopizzi, La Sapienza 
University Rome, Italy, or Ms Lorraine Lawrence, Faculty of Medicine, Imperial 
College London. 
 
2.5.1 Haematoxylin and eosin staining 
Sections were deparaffinised by incubating at 70 ºC for 30 min in a dry oven 
followed by incubating twice in xylene for 10 min each. Samples were re-
hydrated in a step of two times 5 min in 100% ethanol, 2 min in 95% ethanol and 
2 min in 70% ethanol. Sections were washed briefly in distilled water and 
stained with Mayer haematoxylin solution for 5-8 min, rinsed in distilled water 
and washed in warm running tap water for 10-15 min and again rinsed in 
distilled water. Following haematoxylin staining sections were counterstained in 
eosin/Phloxine B solution for 15 sec and dehydrated again using 95% ethanol 
and two changes of 100% ethanol for 15 sec each. Samples were cleared in two 
changes of xylene for 5 min each.  
 
2.5.2 Picro-sirius red staining 
For picro-sirius red staining, paraffin sections were deparaffinised and hydrated 
as described in Section 2.5.1 followed by nuclei staining with Weigert’s 
haematoxylin for 8 min and a 10 min wash in running tap water. After the wash, 
sections were incubated in picro-sirius red for 1 h and washed twice in acidified 
water followed by three incubations in 100% ethanol and clearing in xylene.  
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2.5.3 Histomorphometrical analysis 
Analysis was performed by Dr Massimiliano Mancini, La Sapienza University 
Rome, Italy.  
 
Histological and histomorphometrical studies were performed to evaluate size 
and structure of intramural arterioles. Images of arterioles with a diameter ≤150 
µm were acquired at a 40x magnification and analysis was carried out using 
Metamorph 6.2 software (MDS Analytical Technologies Inc., Molecular Devices, 
USA). Total vessel area and lumen area were measured (Figure 2.1) and the 
following parameters calculated from this:  
 
Medial area: Vessel area – Lumen area 
Media-to-lumen ratio: Medial area / Lumen area 
 
 
 
Figure 2.1: Histomorphometrical analysis of a mouse intramural arteriole.  
Histological section of a mouse left ventricle stained with haematoxylin and 
eosin. Vessel area is indicated by the black circle and lumen area by the red 
circle.   
 
 
 
 
 
Vessel area 
Lumen area 
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2.6 Immunohistochemistry 
Immunohistochemistry (IHC) was used to assess the expression levels and 
localisation of GLUT4 in mouse myocardium at baseline and after insulin 
stimulation. For this, heart sections were deparaffinised as described in Section 
2.5.1 and blocked with goat serum for 30 min followed by incubation with 
primary antibodies against the carboxyterminal end of GLUT4 (1:250; Abcam, 
UK) at 4 ºC over night. After incubation, sections were rinsed three times for 2 
min in PBST and incubated in peroxidase blocking solution for 10 min at room 
temperature. Sections were subsequently incubated with biotinylated secondary 
antibody in PBS for 30 min at room temperature, rinsed three times in PBST and 
incubated in peroxidase-streptavidin solution for 30 min at room temperature. 
Following washes, sections were incubated in peroxidase substrate solution, 
rinsed as above and counterstained with Meyer haematoxylin. Sections were 
dehydrated by incubating in 95% ethanol for 1 min and 100% ethanol twice for 3 
min, cleared in xylene for 5 min twice and mounted. 
 
2.7 Immunofluorescence 
Immunofluorescence was used to assess the expression level and localisation 
of RGS2 in vascular smooth muscle cells in left ventricle of DIO and control 
mice. Sections were deparaffinised as described in Section 2.5.1. Slides were 
rehydrated in sequential steps starting with 95% ethanol twice for 5 min, 
followed by 3 min each in 90%, 70% and 50% ethanol and 4 min in distilled 
water. Antigen retrieval was performed by microwave denaturing (5 min at 60% 
of 950 W) in citric buffer (pH 6.0) for 5 min followed by cooling down to room 
temperature for 30-45 min and washed first in distilled water for 2 min and then 
in PBS for 8 min with PBS changes every 2 min. Subsequently, sections were 
blocked in 5% BSA in PBS at room temperature for 1 h and mouse RGS2 
primary antibody (1:50; Santa Cruz, UK) was added and incubated over night at 
4 °C. The next day, slides were washed (5 x 2 min PBS) and then incubated 
with Goat Alexa 488 anti mouse secondary antibody (1:100; Invitrogen, UK) for 
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60 min in the dark at room temperature. To assess the expression and 
localisation of two proteins of interest on the same section, double staining was 
performed. For this, slides were subsequently washed (5 x 2 min PBS), blocked 
in 5% BSA in PBS for 1 h at room temperature and incubated with a second 
primary antibody, α smooth muscle actin (1:250; Abcam, UK) for 1 h at room 
temperature in the dark. Following primary antibody staining slides were washed 
as before and incubated with Goat Alexa 568 anti-rabbit secondary antibody 
(1:500) for 1 h at room temperature and washed again. The samples were then 
exposed to TO-PRO3 (1:200; Invitrogen, UK) for 20 min at room temperature to 
counterstain the nuclei and washed again for 6 x 2 min in PBS before mounting 
coverslips on slides for imaging using Vectashield (Vector Laboratories, 
Invitrogen, UK) and sealed using nail varnish. Slides were stored at 4 °C over 
night and imaged the next day. 
 
 
2.7.1 Analysis of immunofluorescent staining of vascular 
smooth muscle cells by confocal microscopy 
Myocardial vascular smooth muscle cells were imaged using an inverted laser 
scanning confocal microscope (LSM 510 Meta inverted; Zeiss, Germany) with a 
40x magnification. Samples stained with secondary antibody only were used to 
optimise laser settings and microscope set up to avoid detection of background 
staining or autofluorescence. Vascular smooth muscle actin staining was used 
for identification and localisation of transmural small vessels (≤120 µm). 
Specialised software was used to quantify the fluorescent intensity (Zeiss LSM 
Meta software). Regions of interest were drawn around the vessels and mean 
fluorescence intensity was measured using this software. 
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2.8 Protein expression analysis 
2.8.1 Protein extraction from tissue samples 
Frozen tissue powder was homogenized in ice-cold protein lysis buffer (Cell 
Signaling Technology, UK) supplemented with 1 mM PMSF and 1 mM protease 
inhibitor cocktail (Sigma Aldrich, UK) immediately before use with a Tissue 
Tearor (BioSpec Products Inc., USA) and incubated on ice for 30 min. Cell 
lysates were centrifuged at 10,000 g (Eppendorf 5804R) for 10 min at 4 °C to 
remove cell debris and supernatants were stored at -20 °C until further use. 
 
2.8.2 Total protein concentration estimation 
Total protein concentration from lysates was estimated by the Bradford assay 
method [169] using protein assay reagent (BioRad Laboratories, CA, USA). 
Bovine serum albumin (BSA) was used as the standard ranging from 0 – 40 
µg/µL. Absorbance was read at 595 nm on an Anthos 2001 plate reader and 
protein concentrations of the experimental samples were determined by the 
standard curve generated. 
 
2.8.3 Phosphotyrosine (4G10) pulldown 
For the anti-phosphotyrosine immunoprecipitation, cell lysates with a 
concentration of 1 µg/µL and a total concentration of 250 µg were used. 50 µL of 
a 50% protein agarose beads slurry were added to lysates and rotated for 3 h at 
4 ºC. After the incubation, samples were centrifuged for 5 min at 2,000 rpm at 4 
ºC and supernatant split into two new 1.5 mL microcentrifuge tubes. To one tube 
50 µL anti-phosphotyrosine agarose conjugate (Millipore, clone 4G10) was 
added and to the other 50 µL protein A agarose beads. Samples were rotated 
over night at 4 ºC. The next day, samples were centrifuged for 5 min at 2,000 
rpm at 4 ºC, the supernatant removed and beads washes three times with RIPA 
buffer. After the last wash the supernatant was removed and 50 µL 4 x SDS-
PAGE sample buffer (NuPAGE LDS Sample Buffer, Invitrogen, UK) was added. 
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Samples were heated at 95 ºC for 5 min to dissociate proteins from beads and 
10 µL were loaded onto 7.5% agarose gels (Table 2.2). 
 
2.8.4 Western blotting 
Samples were incubated for 3 min at 95 °C in 4 x NuPAGE LDS Sample Buffer 
(Invitrogen, UK) and aliquots (20-25 µg) were loaded onto 7.5%, 10% or 12% 
acrylamide gels (Table 2.2) and subsequently separated by SDS-PAGE gel 
electrophoresis in 1x running buffer. Proteins were transferred onto 
polyvinylidine fluoride membrane (Immobilon-P, Milipore Corporation, USA) in 
transfer buffer and adequate transfer of proteins was confirmed by staining the 
membrane with Ponceau S Solution and the gel with Coomassie blue protein 
staining solution (Sigma-Aldrich Co.). 
 
 
Table 2.2: Composition of agarose gels for western blotting 
 
 Running gel Stacking gel  
Substances 7.5% (mL) 10% (mL) 12.5% (mL) 4.5% (mL) 
Acrylamide 5 6.8 8.4 1.5 
Tris-HCl, pH 8.8 5 5 5 - 
Water 9.6 7.8 6.2 7.4 
10 % SDS 0.2 0.2 0.2 0.1 
10 % APS 0.1 0.1 0.1 0.1 
10 % TEMED 0.1 0.1 0.1 0.1 
Tris-HCl, pH 6.8 - - - 0.833 
 
Acrylamide: 30% Acrylamide/0.8% Bis-acrylamide in H2O (UltraPure Protogel, 
Fisher Scientific, UK); SDS: Sodium dodecyl sulphate (Sigma Aldrich, UK); APS: 
Ammonium persulfate (Sigma Aldrich, UK); TEMED: N,N,N’,N’-
Tetramethylethylenediamine (BDH Electran, VWR International Ltd, UK) 
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Following transfer, membranes were washed with Tris-buffered saline containing 
0.1% Tween20 (TBST) and blocked for 45 to 60 min at room temperature with 
5% skimmed milk or BSA in TBST. Blots were then probed with primary 
antibodies (Table 2.3) according to manufacturer’s instructions at an optimised 
concentration which was derived from titration experiments. After incubation, 
blots were washed three times for 5 min with fresh TBST and incubated for 1 h 
at room temperature with either horseradish peroxidase-conjugated goat anti-
rabbit IgG or goat anti-mouse IgG secondary antibody at a 1:2500 dilution (Dako 
Cytomation, UK) in 1% skimmed milk or BSA in TBST. Proteins were visualized 
using the ECL Western Blotting Detection System (BioRad Laboratories, UK) 
followed by exposure to CL-XPosure Film (Pierce Biotechnology Inc., UK). 
Developed films were scanned and the relative densitometry was assessed 
using ImageJ software (NIH, Bethesda, MD).  
 
 
Table 2.3: Primary antibodies 
 
Protein Species Source Dilution Size (kDa) 
Akt rabbit CST 1:1000 60 
P-Akt rabbit CST 1:1000 60 
CTGF mouse Abcam 1:1000 38 
GAPDH mouse Abcam 1:2500 36 
GLUT4 rabbit Abcam 1:2500 45 
IRS1 rabbit CST 1:1000 180 
MT2 mouse Abcam 1:1000 15 
RGS2 mouse Santa Cruz 1:1000 32 
 
CST: Cell Signaling Technology 
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2.9 RNA expression analysis 
2.9.1 RNA extraction from frozen tissue 
RNA was extracted using TRIzol reagent (Invitrogen, UK) according to 
manufacturer’s instructions. 50 mg of heart powder was placed in a 7 mL Sterilin 
tube on ice and 1 mL TRIzol reagent was added. Samples were homogenized 
on ice with a Tissue Tearor (BioSpec Products Inc., USA) and incubated at room 
temperature for 5 min for complete dissociation of nucleoprotein complexes. 
After incubation, 200 µL chlorophorm was added, samples were shaken by hand 
for 15 sec and incubated at room temperature for 3 min. To separate the 
aqueous phase containing the RNA, samples were centrifuged for 15 min at 
12,000 g at 4 ºC and the clear aqueous phase was transferred to a new tube 
containing 500 µL isopropanol. Samples were mixed, incubated for 10 min at 
room temperature and centrifuged for 10 min at 12,000 g at 4 ºC. Following 
centrifugation, the supernatant was removed and the pellet washed with 75% 
ethanol. Samples were mixed by hand and centrifuged at 8,000 g for 8 min at 4 
ºC. After washing, the supernatant was removed and the pellet air-dried for 
about 10 min. Isolated RNA was dissolved in 40 µL RNase free water and 
incubated at 55 ºC for 5 min. Centrifugations were carried out in a pre-cooled 
Eppendorf 5804R. 
 
2.9.2 RNA sample cleanup 
Extracted RNA was further purified using the RNeasy Mini kit (Qiagen, UK) 
according to manufacturer’s description. The sample volume was adjusted to 
100 μL with RNase-free water, 350 μL RLT buffer was added and samples were 
mixed by pipetting. 250 μL ethanol (96-100%) was added to the diluted RNA, 
mixed by pipetting and directly transferred to a RNeasy Mini spin column. 
Columns were centrifuged at 8,000 g for 30 sec and the flow-through discarded. 
500 μL RPE buffer was added to the RNeasy spin column and again centrifuged 
at 8,000 g for 30 sec. This step was repeated once, centrifuging for 2 min 
followed by an optional centrifugation step without addition of RPE buffer for 1 
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min at maximum speed. RNeasy spin columns were placed to a new 1.5 mL 
collection tube and 30 μL RNase-free water was directly added onto the 
membrane. Samples were centrifuged at 8,000 g and the elution repeated with 
20 μL RNase-free water.  
 
Total RNA concentration was quantified by measuring optical density using the 
NanoDrop® ND-1000 spectrophotometer. Purity of the isolated RNA was 
assessed by calculating the ratio of the optical density at 260 nm and 280 nm 
and ratios between 1.8 and 2.1 were considered as pure. The total RNA was 
stored at -80 ºC until further use. 
 
2.9.3 cDNA preparation 
cDNA was synthesised from 1 μg of total RNA in reverse transcription reactions 
using SuperScript® III Reverse Transcriptase (RT) supplied with a vial of 5x 
First-Strand Buffer (250 mM Tris-HCl (pH 8.3), 375 mM KCl, 15 mM MgCl2) and 
0.1 M DTT (Invitrogen Ltd, UK). Total RNA was incubated together with dNTP 
mix (10 mM each), random hexamers (50 µM, Applied Biosystems, UK) and 
RNase-free water for 5 min at 65 ºC followed by a quick chill on ice. cDNA 
synthesis mix consisting of 4 μL 5x First-Strand Buffer and 2 μL of 0.1 M DTT 
per reaction was added and samples were incubated for 2 min at 25 ºC. After 
incubation, 1 μL SuperScript® III RT (200U/µL) was added and samples were 
incubated at 25 ºC for 10 min and 42 ºC for 50 min. The reaction was inactivated 
by incubating at 70 ºC for 15 min. The resulting cDNA was stored at -20 ºC until 
further use. 
 
 
 
 
 72 
 
2.9.4 Quantitative real time RT PCR (qRT-PCR) 
Transcript levels were quantified using the SYBR Green Jumpstart Taq Ready 
mix (Sigma Aldrich, UK) according to manufacturer’s recommendations. cDNA 
was diluted to 5 ng/µL (10 ng final concentration) and gene specific primers to a 
final concentration of 200 mM (Table 2.4). Primer sequences were designed 
with GenScript Primer Design Tool [170]. 
To control for technical differences, triplicates were set up in an optical 96-well 
reaction plate (BioRad, UK) and real-time PCR was carried out using the 7900 
HT Fast Real-Time system (Applied Biosystems, UK). Reactions were incubated 
at 94 ºC for 2 min followed by 40 cycles at 94 ºC for 15 sec, 60 ºC for 1 min and 
72 ºC for 1 min. Relative gene expression was calculated using the comparative 
Ct method relative to control samples by comparing the number of thermal 
cycles that were required to generate threshold amounts of product. Cyclophilin 
A was used as a housekeeping control gene. All quantitations were normalised 
to Cyclophilin A to account for variability in the initial concentration and quality of 
total RNA. Ct was calculated for the genes of interest and for the housekeeping 
gene Cyclophilin A. For each cDNA sample, the Ct for Cyclophilin A was 
subtracted from the Ct for each gene of interest to give the parameter ΔCt, thus 
normalising the initial amount of total RNA used. The amount of each target was 
calculated as 2-ΔΔCt, were ΔΔCt is the difference between the ΔCt of the two 
cDNA samples to be compared.  
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Table 2.4: Primer sequences for qRT-PCR 
 
Gene ID Forward primer  (5’ -> 3’) Reverse primer  (5’ -> 3’) 
Acta1 TATTCCTTCGTGACCACAGC GGCCATCTCATTCTCGAAGT 
Arhgef19 GGTCAAGAGCACCAGTGACA TTGGTGACGTAAGGCAGGTA 
Cdkl1 GATGAGGCTCGAGAGAGGTC AGCCTTCTCCAATCTTTCCA 
Cirbp GGAGCAGGTCTTCTCCAAGT GGTCTCCCTGTCCTTTACCA 
Ctgf CTGAGCATGTGTCCTCCACT GCCACAAGCTGTCCAGTCTA 
Ehhadh TGGAGTTCCTGTTGCTCTTG GATGGCTTCTTCAACTGGGT 
Fdft1 TGACATGAGCATCAGTGTGG CACTTGTCGGTCCTTCTCCT 
Gabarapl1 AGGTGAAGACATCGGGAAAC ACAGCCAATGCAACACAAGT 
Gpr22 ACAGAAGAAGAAAGCCCGAA CACCAAACACGACATTCCTC 
Hist1h1c GCTGCTCAGGAAGTGCTATG TTCAAATCACCTTGCAGTCC 
Hmgsc2 GGAGGACATCAACTCCCTGT TTGTCAATGATGGTCTCGGT 
Hrc CAGGGAGAGATTGCTCATCA TGAGAGCTGTGGTCACCTTC 
Lmcd1 CTAAGGACCTCAACCCTGGA CAGACAAGCCACTCCTCTTG 
Mt2 CTGCAAATGCAAACAATGC ACTTGTCGGAAGCCTCTTTG 
Nes CCCTTGCCTAATACCCTTGA GCCTCAGACATAGGTGGGAT 
Nkiras1 GTGGCAATCGTTGTGTTAGG CCCACAGCTTGACTTTCTCA 
Pdk4 CTGCTGGACTTTGGTTCAGA GGCAGGATGTCAATCTCCTT 
Ppp1r3c TGTGGTAAGGGTGTGAGGAA GTTCCCACCAATGGCTTAAT 
Rgs2 GAGAAGGAAGCTCCCAAAGA ACCCTCTTCTGAGCTGTGGT 
Scd4 GCGGTATGCTGTGCTTCTAA TTGAAACGAAGGGATTCTCC 
Tcp11l2 GCTGAAAGCTACCACCAACA TCCATTCTCATGAGGTCCAA 
Tfrc GCATCTGCTAATGAGACCCA ATTGTGGCATTCTTCCTTCC 
Tmem204 TAGAAGCCGAGACAGGGAAT CTGGATGTCCTGCTTCGTAA 
Tmem71 TTCAAGAGCTGGTTTGATGC GGCTAATTCTCCTCCCACAA 
Tmtc1 CCTCCTGGCCTTCAATGTAT TCCACCAGAGGGATACTTCC 
Ucp3 CACGGCCTTCTACAAAGGAT TAAGGCCCTCTTCAGTTGCT 
Cyclophilin A AATGCTGGACCAAACACAAA CCTTCTTTCACCTTCCCAAA 
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2.10 Microarray set-up 
GeneChip® Mouse Exon 1.0 ST Arrays (Affymetrix Inc, UK) were used to 
investigate the effects of high fat diet feeding on cardiac gene expression on the 
whole-genome scale. Unlike the classical 3’ expression microarrays this system 
allows analysis of both gene expression and alternative splicing due to multiple 
probes per exon and approximately 40 probes per gene [171]. The protocol 
used has been validated by the MRC Genomics Laboratory and is based on 
protocols provided by Affymetrix with modifications made by the MRC Genomics 
Laboratory (Version 2, 14/02/2008).  
 
Ribosomal RNA (rRNA) is removed from total RNA in the rRNA reduction step to 
maximise the sensitivity and specificity of the hybridisations. In the next step 
mRNA is copied into double-stranded DNA (cDNA synthesis kit) and amplified 
by in vitro transcription into cRNA. In three second cycle cDNA synthesis 
reactions deoxyuridine is incorporated into each cDNA strand and following 
incorporation double-stranded DNA is fragmented using apurinic/apyrimidinic 
endonuclease (APE1) and uracil DNA glycosylase (UDG) enzymes. Prior to 
hybridisation onto arrays, fragments are end-labelled using terminal 
deoxynucleotidyl transferase (TdT) and DNA labelling reagent.  
 
A summary of the GeneChip® whole transcript assay is provided as a flow chart 
in Figure 2.2.  
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Figure 2.2: Flow chart of GeneChip® Whole Transcript Assay protocol.  
Quality controls (QC) were: QC1 Bioanalyser trace and concentrations of total 
and reduced RNA. QC2 Concentrations, OD values (260/280 nm) and yield (µg) 
(at least 10 µg). QC3 Concentrations, OD values (260/280 nm) and yield (µg) (at 
least 5.5 µg). QC4 Bioanalyser trace before and after fragmentation 
 
 
Total RNA (1µg)
rRNA reduction
Clean-up of RNA
First cycle, first strand cDNA synthesis
First cycle, second strand cDNA synthesis
First cycle in vitro transcription using unlabelled ribonucleotides
First cycle, clean-up of cRNA
Second cycle, first strand cDNA synthesis using random primers
Fragmentation
Terminal labelling
cRNA hydrolysis
Clean-up of cDNA
QC1
QC2
QC3
QC4
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2.10.1 rRNA reduction 
For the rRNA reduction step the RiboMinus Human/Mouse Transcriptome 
Isolation Kit (Human/Mouse) (Invitrogen, UK) was used. The Betaine 
Hybridisation Buffer was prepared by adding 54 μL of 5 M Betaine (Sigma 
Aldrich, UK) and 126 μL Invitrogen Hybridisation Buffer. In a 1.5 mL RNase free 
tube the total RNA/Poly A control mix was prepared by adding 1 μL of Poly A 
controls (provided by the MRC Genomics Laboratory) to 1 μg of total RNA per 
samples (maximum total RNA volume: 4.2 μL). RNase free water was added to 
a final volume of 5.2 μL. A mastermix of the Ribo Minus probe (100 pmol/μL) 
plus the Betaine Hybridisation Buffer was prepared and 30.8 μL of this 
mastermix was added to each reaction tube. Samples were mixed, and 
incubated in a heated block at 70 ºC for 5 min. Following incubation, samples 
were placed back on ice for at least 2 min and briefly spun and placed on ice 
until further use. The magnetic beads were prepared by transferring 55 μL of the 
bead suspension for each reaction into a 1.5 mL tube and placing the tubes on 
the magnetic stand for 1 min. Without disturbing the beads, the supernatant was 
removed and discarded and 55 µL of RNase free water added to each tube. 
Tubes were flicked to re-suspend the beads and spun. Beads were washed for a 
second time and for the third wash 55 µL of Betaine Hybridisation buffer was 
used instead of RNase free water. Tubes were returned to the magnetic stand, 
supernatant removed and 22 µL Betaine Hybridisation buffer added. 20 µL of 
the re-suspended beads were aliquoted into new 1.5 mL tubes, incubated for 2 
min at 37 °C and the total RNA samples transferred to the prepared beads. 
Samples were mixed, incubated for 10 min at 37 °C in a heating block and 
placed again on the magnetic stand for 2 min. For each sample the supernatant 
was transferred to a new tube, 50 µL Betaine Hybridisation buffer added to the 
beads, incubated at 50 °C for 5 min and placed on the magnetic stand. The 
supernatant was transferred to the tubes already containing supernatant, total 
sample volume was determined and then placed on ice and immediately 
concentrated using the GeneChip IVT cRNA Clean-up Kit (Affymetrix Inc, UK) 
according to manufacturer’s instructions.  
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Following this concentrating step the absorbance of the eluate was measured at 
260 nm and 280 nm on a NanoDrop® ND-1000 spectrophotometer. The quality 
of the rRNA-reduced as well as the total RNA sample was assessed by 
visualizing an aliquot on the Agilent 2100 Bioanalyser using the RNA 6000 Nano 
Assay. The remaining sample was placed on dry ice and stored at -80 °C until 
further use. Absorbances and Bioanalyser traces of all samples can be found in 
the Appendix (Appendix C – Microarray Quality Controls). 
 
 
 
 
Figure 2.3: Bioanalyser trace of total RNA before and after rRNA reduction 
treatment  
The red trace represents the total RNA and the blue trace the rRNA reduced 
total RNA. Samples were run by the MRC Genomics Laboratory and the picture 
was taken from the Whole Transcript 1 µg Labelling Assay manual. 
 
 
 
 
 
 
 
Reduced RNA
Total RNA
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2.10.2 cDNA Synthesis 
For the cDNA synthesis the Affymetrix GeneChip WT cDNA Synthesis and 
Amplification Kit (Affymetrix Inc, UK) was used. First, a 1:5 dilution of the 
provided T7-(N)6 primer in RNase free water was prepared. For each sample 4 
µL of the rRNA-reduced Total RNA/PolyA mix and 1 µL of the diluted T7-(N)6 
primer was added to a 0.2 mL RNase free tube, mixed by vortexing and briefly 
spun. Reaction tubes were then placed in a thermal-cycler with heated lid option 
and incubated at 70 °C for 5 min, 4 °C for 2 min, held at 4 °C and then paced on 
ice. For each reaction, a mastermix consisting of 2 µL 5x First strand buffer, 1 
µL 0.1 M DTT, 0.5 µL 10 mM dNTP Mix, 0.5 µL RNase inhibitor and 1 µL 
Superscript®II was prepared and 5 µL transferred to each of the reaction tubes. 
Samples were mixed by pipetting and placed in a thermal-cycler with heated lid 
option with the following programme: 25 °C for 10 min, 42 °C for 1 h, 70 °C for 
10 min, 4 °C for 2 min and held at 4 °C. Following this, samples were briefly 
spun and immediately used for the second strand cDNA synthesis.  
For the second strand cDNA synthesis a fresh dilution of 17.5 mM MgCl2 was 
prepared by diluting 2 µL MgCl2 (1 M) with 112 µL RNase free water. A 
mastermix was prepared (Table 2.5) and 10 µL added to each first strand 
reaction tube. Samples were mixed by pipetting and incubated at 16 °C in a 
thermal-cycler for 2 h without the heated lid option followed by an incubation at 
75 °C for 10 min an a thermal-cycler with heated lid option and finally cooled for 
2 min at 4 °C. After the second strand cDNA synthesis samples were 
immediately used for cRNA synthesis. 
 
Table 2.5: Second strand cDNA synthesis master mix (for one reaction) 
 
RNase free water 4.8 µL 
diluted MgCl2 4.0 µL 
10 mM dNTP mix 0.4 µL 
DNA Polymerase I 0.6 µL 
RNase H 0.2 µL 
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First cycle of the cRNA synthesis was performed by preparing a mastermix for 
each sample consisting of 5 µL 10x IVT Buffer, 20 µL IVT NTP Mix and 5 µL IVT 
Enzyme Mix. The mastermix was transferred to the second strand reaction 
tubes, mixed by pipetting and incubated in a thermal-cycler at 37 °C for 16 h 
with the heated lid option. After the incubation samples were put on hold until 
further processed using the Affymetrix GeneChip Sample Clean-up Module 
(Affymetrix Inc, UK) according to manufacturer’s instructions. First cycle cRNA 
was eluted in RNase-free water and volume of eluate was measured. 
Absorbance at 260 nm and 280 nm of each eluate was measured on a 
NanoDrop® ND-1000 spectrophotometer and the first cycle cRNA yield was 
determined by multiplying the concentration of each sample with the eluate 
volume. For the second cycle cRNA synthesis, 10 µL cRNA at a minimum 
concentrationof 1.54 µg/µL was needed.  
 
In the second cycle, first strand cDNA synthesis was performed using the 
GeneChip WT cDNA Synthesis and Amplification Kit by Affymetrix (Affymetrix 
Inc, UK). For each reaction, 10 µg cRNA from the previous step, 1.5 µL random 
primers (3 µg/µL) and RNase free water were added to a 0.2 mL tube to a final 
volume of 8 µL. Samples were briefly vortexed and placed in a thermal-cycler 
with the heated lid option with the following programme: 70 °C for 5 min, 25 °C 
for 5 min, 4 °C for 2 min and held at 4 °C. After this incubation samples were put 
on ice and a mastermix was prepared for each sample (Table 2.6).  
 
Table 2.6: Second cycle, first strand cDNA synthesis master mix (for one 
reaction) 
 
5x First Strand Buffer 4.00 µL 
0.1 M DTT 2.00 µL 
10 mM dNTP 1.25 µL 
10 mM dUTP 1.25 µL 
Superscript®II 4.75 µL 
 
 80 
 
After mixing by pipetting, 12 µL of the mastermix was transferred to each of the 
reaction tubes and incubated in a thermal-cycler with the following programme: 
25 °C for 10 min, 42 °C for 90 min, 70 °C for 10 min, 4 °C for 2 min and held at 4 
°C. To each single stranded cDNA tube 1 µL of RNase H was added, mixed by 
pipetting and put back in a thermal-cycler with heated lid option at 37 °C for 45 
min, 95 °C for 5 min, 4 °C for 2 min and held at 4 °C. Samples were immediately 
cleaned-up using the GeneChip Sample Clean-up Module according to 
manufacturer’s instructions. At the end absorbance was measured on a 
NanoDrop® ND-1000 spectrophotometer and yield of the single stranded cDNA 
was calculated.  
 
2.10.3 Fragmentation of single-stranded cDNA 
For the fragmentation of single-stranded cDNA, the Affymetrix GeneChip WT 
Terminal Labelling Kit (Affymetrix Inc, UK) was used. For each sample, 5.5 µg 
single-stranded cDNA was transferred to a 0.2 mL tube and RNase free water 
was added to make a total volume of 31.2 µL. Additionally, 16.8 µL of the 
mastermix (Table 2.7) was added to each reaction tube, mixed and spun. The 
tubes were then placed in a thermal-cycler with the heated lid option and run the 
following programme: 37 °C for 60 min, 93 °C for 2 min, 4 °C for 2 min and held 
at 4 °C until further use. An aliquot of 1.5 µL of the fragmented cDNA sample 
was run on a Agilent 2100 Bioanalyser for size analysis using the RNA 6000 
Nano Assay. Along-side the fragmented samples, an unfragmented sample was 
run for comparison (Figure 2.4). Bioanalyser traces can be found in the 
Appendix (Appendix C – Microarray Quality Controls). 
 
Table 2.7: Fragmentation master mix (for one reaction) 
 
RNase free water 10 µL 
10x cDNA Fragentation Buffer 4.8 µL 
UDG (10 U/µL) 1.0 µL 
APE1 (1,000 U/µL) 1.0 µL 
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Figure 2.4: Bioanalyser traces comparing fragmented single-stranded 
cDNA with the unfragmented sample.  
The blue trace represents the single-stranded cDNA before fragementation and 
the red trace the single-stranded cDNA after fragmentation. Samples were 
processed at the MRC Genomics Laboratory and the picture was taken from the 
Whole Transcript 1µg Labelling Assay manual. 
 
 
2.10.4 Labelling of fragmented single-stranded cDNA and 
hybridisation 
For labelling of the fragmented single-stranded cDNA the GeneChip® WT 
Terminal Labelling Kit was used. 45 µL of the fragmented cDNA was transferred 
to a new 0.2 mL RNase free tube and 15 µL of a prepared mastermix consisting 
of 12 µL 5x TdT Buffer, 2 µL TdT and 1 µL DNA Labelling Reagent (5 mM) was 
added to each sample. Tubes were placed in a thermal-cycler with heated lid 
option and the following programme was run: 37 °C for 60 min, 70 °C for 10 min, 
4 °C for 2 min and held at 4 °C until further use. After the incubation, all of the 
labelled extract was transferred to a clean 1.5 mL RNase free tube and the 
volume was measured using a pipette. For each sample, sufficient RNase free 
water was added so that the final volume of the labelled extract was 60 µL.  
Single-stranded cDNA
before fragmentation
Single-stranded cDNA
after fragmentation
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Labelled samples were stored on dry ice and hybridisation to GeneChip® 
Mouse Exon 1.0 ST Arrays (Affymetrix Inc, UK) and scanning was carried out at 
the MRC Genomics Laboratory by Ms Nathalie Lambie.  
 
2.10.5 Data analysis 
Gene expression summary values of the Affymetrix Gene Chip data were 
generated using the robust multichip average (RMA) algorithm [172]. The quality 
of the expression replicates was then determined using principal-components 
analysis, hierarchical clustering and hybridisation control plot using GeneSpring 
GX software (Agilent Technologies, UK) followed by a filtering step which 
included the removal of all values below the 20th percentile and the setting that 
10 out of 10 samples should have probe values greater than the 20th percentile. 
After applying multiple corrections, no differentially expressed genes were 
found. An alternate approach of a fold change ≥ 1.5 and a p value of p<0.01 was 
used as criteria for differential expression. Data analysis was performed at the 
Centre for Bioinformatics, Imperial College London with the great help of Mr 
Arshad Khan. Functional annotation was carried out using Ingenuity Pathway 
Analysis software (Ingenuity Systems Inc, USA). 
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2.11 Preparation of DNA samples for sequencing 
PCR products for sequencing were generated from cDNA prepared as 
described in Section 2.9.3 by PCR amplification using Pfu DNA Polymerase 
according to manufacturer’s instructions (Promega Corporation, USA). In a 50 
µL reaction 100 ng of cDNA was set up on ice together with dNTP mix (10 mM 
each), Pfu DNA Polymerase 10x Buffer (200 mM Tris-HCl (pH 8.8), 100 mM 
KCl, 100 mM (NH4)2SO4, 20 mM MgSO4, 1 mg/mL nuclease-free BSA, 1% 
Triton® X-100), forward and reverse primer (200 µM each, Table 2.8), nuclease 
free water and Pfu DNA Polymerase. The reaction mix was placed in a thermal 
cycler with heated lid and denatured at 95 °C for 2 min followed by 35 cycles of 
denaturation at 95 °C for 30 sec, annealing at 58 °C for 30 sec and extension at 
72 °C for 1 min and a final extension at 72 °C for 5 min. Samples were 
incubated at 4 °C until further use.  
 
Agarose gel electrophoresis of PCR products was carried out in wide Mini-Sub 
Cell GT tanks (Bio-Rad, UK). For 1.5% agarose gels, 1.5 g (w/v) low-melting 
agarose powder (Invitrogen, UK) was dissolved in 100 mL 1x TAE buffer (MRC 
CSC Media Kitchen) and boiled in a microwave. After the agarose was cooled 
down to approximately 55 °C, 4 µL of 10 mg/mL ethidium bromide was added 
before pouring into the plastic mould and left to polymerise. DNA samples were 
mixed 1 in 10 with Orange G and electrophoresis was carried out in 1x TAE 
buffer at between 80 V for 30-90 min. The 1 kb DNA ladder (Invitrogen, UK) was 
used as a DNA size marker. DNA fragments were visualized using a UV 
transilluminator (BioRad, UK), photographed with the gel doc software (BioRad, 
UK) and excised from the agarose gel with a clean scalpel.  
 
DNA was purified from the agarose gel using the QIAquick Gel Extraction Kit 
according to manufacturer’s instructions (Qiagen, UK) and eluted from QIAquick 
columns with 60 µL elution buffer (10 mM Tris-HCl, pH 8.5). DNA concentration 
was measured on a NanoDrop® ND-1000 spectrophotometer. 80 ng of purified 
DNA was submitted to the MRC Genomics Laboratory Sequencing Service with 
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3.2 picomoles of sequencing primer (Table 2.8) and adjusted with water to a 
total volume of 10 µL. Cycle sequencing reactions were run on the 3730xl DNA 
Analyzer (Applied Biosystems, UK). Data were analysed in the BioEdit 
programme (Version 7.0.9) [173]. 
 
 
Table 2.8: Primer sequences for amplification and sequencing of the Rgs2 
coding region  
 
Amplification Primer   
Forward primer (5’ -> 3’) CTGAGAATGCAAAGTGCCAT 
Reverse primer (5’ -> 3’) GGCTGAATTCAAGGTCAGTTT 
 
Sequencing Primer Start position 
SeqFwd 1 (5’ -> 3’) CTGAGAATGCAAAGTGCCAT 26 
SeqFwd 2 (5’ -> 3’) GGCAGAAGCATTTGATGAAC 271 
SeqRev 1 (5’ -> 3’) GTCTTCACAAGCCAACCAGA 366 
SeqRev 2 (5’ -> 3’) GGCTGAATTCAAGGTCAGTTT 750 
 
Primer sequences were designed with GenScript Primer Design Tool [170]. 
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2.12  In vivo assessment of cardiac function using 
cardiac magnetic resonance imaging (CMRI) 
Cardiac magnetic resonance imaging was performed at the MRC CSC 
Biological Imaging Centre with the help of Dr Marzena Wylezinska-Arridge, Dr 
Jordi Lopez Tremoleda and Mr Howard Parker.  
 
Cardiac function was assessed using a high field Varian multinuclear, small-bore 
MRI system (4.7T). Animals were anaesthetised using 2.5% isoflurane in O2 and 
maintained under anaesthesia with 1.5% isoflurane. Physiological parameters 
like heart rate, respiration and body temperature were monitored throughout the 
scan using a small animal imaging system integrated into the Varian scanner. 
Lead 1 ECG electrodes were secured to the chest of the animal and a 
pneumatic pillow was attached to the abdomen of the animal for monitoring 
respiration. Core body temperature was maintained at 37 ºC using a warm air 
fan. The animal was placed in a coil in the supine position and the coil was then 
positioned in the magnet so that the heart was in the isocentre of the magnet. 
Long-axis scout images were acquired for localisation of the heart. Acquisition of 
dual-gated (ECG and respiration) dynamic cine FLASH MRI short axis images 
was performed with a repetition time TR of 4.35 ms, an echo time TE of 1.58 
ms, a field of view of 40x40 mm and a matrix size of 192x192. Four averages of 
8-10 consecutive 1.3 mm thick short-axis slices (6 frames per slice) were 
acquired to cover the entire left ventricle of the animal. (Figure 2.5) 
Data analysis was carried out in a blinded manner using ImageJ software (NIH, 
Bethesda, MD) on reconstructed FDF files. Prior to analysis all FDF images per 
scan were converted to stacks and filtered using the byte swap plug-in in 
ImageJ. For all slices, both end-diastolic and end-systolic frames were visually 
determined by assessing filling size and wall thickening patterns of the LV. 
Endocardial contours were manually traced using ImageJ at end-systole and 
end-diastole for each slice to obtain the LV end systolic and end diastolic area 
(Figure 2.6).  
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Figure 2.5: Long- and short-axis views of mouse heart.  
(A) Long-axis scout image for localisation of the heart. (B) Short-axis cine 
FLASH image of left and right ventricles at end diastole. (C) Short-axis image 
shows left and right ventricles, septum and papillary muscles. LV, left ventricle; 
RV, right ventricle; Septum, interventricular septum. 
 
 
 
 
A B
RV
Septum
LV
Papillary 
muscles
LVRV
C
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Figure 2.6: Manual planimetry of the mouse heart for functional analysis. 
Functional cardiac parameters were determined by tracing the endocardial 
border of the left ventricle using ImageJ software. (A) Area of the blood pool 
(bright) in the left ventricle at the end of diastole (B) Area of the blood pool 
(bright) in the left ventricle at the end of systole. Papillary muscle was excluded 
from the area measurement.  
 
 
Left ventricular end diastolic volume (LVEDV) and left ventricular end systolic 
(LVESV) volume was calculated as follows:  
 
      all slices 
  LVEDV = ∑ (end diastolic area) x slice thickness 
 
      all slices 
  LVESV = ∑ (end systolic area) x slice thickness 
 
 
LV stroke volume (SV) and ejection fraction (EF in %) were calculated with the 
following formulae: 
 
SV = LVEDV – LVESV 
 
EF = (SV/LVEDV) x 100 
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2.13 Invasive blood pressure measurements 
For direct invasive measurements under terminal general anaesthesia animals 
were anaesthetised with 1.5% isoflurane in O2 and placed on a heating pad to 
maintain the body temperature at 37 ºC. Mean arterial pressure (MAP) was 
determined by cannulating the left carotid artery with a heparin-saline-filled 
polyethylene tube connected to a pressure transducer. MAP was recorded using 
CardioSOFT Pro (SonoMetrics Corporation, USA).   
 
2.14 Ex vivo assessment of coronary flow using 
Langendorff perfusion 
After invasive blood pressure measurement under general anaesthesia, the 
heart was removed and placed in a Petri dish with ice-cold heparinised Krebs-
Henseleit buffer. Excess tissue was quickly removed under a dissection 
microscope, the aorta identified and attached to a mouse Langendorff cannula. 
Two sutures were tied around the aorta to ensure effective perfusion of the 
heart. The cannulated heart was attached to the Langendorff apparatus and 
allowed to equilibrate for at least 15 min at a perfusion pressure of 80 mmHg 
with oxygen-saturated Krebs-Henseleit buffer (5% CO2 - 95% O2 gas mixture). 
Perfusion was monitored via an integrated force transducer connected to an 
amplifier and PowerLab system (AD Instruments, UK) (Figure 2.7). Baseline 
coronary flow (CF) was measured using a Doppler flow probe (Transonic 
Systems Inc., USA) connected to a PowerLab amplifier. Hearts were subjected 
to a 1 min stop-flow (global ischaemia) and following reperfusion CF was 
measured and recorded at the peak of reactive hyperaemia. After returning to 
baseline, perfusion was stopped and hearts were weighed and fixed in 10 % 
neutral buffered formalin solution (Sigma Aldrich, UK). Baseline flow was 
calculated by averaging CF for one minute prior to ischaemia. Peak-to-baseline 
ratio of CF was calculated by dividing peak CF by baseline CF. Additionally, total 
peak area was calculated from CF traces and time to return to baseline after 
global ischaemia was recorded.  
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Figure 2.7: Example of a mouse heart attached to the Langendorff 
perfusion system.  
The cannulated mouse heart is attached to a Langendorff apparatus and 
perfused with oxygen-saturated Krebs-Henseleit buffer. Coronary flow is 
measured using a Doppler flow probe.  
 
 
 
 
 
Flow probe
Cannula with 
heart attached
ECG electrodes
Heated water jacket
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2.15 Assessment of vascular function 
2.15.1 In vivo assessment of vascular function 
Vascular function was assessed in vivo during MAP measurement. As described 
in Section 2.13 animals were anaesthetised with 1.5% isoflurane in O2 and 
placed on a heating pad to maintain the body temperature at 37 ºC. Baseline 
MAP was determined by cannulating the left carotid artery with a heparin-saline-
filled polyethylene tube connected to a pressure transducer and MAP was 
recorded using CardioSOFT Pro (SonoMetrics Corporation, USA). For the 
assessment of vascular function, acetylcholine (Sigma Aldrich, UK) was 
dissolved in physiological saline and a final concentration of 5 µmol was given 
by intravenous injection. Vasodilation was assessed by recording the immediate 
drop in MAP upon drug injection and the time needed to return to baseline MAP 
was recorded.  
 
2.15.2 Ex vivo assessment of vascular function 
For the ex vivo assessment of vascular function in DIO and control mice, wire 
tension myography on aortic rings was carried out by Dr Elizabeth Sujkovic, 
MRC CSC Nitric Oxide Signalling Group. 
 
After sacrificing the animals by cervical dislocation, the thoracic aorta was 
dissected and placed in Krebs-Henseleit buffer. Connective tissue and fat were 
removed and the aorta cut into ring segments of 2-3 mm length. Special care 
was taken not to damage the endothelium during this procedure. Vascular rings 
were mounted in a wire tension myograph (Danish Myo Technology, Denmark), 
transferred to water-jacketed organ baths containing equilibrated Krebs-
Henseleit buffer (95% O2 - 5% CO2 at 37°C, pH 7.4) and connected to force 
transducers. Resting tension was gradually increased to the optimal level as 
determined by the programme (PowerLab, AD Instruments, UK). Viability and 
maximal contractile capacity of the vessels were assessed by depolarizing the 
ring segments with potassium chloride (KCl, 70 mM). Viable segments were 
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then contracted with phenylephrine (PE) (dose response curve ranging from 10-9 
to 10-5 M) and the integrity of the endothelium was determined by adding 
acetylcholine (ACh, 10-7 M). Endothelium-dependent vasodilation was assessed 
by precontracting arterial rings with PE (70% of KCl) and constructing 
cumulative relaxation curves of ACh (10-9 to 10-5 M). Endothelium-independent 
vasodilation was investigated using the NO donor sodium nitroprusside (SNP, 
10-10 to 10-7 M). 
 
 
2.16 Statistical analysis 
All quantitative analyses display either the mean value ± standard deviation (SD) 
or ± standard error of the mean (SEM). Statistical analysis was performed using 
unpaired Student’s t test when only two experimental groups were tested. One-
way analysis of variance (ANOVA) (with Bonferroni’s multiple comparison test) 
was used when more than two groups were tested. All statistical analysis was 
performed on Prism TM software (Version 5, GraphPad Software Inc., USA). 
Statistical significance was defined as p<0.05.  
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Chapter Three: Generation and 
characterisation of a diet-induced 
obese mouse model 
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3.1 Introduction 
The metabolic changes associated with insulin resistance manifest themselves 
in insulin-sensitive tissues like skeletal muscle, adipose tissue, or the liver and 
over years, chronic hyperglycaemia will lead to kidney damage, and other 
diabetic complications such as neuropathy, cardiomyopathy, atherosclerosis, 
and hypertension [85]. In addition, increased levels of FFA in the blood will 
overload muscle, liver and pancreatic β-cells with triglycerides and thus further 
add significantly to insulin resistance, dyslipidaemia and hyperinsulinaemia [46]. 
In the liver this ectopic lipid accumulation together with de novo lipogenesis will 
result in the development of nonalcoholic fatty liver disease, occurring in a wide 
spectrum of degrees ranging from the build-up of fat (hepatic steatosis) to 
inflammation often with fibrosis (non-alcoholic steatohepatitis) to cirrhosis and 
ultimately liver failure [174]. Furthermore, insulin resistance and the prolonged 
exposure to hyperglycaemia and dyslipidaemia will impair myocardial function 
leading to the development of diabetic cardiomyopathy and consequently 
increasing the risk of cardiovascular complications, which are the major cause of 
mortality in diabetic subjects [90].  
 
Given the consequences of the metabolic dysfunction in diabetes, it is essential 
to understand the pathogenesis and underlying mechanisms of insulin 
resistance and diabetic complications like cardiomyopathy or nephropathy. The 
use of animal models allows detailed characterisation at the molecular, cellular 
and tissue level usually not feasible in humans and therefore offers promising 
new insights into human diabetes [8]. Models of insulin resistance and T2DM 
can be generated either by genetic, chemical, or nutritional manipulation or 
occur by spontaneous mutations. The expression and severity of metabolic, 
hormonal and pathologic abnormalities of diabetes can vary in different animal 
models according to genetic background, nutrition, age, sex, species and even 
strain. Additionally, due to the complex nature of the disease, monogenic or 
pharmacologically induced models must be interpreted with care. For example, 
the ob/ob mouse displays many pathological features of diabetes and diabetic 
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cardiomyopathy, however, the relevance of this model to human insulin 
resistance syndromes, with intact leptin signalling pathways and diabetic 
cardiomyopathy is less straightforward. As an alternative to genetically modified 
animals, the high-fat diet fed mouse was introduced in an attempt to generate a 
model more relevant to human pathology, and has become a clinically relevant 
tool to study insulin resistance and metabolic changes [175]. Animals on a high 
fat diet will gradually develop visceral adiposity, hyperglycaemia and insulin 
resistance as well as hepatic steatosis. The diet-induced obese model in male 
C57BL/6 mice is a commonly used experimental tool to investigate the 
pathophysiology of nonalcoholic fatty liver disease as it resembles closely the 
development of the metabolic syndrome in humans [176]. However, the 
multitude of different high fat diets ranging from 20% to 60% calories from fat 
makes it difficult to compare data from different studies and therefore make 
conclusive interpretations. Additionally, the high variety in fat components i.e. 
animal-derived fats like lard or beef tallow or plant oils like corn or safflower oil 
will result in various diets with different fatty acid compositions. Thus, it is 
important to standardise and validate certain metabolic parameters when 
conducting a study using a high fat diet model. 
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3.2 Aim 
The aim of this chapter was to generate a diet-induced obesity mouse model by 
feeding male C57BL/6 mice a 45% lard-based high fat and characterise the 
resulting whole body, structural, and metabolic changes. Initially, animals were 
fed the high fat diet for 14 weeks and based on these results two further study 
periods with test time points at 8 and 11 weeks were introduced in order to gain 
information on the natural history of metabolic disturbances and pathological 
alterations of the diet-induced obesity model. Moreover, the most appropriate 
time point was determined to further study the molecular and genetic 
mechanisms of myocardial insulin resistance in humans and mice. The following 
points were investigated: 
 
1. Whole body diet effects looking at both body weight and organ weight 
gain 
 
2. Metabolic changes focusing on oral glucose tolerance, fasting glucose 
and insulin levels 
 
3. Histological effects of high fat diet in heart, liver and kidneys  
 96 
 
3.3 Results 
3.3.1 Generation of a high fat diet-induced obesity model 
Five week old male C57BL/6 mice were divided into two groups. The control 
group was fed a normal rodent chow whereas the other group was fed a 45% 
high fat, lard-based diet for 8, 11 and 14 weeks ad libitum (Table 3.1). After 6 
weeks, the high fat diet group was further divided into mice that responded to 
the high fat diet by significantly gaining weight (DIO) and those that did not (diet-
induced resistant, DIO-R). Body weight gain was recorded weekly and at the 
end of the feeding period, whole body and metabolic changes of diet-induced 
mice were investigated and compared to age-matched wild-type controls and 
ob/ob mice fed a normal rodent chow.  
 
In order to show the development of metabolic disturbances and pathological 
alterations results are presented in a chronological way, starting with 8 weeks of 
high fat diet feeding.  
 
Table 3.1: Composition of diets 
 
 Normal rodent chow High fat diet 
Protein 27.3% 20% 
Carbohydrate 61.2% 35% 
Fat 11.5% 45% 
 
     % of calories consumed 
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3.3.2  Effects of 8 weeks of high fat diet feeding 
3.3.2.1 Weight gain and body composition 
At baseline, no significant differences were found in initial body weight or tibia 
length between controls and DIO mice. After 8 weeks of high fat diet feeding 
70% of the mice were defined as DIO whereas 30% were defined as DIO-R. 
DIO mice had a significant increase in body weight gain of 19.86±1.49 g 
compared to 7.7±1.6 g body weight gain of age-matched wild-type controls 
(p<0.0005). Accordingly, visceral fat pad masses were significantly heavier than 
in the control mice (2.97±0.51 g vs. 0.58±0.11 g, p<0.0005) (Table 3.2). Body 
weight, heart weight and fat weight were corrected for differences in animal size 
using the tibia length of each animal. Both body weight-to-tibia ratio 
(1.511±0.04403 g/mm vs. 2.179±0.1180 g/mm, p<0.005) and fat weight-to-tibia 
ratio (30.81±5.354 mg/mm vs. 159.7±25.86 mg/mm, p<0.005) was significantly 
increased in DIO mice whereas no significant differences were observed in heart 
weight-to-tibia ratio (7.088±0.6001 mg/mm vs. 7.997±0.4751 mg/mm, p=ns) 
(Figure 3.1).  
 
 
Table 3.2: Body composition after 8 weeks 
 
 Control (n=5) DIO (n=7) DIO-R (n=3) 
Body weight (g)    
Initial body weight 20.7±1.25 20.57±1.84 20.0±0.50 
End body weight 28.4±1.14 40.43±2.07*** 33.0±0.00** 
Body weight gain 7.7±1.60 19.86±1.49*** 13.0±0.50** 
    
Fat pad masses (g) 0.58±0.11 2.97±0.51*** 2.62±0.67*** 
    
Tibia length (mm) 18.80±0.45 18.57±0.79 18.83±0.29 
  
** p<0.005; *** p<0.0005 
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Figure 3.1: Body composition analysis after 8 weeks of high fat diet 
feeding.  
(A) Body weight measured every two weeks in DIO (red) and control animals 
(black). (B) End body weight normalised to tibia length in g/mm. (C) Fat weight 
normalised to tibia length in mg/mm. (D) Heart weight normalised to tibia length 
in mg/mm. Data are expressed as mean±SD with n=5 for controls and n=7 for 
DIO mice. Data were analysed using Student’s t-test.ns, not significant; * 
p<0.05, ** p<0.005.  
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3.3.2.2 Fasting serum insulin, glucose levels and oral glucose 
tolerance  
Fasting serum insulin levels were measured in DIO after 8 weeks of high fat diet, 
age-matched ob/ob and control mice. DIO and ob/ob mice had increased fasting 
insulin levels compared to controls. However, a significant increase was only 
observed in ob/ob mice whereas only a trend was observed in DIO mice 
(2.67±0.56 ng/mL vs. 0.42±0.03 ng/mL for DIO vs. controls, p=ns and 3.98±0.68 
ng/mL vs. 0.42±0.03 ng/mL for ob/ob vs. controls, p<0.005) (Figure 3.2). 
 
Baseline fasting glucose levels in DIO after 8 weeks of high fat diet were slightly 
elevated compared to controls and age-matched ob/ob mice (10.80±1.05 
mmol/L vs. 7.40±1.27 mmol/L, p=ns for DIO vs. ob/ob and 10.80±1.05 mmol/L 
vs. 6.88±1.48 mmol/L, p=ns for DIO vs. control) (Figure 3.3 A). After an oral 
glucose challenge, blood glucose levels peaked after 30 min for all three groups 
and returned back to baseline after 120 min in 8 weeks DIO and age-matched 
ob/ob mice. In DIO mice an increase in the area under the curve (AUC) of 53% 
and an increase of 28% was observed in age-matched ob/ob mice compared to 
controls (p=ns) (Figure 3.3 A and B). 
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Figure 3.2: Effects of 8 weeks high fat diet on fasting serum insulin levels 
DIO mice.  
Serum insulin levels in DIO after 8 weeks of high fat diet, and compared to 
control and ob/ob mice on normal rodent chow using an insulin ELISA. Insulin 
levels of each animal were analysed in duplicates. Data are expressed as 
mean±SEM with n=3 for each group. Data were analysed using one-way 
ANOVA with Bonferroni’s multiple comparison. ns, not significant; ** p<0.005.  
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Figure 3.3: Oral glucose tolerance test (OGTT) in DIO animals after 8 
weeks of high fat diet feeding, age-matched ob/ob and control mice.  
(A) OGTT in DIO after 8 weeks of high fat diet (red) as well as age-matched 
ob/ob (blue) and control animals (black). Blood glucose levels at baseline, 30, 
60 and 120 min after an oral glucose load. (B) Area under the curve (AUC) 
analysis of OGTT. Data are expressed as mean±SEM with n=3 for each group. 
Data were analysed using one-way ANOVA with Bonferroni’s multiple 
comparison. ns, not significant. 
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3.3.3 Effects of 11 weeks of high fat diet feeding  
3.3.3.1 Weight gain and body composition 
After 11 weeks of high fat diet, 75% of the animals were defined as DIO. Over 
the feeding period, DIO mice had a significant increase in body weight gain 
(Figure 3.4) and a total body weight gain of 22.56±3.19 g compared to 
9.04±3.59 g of controls (p<0.0005). As already observed after 8 weeks of high 
fat diet feeding, visceral fat pad masses were significantly heavier than in the 
control mice (2.99±0.46 g vs. 0.70±0.33 g, p<0.0005) (Table 3.3). No significant 
differences were found in initial body weight or tibia length among the high fat 
diet and control groups. However, when examining the animals that did not 
respond to the high fat diet, lower initial body weight in this group was observed 
compared to DIO and control mice (17.52±2.105 g vs. 20.33±1.733 g, p<0.0005 
for DIO-R vs. control mice and 17.52±2.105 g vs. 19.51±1.629 g, p<0.005 for 
DIO-R vs. DIO). Body weight, heart weight and fat weight were corrected for 
differences in animal size using the tibia length of each animal. As seen after 8 
weeks, a significant increase in body weight-to-tibia (2.230±0.1520 g/mm vs. 
1.576±0.1337 g/mm, p<0.0005) and fat weight-to-tibia ratio (158.1±22.80 
mg/mm vs. 39.63±16.06 mg/mm, p<0.0005) was observed in DIO compared to 
age-matched controls. Additionally, significant changes in heart weight-to-tibia 
ratio were observed (7.492±0.7744 mg/mm vs. 6.844±0.6091 mg/mm, p<0.05) 
(Figure 3.4).  
 
Table 3.3: Body composition after 11 weeks 
 Control (n=18) DIO (n=30) DIO-R (n=10) 
Body weight (g)    
Initial body weight 20.33±1.73 19.51±1.63 17.52±2.11*** 
End body weight 28.8±2.73 42.07±3.15*** 33.70±2.87*** 
Body weight gain 9.04±3.59 22.56±3.19*** 16.18±3.47*** 
    
Fat pad masses (g) 0.70±0.33 2.99±0.46*** 2.37±0.54*** 
    
Tibia length (mm) 18.95±0.63 18.87±0.70 18.50±0.79 
  
*** p<0.0005 
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Figure 3.4: Body composition analysis after 11 weeks of high fat diet 
feeding.  
(A) Body weight measured every two weeks in DIO (red) and control animals 
(black). (B) End body weight normalised to tibia length in g/mm. (C) Fat weight 
normalised to tibia length in mg/mm. (D) Heart weight normalised to tibia length 
in mg/mm. Data are expressed as mean±SD with n=18 for controls and n=30 for 
DIO mice. Data were analysed using Student’s t-test. * p<0.05, *** p<0.0005.  
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3.3.3.2 Fasting serum insulin, glucose levels and oral glucose 
tolerance  
DIO mice after 11 weeks of high fat diet feeding and age-matched ob/ob mice 
had significantly increased serum insulin levels after a 12 h over night fast 
(2.27±0.37 ng/mL vs. 0.59±0.03 ng/mL, p<0.005 for DIO vs. controls and 
4.26±0.23 ng/mL vs. 0.59±0.03 ng/mL, p<0.0005 for ob/ob vs. controls) (Figure 
3.5). 
 
Serum glucose levels were measured in DIO after 11 weeks of high fat diet 
feeding, age-matched ob/ob and control mice after a 12 h over night fast. 
Baseline glucose levels were significantly elevated in DIO but not in ob/ob mice 
compared to controls (10.42±0.45 mmol/L vs. 7.17±0.40 mmol/L for DIO vs. 
controls, p<0.0005 and 7.95±0.78 mmol/L vs. 7.17±0.40 mmol/L for ob/ob vs. 
controls, p=ns). After an oral glucose challenge, impaired glucose tolerance in 
DIO was observed, evidenced by an increase in the AUC of 99% (p<0.0005) 
compared to only 34% in age-matched ob/ob mice (Figure 3.6). End glucose 
levels tended to be higher after 120 min in both DIO and ob/ob mice.  
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Figure 3.5: Effects of 11 weeks high fat diet on fasting serum insulin levels 
DIO mice.  
Serum insulin levels in DIO after 11 weeks of high fat diet, and compared to 
control and ob/ob mice on normal rodent chow using an insulin ELISA. Insulin 
levels of each animal were analysed in duplicates. Data are expressed as 
mean±SEM with n=3 for ob/ob and n=10 for DIO and controls. Data were 
analysed using one-way ANOVA with Bonferroni’s multiple comparison.  
* p<0.05; ** p<0.005, *** p<0.0005.  
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Figure 3.6: Oral glucose tolerance test (OGTT) in DIO animals after 11 
weeks of high fat diet feeding, age-matched ob/ob and control mice.  
(A) OGTT in DIO after 11 weeks of high fat diet (red) as well as age-matched 
ob/ob (blue) and control animals (black). Blood glucose levels at baseline, 30, 
60 and 120 min after an oral glucose load. (B) AUC analysis of OGTT. Data are 
expressed as mean±SEM with n=3 for controls and ob/ob mice and n=6 for DIO 
mice. Data were analysed using one-way ANOVA with Bonferroni’s multiple 
comparison. * p<0.05, ** p<0.005. 
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3.3.4  Effects of 14 weeks of high fat diet feeding 
3.3.4.1 Weight gain and body composition 
After 14 weeks of high fat diet feeding, 70.6% of the mice were defined as DIO. 
Animals showed a significant increase in body weight over the 14 weeks with a 
total body weight gain of 25.41±1.85 g compared to 12.22±1.56 g of the age-
matched control group (p<0.0005) (Table 3.4). Accordingly, visceral fat-pad 
masses were significantly increased compared to age-matched controls 
(2.71±0.31 g vs. 0.75±0.28 g, p<0.0005) (Figure 3.8). Upon visual examination 
of the whole body, a larger amount of white adipose tissue was observed around 
the heart of DIO mice compared to age-matched controls (Figure 3.7). No 
significant differences were found in initial body weight (20.80±1.64 g vs. 
20.74±1.61 g, p=ns) or tibia length (19.23±0.5250 mm vs. 18.88±0.3769 mm, 
p=ns) between high fat diet and control groups. Body, fat and heart weight was 
corrected for possible size differences between groups using tibia length. For all 
three parameters a significant difference was observed between DIO and age-
matched control mice.  
 
 
Table 3.4: Body composition after 14 weeks 
 
 Control (n=10) DIO (n=12) DIO-R (n=5) 
Body weight (g)    
Initial body weight 20.74±1.61 20.80±1.64 18.90±0.65 
End body weight 32.66±2.29 46.21±1.41*** 37.00±2.92** 
Body weight gain 12.22±1.56 25.41±1.85*** 18.10±2.68*** 
    
Fat pad masses (g) 0.75±0.28 2.71±0.31*** 2.46±0.61*** 
    
Tibia length (mm) 18.88±0.38 19.23±0.53 18.80±0.27 
 
** p<0.005; *** p<0.0005 
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         CTRL            DIO 
 
 
Figure 3.7: Visual comparison between DIO mouse after 14 weeks of high 
fat diet feeding and age-matched control mouse.  
(A) Whole body view of control mouse (left) and DIO mouse (right). (B and C) 
Close-up image of representative control and DIO heart. A larger amount of 
visceral adipose tissue is noticeable around the heart of the DIO mouse (C) 
compared to the control heart (B). Black arrows indicate visceral adipose tissue 
whereas black asterisks indicate subcutaneous adipose tissue. 
 
*
*
 109 
 
 
 
Figure 3.8: Body composition analysis after 14 weeks of high fat diet 
feeding.  
(A) Body weight measured every two weeks in DIO (red) and control animals 
(black). (B) End body weight normalised to tibia length in g/mm. (C) Fat weight 
normalised to tibia length in mg/mm. (D) Heart weight normalised to tibia length 
in mg/mm. Data are expressed as mean±SD with n=10 for controls and n=12 for 
DIO mice. Data were analysed using Student’s t-test. * p<0.05, *** p<0.0005.  
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3.3.4.2 Fasting serum insulin, glucose levels and oral glucose 
tolerance  
After 14 weeks of high fat diet serum insulin levels of DIO mice were significantly 
elevated after a 12 h fast compared to normal controls (3.394±0.7452 ng/mL vs. 
0.6628±0.1395 ng/mL, p<0.05) (Figure 3.9). Age-matched ob/ob mice had a 
significant increase in fasting serum insulin levels compared to controls and DIO 
mice (7.76±0.8492 ng/mL vs. 0.6628±0.1395 ng/mL, p<0.0005 for ob/ob vs. 
control) (Figure 3.9). 
 
Baseline glucose levels were significantly elevated in DIO compared to age-
matched controls (11.97±1.162 mmol/L vs. 8.733±0.4937 mmol/L, p<0.05) but 
not in ob/ob mice (7.067±0.2728 mmol/L vs. 8.733±0.4937 mmol/L, p=ns). After 
an oral glucose challenge the AUC was significantly increased by 224% 
compared to only 72% in age-matched ob/ob mice (p<0.0005 for DIO vs. 
controls and p<0.05 for ob/ob vs. controls) (Figure 3.10). Two hours after 
administration of the oral glucose bolus plasma glucose levels in DIO had not 
yet returned to the fasting baseline value (p<0.0005). 
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Figure 3.9: Effects of 14 weeks high fat diet on fasting serum insulin levels 
DIO mice.  
Serum insulin levels in DIO after 14 weeks of high fat diet, and compared to 
control and ob/ob mice on normal rodent chow using an insulin ELISA. Insulin 
levels of each animal were analysed in duplicates. Data are expressed as 
mean±SEM with n=9 for controls, n=8 for DIO and n=11 for ob/ob mice. Data 
were analysed using one-way ANOVA with Bonferroni’s multiple comparison. * 
p<0.05; *** p<0.0005.  
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Figure 3.10: Oral glucose tolerance test (OGTT) in DIO animals after 14 
weeks of high fat diet feeding, age-matched ob/ob and control mice.  
(A) OGTT in DIO after 14 weeks of high fat diet (red) as well as age-matched 
ob/ob (blue) and control animals (black). Blood glucose levels at baseline, 30, 
60 and 120 min after an oral glucose load. (B) Area under the curve (AUC) 
analysis of OGTT. Data are expressed as mean±SEM with n=6 for controls, n=4 
for DIO and n=3 for ob/ob mice. Data were analysed using one-way ANOVA 
with Bonferroni’s multiple comparison. ** p<0.005, *** p<0.0005. 
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3.3.4.3 Effects of high fat diet on of heart, liver and kidney after 14 
weeks 
The results described above clearly show that feeding a lard-based high fat diet 
will lead to a gradual increase in body weight, fasting insulin and glucose levels 
as well as to a gradual impairment of glucose tolerance with the most severe 
phenotype after 14 weeks of high fat diet. Since elevated blood glucose and 
insulin levels are associated with pathological changes in heart, liver and kidney 
of diabetic patients [85, 177, 178] the aim of this part of the study was to identify 
whether histopathological changes are associated with prolonged exposure to 
hyperglycaemia and hyperinsulinaemia. For this, histological sections from DIO 
animals fed the high fat diet for 14 weeks were examined.  
 
3.3.4.3.1 Phenotypical analysis of the heart 
In the development of diabetic cardiomyopathy structural changes such as 
cardiomyocyte hypertrophy, interstitial and perivascular fibrosis or increased 
matrix collagen have been described in the heart [13, 127]. To investigate 
whether high fat diet feeding lead to cardiomyocyte hypertrophy we looked at 
the heart weight as well as the nucleus-to-myocyte ratio in left ventricle of DIO 
mice after 14 weeks of high fat diet. Analysis of DIO hearts showed a significant 
increase in the heart weight-to-tibia ratio (8.520±0.9088 mg/mm vs. 
7.651±0.9925 mg/mm, p<0.05) compared to age-matched control hearts. 
Concomitantly to the increase in heart weight-to-tibia ratio a significant increase 
in interstitial fibrosis (measuring the total area of fibrosis) was observed in DIO 
mice compared to age-matched controls (7205±921 μm2 vs. 2891±416.7 μm2, 
p<0.05) (Figure 3.11). No significant differences in the nucleus-to-myocyte ratio 
were observed between DIO and control hearts.  
Furthermore, investigation of intramyocardial coronary arterioles in left ventricles 
of DIO mice showed inward muscular remodelling with slight thickening of the 
intimal layer after 14 weeks of high fat diet feeding. Interestingly, no coronary 
microvascular remodelling was observed in age-matched controls as well as 
age-matched ob/ob mice (Figure 3.12). 
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Figure 3.11: Histological analysis of the left ventricle in 14 weeks DIO and 
control animals.  
Histological sections of left ventricles from control (A and C) and DIO (B and D) 
mice. (A and B) Haematoxylin and eosin staining. Nuclei are stained in dark blue 
whereas eosinophilic structures like cytoplasm or intra- and extracellular 
proteins are stained in shades of red. (C and D) Picro-sirius red staining of 
collagen (red) on a pale yellow background (cardiomyocytes). Images were 
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taken at 40x magnification and are representative for n=4 in each group. Black 
scale bars indicate 50 µm. (E) Nucleus-to-myocyte ratio of left ventricular 
sections in DIO and control animals. Data are expressed as mean±SEM. (F) 
Quantification of interstitial fibrosis in μm2 in DIO and controls. Data are 
expressed as mean±SD. Data was analysed using Student’s t-test. ns, not 
significant, * p<0.05. Histological analysis was carried out by Dr Massimiliano 
Mancini, La Sapienza University, Rome. 
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Figure 3.12: Histological changes in small intramyocardial coronary 
arterioles in left ventricles of 14 weeks DIO mice.  
Representative histological sections of small arterioles in left ventricles of control 
(A) (n=4), DIO (B) (n=4) and ob/ob mice (C) (n=3) stained with haematoxylin 
and eosin using 40x magnification. Nuclei are stained in dark blue whereas 
eosinophilic structures like cytoplasm, intra- and extracellular proteins or red 
blood cells are stained in shades of red. Thickening of the medial area is present 
in DIO (B) but not in age-matched controls (A) and ob/ob mice (C). Black scale 
bars indicate 25 µm. Histological analysis was carried out by Dr Massimiliano 
Mancini, La Sapienza University, Rome. 
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3.3.4.3.2 Phenotypical analysis of the liver 
In the liver, lipid accumulation has been associated with high fat diet feeding [59, 
174, 176]. After 14 weeks of high fat diet livers of DIO mice were paler in colour 
and significantly increased in weight compared to age-matched controls 
(2364±461.0 mg vs. 1330±141.1 mg, p<0.005). Additionally, when correcting for 
size differences between animals, a significant increase in the liver weight-to-
tibia ratio was observed in DIO mice compared to controls (119±23.20 mg/mm 
vs. 68.39±7.384 mg/mm, p<0.005). 
 
Histological analysis of haematoxylin and eosin-stained liver sections revealed 
normal hepatic architecture in control animals whereas in DIO mice cytoplasmic 
lipid accumulation (microvescicular steatosis) but mostly distortion of the 
nucleus by lipid accumulation (macrovescicular hepatic steatosis) involving up to 
99% of hepatocytes was observed. Micro- and macrovescicular steatosis were 
present predominantly in the periportal and midzone areas. No signs of 
inflammation (steatohepatitis) were found in either control or DIO group (Figure 
3.13).  
 
3.3.4.3.3 Phenotypical analysis of the kidney 
Kidney weight in DIO animals was significantly increased compared to age-
matched control mice (181.3±11.17 mg vs. 144.0±22.61 mg, p<0.05). After 
correcting for size differences the kidney-to-tibia ratio in DIO mice was also 
significantly elevated (9.510±0.4840 mg/mm vs. 7.351±1.171 mg/mm, p<0.05). 
Analysis of DIO kidneys showed no substantial histological changes in 
haematoxylin and eosin as well as picro-sirius red-stained sections at low 
magnification (see Appendix B – Kidney Histology). At a higher magnification, 
kidneys from DIO animals showed a significant increase in glomerulus area 
compared to controls (16699± 879.6 µm2 vs.12703±261.0 µm2, p<0.05, n=3) 
(Figure 3.14).  
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Figure 3.13: Histological changes in liver after 14 weeks of high fat diet 
feeding.  
Histological sections of of livers from control (A and C) and DIO mice (B and D) 
stained with haematoxylin and eosin. (A and B) Low magnification (10x) of liver 
sections from control animals (A) and DIO mice (B). White scale bars indicate 
100 µm. (C and D) High magnification (40x) of liver tissue from control animals 
(C) and DIO mice (D). White scale bars indicate 50 µm. Nucei are stained dark 
blue whereas eosinophilic structures like cytoplasm are stained in shades of red. 
White droplets in DIO sections (B and D) indicate lipid accumulation. Images are 
representative for n=4 in each group. Histological analysis was carried out by Dr 
Massimiliano Mancini, La Sapienza University, Rome. 
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Figure 3.14: Histological changes of glomeruli in the kidney after 14 weeks 
of high fat diet feeding.  
Representative histological sections of a glomerulus from control animals (A) 
and DIO (B) stained with haematoxylin and eosin (20x magnification). Nuclei are 
shown in black and eosinophilic structures in shades of grey. Black scale bars 
indicate 50 µm. Results are representative for n=3 in each group. (C) 
Quantification of glomerulus area in kidneys from control and DIO mice. Data 
are expressed as mean±SEM and representative for n=3 in each group. More 
than 20 glomeruli were measured in each kidney using ImageJ software. Data 
was analysed using Student’s t-test. * p<0.05. 
 
B
C
CTRL DIO
0
5000
10000
15000
20000 *
G
lo
m
er
ul
us
 a
re
a 
( µ
m
2 )
n=3 n=3
A
 120 
 
3.4 Discussion 
The high fat diet fed C57BL/6 mouse is a recognised model of environmentally 
induced T2DM and obesity [160]. In our study animals were fed a high fat diet 
with 45% of its energy derived from fat for 8, 11 and 14 weeks to gain insight 
into the natural history of metabolic disturbances and pathological alterations of 
the DIO model but also to determine the most appropriate time point to study 
molecular and genetic mechanisms of myocardial insulin resistance. The main 
findings in the pilot study are that a lard-based high fat diet will gradually lead to 
an increase in the characteristic risk factors contributing to the development of 
insulin resistance and eventually T2DM. Microscopic changes in the liver and 
kidney exposed to hyperglycaemia and hyperinsulinaemia were observed and 
most importantly, previously not described coronary microvascular remodelling 
was observed in hearts of the diet-induced mouse models. 
 
3.4.1 Effects of high fat diet feeding on metabolic parameters 
The diet fed to our animals was a 45% fat diet with lard as the fat source. The 
term ‘high fat diet’ is used in the literature for various diets with different fatty 
acid compositions and this increases the variability of results and complicates 
comparisons between different studies [179]. Compared to the very high fat diet 
with 60% fat which is commonly used in obesity studies, the 45% fat diet has 
been suggested to mimic more a Western-style diet [161]. With 45% of calories 
deriving from fat, the relative caloric load of proteins and carbohydrates changes 
(20% from protein and 35% from carbohydrates) and therefore the 
macronutrient composition is different to the normal rodent chow used (11.5% 
from fat, 27.3% from protein and 61.2% from carbohydrates). With regards to 
the fatty acid profile, studies have shown that diets based on polyunsaturated 
omega-3 fatty acids have a beneficial effect on body composition and insulin 
action and therefore might decrease cardiovascular morbidity and mortality 
[180]. Diets based on lard have comparable quantities of saturated and 
monounsaturated fatty acids. Compared to other fat sources like coconut fat 
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(saturated fatty acids), olive oil (monounsaturated fatty acids), or fish oil 
(polyunsaturated fatty acids) lard is known to induce the typical high fat diet 
phenotype [179] and together with the altered macronutrient composition will 
lead to the development and progression of metabolic changes associated with 
insulin resistance and T2DM. However, as the human diet is more complex, a 
diet rich in carbohydrates together with fat might be closer to the human 
(Western) diet than a high fat diet alone [163]. 
 
Despite identical backgrounds, in our experiments on average only 73% of the 
mice significantly gained weight whereas the remaining 27% were able to 
maintain a normal body weight. This phenomenon has been previously reported 
in a study by Enriori et al. in which these animals were defined as having body 
weights ranging between the average ± 3 standard deviations of the control 
group and were termed diet-induced obese resistant (DIO-R) [167]. Enriori and 
co-workers studied leptin resistance in the brain by feeding C57BL/6 mice a 
45% high fat diet for 20 weeks. They found that the only predictor of DIO-R 
versus DIO mice was the lower initial body weights at 6 weeks of age, which 
significantly correlated to final body weights [167]. In our study, a significant 
difference in initial body weight between DIO-R and DIO mice was observed in 
the 11 weeks high fat diet group which is in accordance with their finding. Mice 
which were defined as DIO-R in our study had a significantly lower initial body 
weight compared to both controls and DIO mice. Additionally, Enriori and co-
workers showed that calorie intake in DIO-R animals decreased significantly 
from the fifth week until the end of the experiment [167]. It would be of interest to 
further investigate the underlying mechanisms of this phenomenon of resistance 
to high fat diet and therefore gain further insight into why some people are more 
prone to obesity than others and which genetic and environmental factors are 
associated with the development of obesity.  
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High fat diet feeding resulted in a gradual increase in the characteristic 
metabolic features associated with T2DM with the most prominent metabolic 
changes in DIO mice after 14 weeks of high fat diet (Table 3.5). After 14 weeks 
of high fat diet animals had significantly increased serum insulin levels and a 
severely impaired oral glucose tolerance compared to age-matched ob/ob mice 
and controls. Both DIO groups after 8 and 11 weeks of high fat diet showed 
elevated serum insulin levels but only in 11 weeks DIO mice insulin levels were 
significantly increased compared to age-matched controls. Although the insulin 
levels are similar between the 8 and 11 weeks groups, only a trend was 
observed in 8 weeks DIO mice which can be explained by the smaller sample 
size and larger variation between animals compared to the 11 weeks DIO group. 
Similarly, the response of 11 weeks DIO mice to an oral glucose load was an 
intermediate between the 8 and 14 weeks DIO mice and both 8 and 11 weeks 
DIO mice showed poor glucose disposal. Moreover, fasting serum glucose 
levels in 11 and 14 weeks DIO were significantly increased compared to age-
matched ob/ob mice and controls.  
 
 
Table 3.5: Summary of metabolic changes in DIO relative to age-matched 
controls 
 
 8 weeks 11 weeks 14 weeks 
Fasting insulin ↑ (ns) ↑ (**) ↑ (*) 
Fasting glucose ↑ (ns) ↑ (***) ↑ (*) 
OGTT (AUC, % increase) 53 (ns) 99 (**) 224 (***) 
 
OGTT: oral glucose tolerance test; AUC: area under the curve;  
↑: increase; ns, not significant; * p<0.05, ** p<0.005, *** p<0.0005 
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Our results are in line with the metabolic data from other recently published 
studies [74, 75, 166]. Park et al. showed that high fat diet feeding (55% fat) 
resulted in a significant increase in body weight and whole-body fat mass 
already after 1.5 weeks and an increase in basal plasma insulin levels after 3 
and 6 weeks of high fat diet feeding [75]. These results are further supported by 
a publication of Wright and co-workers in which no changes in fasting serum 
glucose and triglyceride levels but modestly increased insulin levels and a mildly 
impaired intraperitoneal glucose tolerance was observed after only two weeks 
on a 45% high fat/high sucrose diet [74]. The observed changes in fasting serum 
glucose levels in DIO mice represent the counterpart of impaired fasting glucose 
observed in the early phases of human T2DM. A study assessed the 
significance of glycaemic control for micro- and macrovascular complications in 
subjects with late-onset diabetes [181] and showed that hyperglycaemia is likely 
to be a stronger risk factor for microvascular complications than it is for 
cardiovascular disease [181]. However, numerous reports have also described 
the importance of hyperglycaemia in the development and progression of 
diabetic macrovascular disease in T2DM [182-187] and a correlation of both 
fasting and postchallenge hyperglycaemia with cardiovascular risk [186]. For 
example, subjects with impaired glucose tolerance have about a twofold 
increase in the risk of macrovascular disease including coronary heart disease 
and stroke compared to healthy subjects [188, 189] and higher CV mortality 
compared with individuals with impaired fasting glucose [190]. Moreover, in a 
study on Finnish patients with T2DM at baseline, high fasting plasma glucose 
predicted CHD events [191], and high fasting plasma glucose and HbA1 
predicted fatal and nonfatal stroke [192]. This study, similar to the UKPDS study 
[193], also demonstrated that conventional CV risk factors like dyslipidaemia, 
blood pressure or smoking are important contributors to macroangiopathic 
complications in patients with T2DM. 
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3.4.2 Effects of high fat diet feeding on body composition and 
individual organs  
At the whole body level the 14 weeks DIO group had an average body weight 
gain of about 25 g concomitant with a significant increase in visceral fat pad 
mass and organ weight. Although a gradual increase in body weight from 11 to 
14 weeks of high fat diet was observed, visceral fat pad mass did not increase. 
This could be explained by the fact that not only visceral but also subcutaneous 
fat mass increased as shown in Figure 3.7 and thus further contributed to the 
increase in body weight. It is important to note that a large amount of ectopic fat 
around the kidneys and heart and within the liver was observed, which can 
impair the organ function by either physical compression or the secretion of 
locally acting substances by periorgan fat cells [194]. Also, accumulation of fat 
within the organ could lead to cell dysfunction and cell death (lipotoxicity) [194].  
 
Our results show that together with the gradual development of visceral 
adiposity accumulation of fat droplets in the liver was observed. Livers of DIO 
animals after 14 weeks of high fat diet were paler in colour which suggests lipid 
accumulation and liver weight was significantly increased. Histological analysis 
revealed micro- and macrovescicular steatosis with up to 99% of the 
hepatocytes being affected which is the basis of NAFLD. Kirpich et al. showed 
that a high fat diet consumed for 8 weeks results in obesity with insulin 
resistance and NAFLD [174]. Similar to our findings, they observed a 2.4 fold 
increase in insulin levels but no differences in glucose concentrations [174]. 
Additionally, de Meijer and co-workers recently demonstrated that the 
development of hepatic steatosis in the C57BL/6 high fat diet mouse model 
directly results from an increased fat intake that is independent from the amount 
of calories consumed [176]. Similar to the diet consumed by obese and NAFLD 
patients, their experimental diet contained predominantly saturated fat and only 
small amounts of polyunsaturated fat. They hypothesised that saturated fatty 
acids may promote endoplasmatic reticulum stress and hepatocyte injury 
resulting in hepatic dysfunction in rodents [176]. 
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Similarly, the kidneys of DIO animals were surrounded by large amounts of fat 
and showed a significant increase in weight compared to controls. It has been 
shown that obese rabbits also have larger kidneys as well as large fat deposits 
in the renal sinus but no fat accumulation in the kidney parenchyma [194]. 
Furthermore, structural renal changes like glomerulosclerosis, interstitial fibrosis 
and small vessel disease have been previously demonstrated in other mouse 
models of T2DM such as the FVB db/db mouse as well as in human diabetes 
[195-197]. After 14 weeks of high fat diet histological changes in DIO kidneys 
and signs of diabetic nephropathy were expected. Kidney sections from DIO 
mice showed a significant increase in glomerulus area compared to controls 
indicating glomerular hypertrophy. These results are supported by a study by 
Wei et al. which has shown glomerular hypertrophy and hyperfiltration in high fat 
diet fed C57BL/6 mice [198]. Glomerular hypertrophy is associated with diabetic 
nephropathy and is often observed along with hyperfiltration and 
hyperglycaemia in T1DM whereas in T2DM it is also possible that other factors 
like insulin, lipids or leptin may play a role [198]. Studies have shown that 
glomerular volume correlates with fasting insulin levels in non-diabetic patients 
with glomerulosclerosis [199] and mesangial expansion in obese Zucker rats 
[200] which suggests that hyperinsulinaemia in T2DM may evoke glomerular 
hypertrophy.  
 
In human hearts, Szczepaniak et al. have shown a strong association between 
obesity and increased myocardial lipid accumulation, which correlated with left 
ventricular hypertrophy and systolic dysfunction [201]. This has been confirmed 
in models of obesity like the ob/ob mouse and Zucker diabetic fatty rat [202, 
203]. In Zucker diabetic fatty rats a poor systolic function was observed whereas 
systolic function was only marginally affected in ob/ob mice. However, a clear 
association between intramyocardial lipid accumulation and diastolic dysfunction 
was observed in ob/ob mice [202]. Besides functional changes, characteristic 
features in the development of diabetic cardiomyopathy are also structural 
changes at the macroscopic and microscopic levels such as myocyte 
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hypertrophy, perivascular fibrosis, increased quantities of matrix collagen, or 
cellular triglyceride [13]. To investigate myocyte hypertrophy we examined the 
heart weight as well as the nucleus-to-myocyte ratio in DIO hearts. We observed 
a significant increase in the corrected heart weight in DIO mice after 11 and 14 
weeks of high fat feeding but no significant changes in the nucleus-to-myocyte 
ratio after 14 weeks of high fat diet were observed compared to controls (a trend 
to a higher ratio was observed). However, picro-sirius red staining revealed a 
significant increase in interstitial fibrosis after 14 weeks of high fat diet compared 
to age-matched controls. Park et al. also support this finding showing a 
significant increase in heart weight of C57BL/6 mice fed a 55% high fat diet only 
after 20 weeks [75] whereas a significant increase in cardiomyocyte cross-
sectional area was observed after 6 months of 45% high fat diet feeding in FVB 
mice [204]. The duration of high fat diet feeding could in part explain why we did 
not observe a significant change in nucleus-to-myocyte ratio. However, in 
genetically induced mouse models of diabetes such as the CIRKO or the 
dominant negative form of PI3K mouse increased replacement/interstitial fibrosis 
as well as the development of cardiac hypertrophy was observed [205].  
 
A novel and previously unrecognised finding in our pilot study was the presence 
of inward muscular remodelling with slight intimal thickening of coronary 
arterioles after 14 weeks of high fat diet. Microvascular remodelling is defined as 
alterations in vessel morphology due to restructuring of VSMC and extracellular 
matrix components [93]. It has been extensively studied in patients with 
hypertension [104] and been reported in patients with diabetes [100, 206] as 
well as various animal models of hypertension and diabetes [207-209]. For 
T2DM, Rizzoni et al. showed an increased media-to-lumen ratio in 
subcutaneous small arteries in T2DM patients [100] and Schofield et al. 
demonstrated abnormalities in myogenic responsiveness in small arteries of 
diabetic patients which they suggest may explain the observed structural 
alterations [206]. In a drug-induced rat model of T1DM, Fukuda et al. 
demonstrated the presence of vascular hypertrophy and remodelling in aortas 
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[210]. In addition, medial thickening and increased media-to-lumen ratio has 
been observed in the mesenteric microvasculature of STZ-treated rats [211, 
212] as well as the GK rat, a spontaneously diabetic, non-obese and 
normotensive rat model of T2DM [93]. Furthermore, it has been shown that 
coronary risk factors like diabetes, hypertension, smoking or hyperlipidaemia 
promote the development of structural and functional changes associated with 
coronary microvascular remodelling [92]. For example, the spontaneously 
hypertensive rat (SHR) is characterised by insulin resistance, hyperinsulinaemia, 
dyslipidaemia, and hypertension [213] and is therefore commonly used to study 
coronary microvascular remodelling in the context of hypertension [214]. 
Coronary microvascular remodelling has also been described in patients with 
HCM, a disease with increased susceptibility to cardiac arrhythmias and risk of 
sudden death caused by sarcomere protein gene mutations. Despite its clinical 
relevance, to the best of our knowledge there is no valid rodent model to study 
microvascular remodelling in the context of HCM, which fully mimics the 
histopathological and phenotypical characteristics of the disease. Attempts to 
generate a genetic mouse model of HCM, like the MHC403/+ have only been 
partially successful. The MHC403/+ mouse carries a missense mutation in codon 
403 (Arg403Gln) of the myosin heavy chain (MHC) gene which is associated 
with a particularly severe HCM histopathology [215, 216]. Wolf et al. showed 
characteristic features of the disease like LV hypertrophy, myocyte fibrosis and 
disarray [217], however, in collaboration with our group it has been shown that 
despite the histopathological features of HCM, this mouse model does not show 
the characteristic microvascular remodelling described in humans (unpublished 
observations by Prof G. d’Amati, La Sapienza University, Rome). Despite the 
fact that the microvascular remodelling observed in our DIO model is most likely 
due to the effects of high fat diet, it is the first model that phenotypically clearly 
mimics the microvascular remodelling observed in the hearts of patients with 
arterial hypertension or HCM.  
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Interestingly, coronary microvascular remodelling was only observed in DIO 
hearts whereas it was completely absent in age-matched ob/ob hearts. It has 
been recently suggested that a linear relationship between hyperglycaemia and 
microvascular complications exists [94] and that glycaemic control might 
influence the degree of coronary microangiopathy [108]. Since hyperglycaemia 
is subsiding after 14 to 16 weeks of age in ob/ob mice [218], we also looked at 
coronary small vessel morphology in 12 week old, hyperglycaemic and 
hyperinsulinaemic ob/ob mice but again, no remodelling was observed. Since 
the development of metabolic changes and thus T2DM is highly genetically 
determined in ob/ob mice it is difficult to compare histomorphometrical results in 
DIO and ob/ob mice and thus be able to exclude hyperglycaemia and 
hyperinsulinaemia as contributing factors to coronary microvascular remodelling.  
 
Furthermore, observations in our group have shown that the microvascular 
remodelling in DIO hearts is clearly distinguishable from the strong muscular 
outward remodelling of coronary small vessels seen in hearts of SHR. Although 
the structural characteristics suggest that microvascular remodelling in DIO 
hearts is independent of hypertension, this still needs to be confirmed and 
further studies are needed to ascertain whether the microvascular remodelling is 
also present after the two shorter periods of high fat diet feeding. With this novel 
finding our model provides the possibility to directly study potential links between 
metabolic and coronary microvascular changes.   
 
In conclusion, our results demonstrate that a period of 14 weeks of high fat diet 
results in an extreme phenotype of clinical obesity whereas 11 weeks DIO mice 
represent a good model to study the early onset of T2DM. Our high fat diet 
model has clear advantages over the use of the leptin-deficient ob/ob mouse. 
Firstly, our high fat diet model allows the study of pathophysiological changes 
associated with both environmental and genetic risk factors of T2DM compared 
to the ob/ob mouse model in which the onset of symptoms is highly determined 
by genetic factors alone. Secondly, in contrast to normal basal blood glucose 
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levels in the ob/ob mouse model, our model exhibits both fasting and post-
prandial hyperglycaemia as well as the majority of the characteristic features of 
patients with genetic predisposition to develop T2DM when they become obese. 
Finally, only our model shows the presence of coronary microvascular 
remodelling which allows one to study the link between metabolic and coronary 
microvascular changes.  
 
Based on the results from this pilot study, DIO mice after 11 weeks of high fat 
diet feeding were chosen as the most appropriate model to further characterise 
and study genetic and molecular mechanisms of myocardial insulin resistance 
and microvascular remodelling.  
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Chapter Four: Myocardial insulin 
resistance and coronary microvascular 
remodelling in DIO 
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4.1 Introduction 
Hyperglycaemia, hyperinsulinaemia and hyperlipidaemia promote the 
development of pathological changes in cardiac structure and cardiomyocyte 
ultrastructure and function [13]. It has been shown that the heart of diabetic 
patients is insulin resistant [70] resulting in a decrease in glucose utilisation 
possibly due to an impaired insulin signalling pathway [72]. Moreover, diabetes 
markedly affects the function of the cardiovascular system, both in the 
microcirculation as well as in large conduit arteries supplying vital organs such 
as the heart, brain, and kidney [219] leading to micro- and macrovascular 
complications. Despite different mechanisms contributing to the complex 
pathophysiology of chronic T2DM complications, dysregulation of vascular 
function and structure is a common finding [93]. Vascular and endothelial 
dysfunction play an important role in the development of atherosclerosis and 
other CVDs in T2DM. Additionally, vascular remodelling has been shown in 
small arteries of patients with diabetes or left ventricular hypertrophy [93, 220, 
221] as well as in various animal models of hypertension and diabetes [207, 
208, 210]. Vascular remodelling is associated with alterations in the vessel 
morphology leading to an increase in the medial area [93]. Although the 
phenomenon has been extensively researched in hypertension [104], the 
potential mechanisms of vascular remodelling in diabetes are not fully 
understood. Furthermore, the presence of vascular remodelling in the coronary 
microcirculation and the resulting coronary microvascular dysfunction has been 
observed in different diseases like T2DM, hypertension, or hypertrophic 
cardiomyopathy [92] and may lead to myocardial ischaemia and fibrosis as well 
as to an increased risk of myocardial infarction. In the previous chapter we have 
described the coronary microvascular remodelling occurring in our high fat diet 
induced model of insulin resistance which resembles microvascular remodelling 
seen in patients with HCM. However, no microvascular remodelling was 
observed in hearts of the leptin-deficient ob/ob mouse both in the presence (at 
12 weeks of age, data not shown) or absence of hyperglycaemia (above 16 
weeks of age; [218]). At this stage it is not clear whether the described coronary 
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microvascular remodelling in DIO hearts is due to structural and functional 
changes caused by hypertension, which is often present in diabetic patients 
[178]. 
 
 
4.2 Aims 
Exposure to metabolic abnormalities like hyperglycaemia and hyperinsulinaemia 
due to diet-induced obesity leads to functional and structural changes in the 
cardiovascular system as well as the myocardium itself. To assess molecular 
and genetic mechanisms of myocardial insulin resistance and investigate our 
novel finding of microvascular remodelling in DIO hearts, the following aims 
were addressed: 
 
1. Investigate coronary microvascular remodelling in DIO 
 
2. Investigate cardiac and endothelial function in DIO 
 
3. Examine gene expression profile in left ventricles of DIO and control mice 
by conducting a genome-wide microarray study  
 
4. Examine myocardial insulin signalling in DIO mice 
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4.3 Results 
4.3.1 Metabolic parameters after 11 weeks of high fat diet 
feeding  
As described in Chapter 3, DIO mice after 11 weeks of high fat diet feeding 
show elevated fasting serum insulin and glucose levels as well as a significantly 
impaired tolerance to an oral glucose load (see Figure 3.5 and Figure 3.6). In 
addition, serum FFA concentrations as well as baseline serum leptin levels were 
investigated as additional markers of insulin resistance and T2DM. Leptin is 
produced by adipose tissue and blood leptin concentrations have been shown to 
correlate with body weight and the amount of adipose tissue [222]. An increase 
in adipose tissue mass results in increased leptin levels in serum. After 11 
weeks of high fat diet, serum leptin levels quantified by ELISA were significantly 
increased in DIO mice compared to age-matched controls (59.86±5.417 ng/mL 
vs. 4.528±0.7614 ng/mL, p<0.0005, n=11-13) and positively correlated with 
visceral fat mass (r= 0.91, p<0.005) (Figure 4.1 A and B). Ob/ob mice were used 
as additional controls due to their leptin-deficiency. No leptin levels were 
detected in serum samples of ob/ob mice (-0.02033±0.01827 ng/mL vs. 
4.528±0.7614 ng/mL, p<0.0005, n=6) (Figure 4.1 A).  
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Figure 4.1: Serum leptin levels in DIO and age-matched ob/ob and control 
mice.  
(A) Serum leptin levels in DIO, age-matched controls and ob/ob mice. (B) 
Correlation between serum leptin and visceral fat mass in DIO (red dots) and 
age-matched controls (black dots). Data are expressed as mean±SEM for three 
independent experiments with n=11for controls, n=13 for DIO mice and n=6 for 
ob/ob mice. Data were analysed using one-way ANOVA with Bonferroni’s 
multiple comparison for serum leptin levels. To test for correlation linear 
regression analysis was performed. ns, not significant; *** p<0.0005. 
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To determine whether high fat diet feeding is associated with the previously 
described increase in FFA in the blood [223] FA concentrations in serum were 
measured in DIO after 11 weeks of high fat diet, compared to age-matched 
controls and ob/ob mice. FA concentrations in ob/ob mice were significantly 
increased compared to age-matched controls and DIO mice (1.342±0.1848 
nmol/μL vs. 0.5626±0.06857 nmol/μL vs. 0.8437±0.08455 nmol/μL; p<0.05, 
n=15 for ob/ob vs. controls and p<0.0005, n=15-25 for DIO vs. ob/ob) (Figure 
4.2). In contrast, baseline levels in DIO mice were slightly lower compared to 
control mice but did not reach statistical significance (0.5626±0.06857 nmol/μL 
vs. 0.8437±0.08455 nmol/μL; p=ns, n=15-25) (Figure 4.2). All metabolic 
parameters are summarised in Table 4.1. 
 
 
 
Figure 4.2: Fatty acid concentrations in serum of DIO mice, age-matched 
ob/ob and control mice at baseline.  
Serum fatty acid concentrations in DIO, age-matched controls and ob/ob mice. 
Data are expressed as mean±SEM for three independent experiments with 
n=15 for control mice, n=25 for DIO and n=12 for ob/ob mice. Data were 
analysed using one-way ANOVA with Bonferroni’s multiple comparison. ns, not 
significant; * p<0.05 and *** p<0.0005. 
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Table 4.1: Summary of metabolic parameters in DIO mice after 11 weeks of 
high fat diet (HFD) relative to age-matched controls 
 
 11 weeks HFD 
Fasting Insulin ↑ (**) 
Fasting Glucose ↑ (***) 
OGTT (AUC, % increase) 99 (**) 
Fasting Leptin ↑ (***) 
Serum Fatty Acids ↓ (ns) 
 
OGTT: oral glucose tolerance test; AUC: area under the curve 
↑: increase; ↓: decrease; ns: not significant; ** p<0.005, *** 
 p<0.0005 
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4.3.2 Coronary microvascular remodelling in DIO mice 
As shown in Chapter 3 histological analysis of DIO mice hearts after 14 weeks 
of high fat diet showed a significant increase in interstitial fibrosis compared to 
age-matched controls (Figure 3.11). Additionally, a previously unrecognised 
inward muscular remodelling with intimal thickening was demonstrated in 
intramyocardial coronary arterioles of the left ventricles in DIO mice after 14 
weeks of high fat diet feeding but not in age-matched controls or ob/ob mice with 
or without hyperglycaemia (Figure 3.12).  
 
To investigate the onset of microvascular remodelling, small coronary arterioles 
and medial area were measured in DIO mice after 8 and 11 weeks of high fat 
diet feeding. At both time points inward muscular remodelling with a slightly 
thickened intima was observed. Histomorphometrical analysis showed a 
significant increase in medial area compared to control mice after both 8 and 11 
weeks of high fat diet feeding (3358±459.2 μm2 vs. 879.9±89.08 μm2 for 8 
weeks, p<0.0005) (Figure 4.3) (2852±247.8 μm2 vs. 1499±221.4 μm2 for 11 
weeks, p<0.0005) (Figure 4.4) . However, a significant increase in the media-to-
lumen ratio was observed only in 11 weeks DIO compared to age-matched 
controls (3.966±0.5309 vs. 2.771±0.3469, p=ns for 8 weeks DIO vs. control and 
2.791±0.2530 vs. 1.617±0.1648, p<0.005 for 11 weeks DIO vs. control) (Figure 
4.3 and Figure 4.4).  
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Figure 4.3: Effects of high fat diet on coronary small vessel morphology 
after 8 weeks of HFD.  
(A) Histological sections of small arterioles (circled by dashed line) in left 
ventricles of control (left) and 8 weeks DIO mice (right) stained with 
haematoxylin and eosin. Nuclei are stained in dark blue whereas eosinophilic 
structures like cytoplasm, intra- and extracellular proteins or red blood cells are 
stained in shades of red. Images were taken using 40x magnification. Black 
scale bars indicate 25 µm. (B and C) Histomorphometrical analysis of 
intramyocardial arterioles. (B) Quantification of medial area in DIO and control 
mice. (C) Quantification of media-to-lumen area in DIO and control mice. Data 
are expressed as mean±SEM for 3 animals per group and at least 6 vessels per 
heart. Data were analysed using Student’s t-test. ns, not significant and *** 
p<0.0005. Histomorphometrical analysis was carried out by Dr Massimiliano 
Mancini, La Sapienza University, Rome. Data analysis was performed by 
Christina Kleinert. 
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Figure 4.4 Effects of high fat diet on small vessel morphology after 11 
weeks of HFD.  
(A) Histological sections of small arterioles (circled by dashed line) in left 
ventricles of control (left) and 11 weeks DIO mice (right) stained with 
haematoxylin and eosin. Nuclei are stained in dark blue whereas eosinophilic 
structures like cytoplasm, intra- and extracellular proteins or red blood cells are 
stained in shades of red. Images were taken using 40x magnification. Black 
scale bars indicate 25 µm. (B and C) Histomorphometrical analysis of 
intramyocardial arterioles. (B) Quantification of medial area in DIO and control 
mice. (C) Quantification of media-to-lumen area in DIO and control mice. Data 
are expressed as mean±SEM for n=4 for control and n=8 for DIO mice and at 
least 6 vessels per heart. Data were analysed using Student’s t-test. ** p<0.005 
and *** p<0.0005. Histomorphometrical analysis was carried out by Dr 
Massimiliano Mancini, La Sapienza University, Rome. Data analysis was 
performed by Christina Kleinert. 
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4.3.3 Cardiovascular function in DIO mice  
4.3.3.1 Stroke volume and ejection fraction 
To investigate the effect of high fat diet feeding on cardiac function in DIO mice 
we initially aimed to use echocardiography, a commonly used technique to 
investigate cardiac function in murine models [224-226]. However, due to the 
increased amount of pericardial fat in DIO mice (see Figure 3.7) we failed to 
obtain reliable data (data not shown). Thus, cardiac MRI was used as an 
alternative method to investigate stroke volume and ejection fraction in DIO mice 
after 11 weeks of high fat diet feeding and age-matched controls. Long-axis MRI 
images showed a change in axial orientation of the DIO hearts probably due to 
the increase in pericardial fat which might also explain why we failed obtain 
reliable data with echocardiography (Figure 4.5). Stroke volume was calculated 
by subtracting mean left ventricular end-systolic volume (LVESV) from mean left 
ventricular end-diastolic volume (LVEDV) and ejection fraction by dividing stroke 
volume by LVEDV. Analysis showed that there was no difference in stroke 
volume (30.87±5.776 µL vs. 27.12±2.680 µL, p=ns) (Figure 4.6 A) or ejection 
fraction (70.70±7.501% vs. 70.92±3.473%, p=ns) between DIO and age-
matched controls (Figure 4.6 B).  
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      CTRL         DIO 
 
 
Figure 4.5: Cardiac function in DIO and controls using MRI.  
(A and B) Long-axis scout images of control (A) and DIO (B) heart. Red line 
indicates axial orientation of the heart. DIO hearts had a different axial 
orientation compared to control hearts caused by increased deposits of white 
adipose tissue in the thorax. (C and D) Examples of short-axis MRI images of 
control (C) and DIO (D) heart at end diastole. (E and F) Examples of short-axis 
MRI images of control (E) and DIO (F) heart at end systole. Cardiac MRI was 
carried out by Dr Marzena Wylezinska-Arridge and Dr Jordi Lopez Tremoleda 
(MRC CSC Biological Imaging Centre). Data analysis was performed by 
Christina Kleinert. 
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Figure 4.6: Stroke volume and ejection fraction in 11 weeks DIO and age-
matched controls.  
Cardiac MRI was used to measure left ventricular end systolic and end diastolic 
volumes. No significant changes were observed in stroke volume (A) as well as 
ejection fraction (B) in DIO animals compared to age-matched controls. Data are 
expressed as mean±SD for 7 animals per group. Data were analysed using 
Student’s t-test. ns, not significant.  
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4.3.3.2 Mean arterial pressure (MAP) and coronary flow 
To determine whether DIO mice develop hypertension with high fat feeding, 
MAP pressure was measured in the left carotid artery using a heparin-saline-
filled polyethylene tube connected to a pressure transducer. There was no 
difference in mean arterial pressure between DIO and control mice (88.00±3.546 
mmHg vs. 87.14±4.914 mmHg, p=ns) (Figure 4.7).  
 
 
 
Figure 4.7: MAP in DIO and age-matched control mice.  
MAP was measured invasively in the left carotid artery. No significant changes 
were observed between DIO and control mice. MAP is expressed as 
mean±SEM for 7 animals per group. Data were analysed using Student’s t-test. 
ns, not significant. 
 
 
  
CTRL DIO
0
20
40
60
80
100
ns
M
AP
 (m
m
Hg
)
n=7 n=7
 144 
 
To further investigate the effect of high fat diet on cardiac function in DIO, 
coronary flow and coronary flow reserve after an ischaemic event were 
measured using ex vivo Langendorff perfusion. This technique is commonly 
used in physiological research and allows the examination of heart rate, 
contractile strength, and vascular effects ex vivo. Baseline and peak coronary 
flow as well as time to return to baseline flow were recorded (Figure 4.8 A). 
Analysis of Langendorff data resulted in no difference in peak-to-baseline ratio 
after a 60 seconds ischaemic event between DIO and control animals 
(4.126±0.1491 vs. 4.207±0.3681, p=ns) (Figure 4.8 B). However, when looking 
at total peak area (area under the curve) (82.40±12.15 vs. 48.45±3.985, p<0.05) 
and time to return to baseline flow (144.5±30.44 sec vs. 57.60±10.49 sec, 
p<0.05), a significant increase was observed in DIO hearts compared to controls 
(Figure 4.8 C and D) which suggests that high fat diet does not have an effect 
on the amount of ischaemia-induced vasodilation but on the duration. 
 
A summary of functional and histological changes after 11 weeks of high fat diet 
feeding is shown in Table 4.2. 
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Figure 4.8: Effects of high fat diet on coronary flow. 
(A) Representative trace of coronary flow in control (black) and DIO hearts (red). 
(B) Quantification of peak-to-baseline ratio of DIO and control hearts. (C) Total 
peak area (AUC) after a 1 min ischaemic event in DIO and control hearts. (D) 
Time to return to baseline coronary flow after a 1 min ischaemic event in DIO 
and control hearts. Data are expressed as mean±SD for 6 animals in each 
group. Data were analysed using Student’s t-test. ns, not significant; * p<0.05. 
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Table 4.2: Summary of functional and histological changes after 11 weeks 
of high fat diet 
 
 CTRL DIO 
MAP (mmHg) 87.14±4.914 88.00±3.546 
Resting CF (mL/min) 1.177±0.2564 1.145±0.1778 
Hyperaemic CF (mL/min) 4.763±0.3355 4.725±0.8060 
Peak-to-baseline CF 4.207±0.3681 4.126±0.1491 
Total peak area (AUC) 48.45±3.985 82.40±12.15 (*) 
Time to return to baseline (sec) 57.60±10.49 144.5±30.44 (*) 
Medial area (µm2) 1499±221.4 2852±247.8 (***) 
Media-to-lumen ratio 1.617±0.1648 2.791±0.2530 (**) 
* p<0.05, ** p<0.005 and *** p<0.0005 
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4.3.3.3 In vivo assessment of vascular reactivity 
To ascertain whether microvascular remodelling was not only occurring in 
coronary arterioles but also in the periphery, vascular reactivity in the carotid 
artery was investigated. Intravenous injection of the endothelium-dependent 
vasodilator acetylcholine resulted in a significant difference in the drop of MAP 
between DIO and control mice (42.38±7.981 mmHg vs. 30.60±8.877 mmHg, 
p<0.05) as well as a significant reduction of the recovery time back to baseline 
MAP after this challenge in DIO mice compared to controls (51.00±10.10 sec vs. 
123.0±5.715 sec, p<0.0005) (Figure 4.9). 
 
 
 
Figure 4.9: MAP changes in DIO and control mice after injection of 
acetylcholine.  
A significant difference in the drop of MAP was observed between DIO and 
control mice. Additionally, the time to return to baseline MAP was significantly 
shorter in DIO mice compared to controls. Data are expressed as mean±SD for 
7 animals in each group. Data were analysed using Student’s t-test. *** 
p<0.0005. 
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4.3.3.4 Ex vivo assessment of vascular reactivity 
Wire tension myography on aortic rings of DIO and control animals was chosen 
as an ex vivo functional measurement of vascular reactivity. First, maximal 
contractile capacity and viability of the vessel were determined by depolarising 
ring segments with KCl followed by dose-dependent contraction of segments 
with the vasoconstrictor phenylephrine (PE). Finally, the vasodilator 
acetylcholine (ACh) was added to determine the integrity of the endothelium. 
Once viability and maximal contractile capacity of the vessels was confirmed, 
endothelium-dependent and –independent relaxation in DIO and control aortic 
rings was measured. To study the endothelium-dependent relaxation, vessels 
were pre-contracted with PE to 70% of the maximal contractile force of the 
artery (EC70) and cumulative relaxation curves of ACh were constructed. 
Endothelium-independent relaxation was measured by cumulative addition of 
the nitric oxide donor sodium nitroprusside (SNP).  
 
There was a trend to a lower maximal contraction of arterial smooth muscle to 
KCl in DIO segments compared to controls (4.961±0.4495 for DIO vs. 
6.046±0.4548 for controls, p=0.0641) (Figure 4.10 A) whereas no differences in 
the amount of PE needed to elicit EC70 were observed between the two groups 
(Figure 4.10 B). Endothelium-dependent relaxation was investigated by 
constructing cumulative relaxation curves of ACh (10-9 to 10-5 M). Ring 
segments of DIO mice showed significantly decreased endothelium-derived 
relaxation to ACh compared to control mice (p<0.05 at all concentrations starting 
at 10-6 M) (Figure 4.11 A). Endothelium-independent relaxation was investigated 
using SNP. Arterial segments of both groups relaxed to SNP in a dose-
dependent manner (Figure 4.11 B). At maximal SNP concentration (10-7 M) the 
control group relaxed by 94.75±2.136% and the DIO group by 89.20±5.305%. 
There were no significant differences between the two groups which would 
suggest that high fat diet feeding does not affect endothelium-independent 
vasodilation (Figure 4.11 B).  
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Figure 4.10: Effect of high fat diet on maximal contractile capacity and 
contraction to PE.  
(A) Maximal contraction of ring segments in response to depolarization by KCl in 
control and DIO ring segments. (B) Cumulative concentration-response curves 
to PE in controls (black) and DIO mice (red). No significant differences in the 
percentage of contraction in response to PE were observed in DIO compared to 
controls. Data are expressed as mean±SEM for 5 animals per group. Data were 
analysed using Student’s t-test. ns, not significant. Myography experiments were 
carried out by Dr Elizabeth Sujkovic (MRC CSC Nitric Oxide Signalling Group). 
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Figure 4.11: Effect of high fat diet on dose-dependent endothelium-
dependent and endothelium-independent relaxation to ACh and SNP.  
(A) Endothelium-dependent relaxation to ACh in DIO and control mice. (B) 
Endothelium-independent relaxation responses to SNP. Results are presented 
as means±SEM from 5 animals in each group Data were analysed using 
Student’s t-test. * p<0.05. Myography experiments were carried out by Dr 
Elizabeth Sujkovic (MRC CSC Nitric Oxide Signalling Group). 
1.0
×1
0
-10
1.0
×1
0
-09
1.0
×1
0
-08
1.0
×1
0
-07
0
25
50
75
100
125
Controls
DIO
SNP
(endothelium-independent vasodilator)
%
 R
el
ax
at
io
n
n=5
n=5
1.0
×1
0
-09
1.0
×1
0
-08
1.0
×1
0
-07
1.0
×1
0
-06
1.0
×1
0
-05
0
25
50
75
100
125
Controls
DIO
* * *
Acetylcholine
(endothelium-dependent vasodilator)
%
 R
el
ax
at
io
n
n=5
n=5
A
B
 151 
 
4.3.3.5 Measurement of asymmetric dimethylarginine (ADMA), an 
endogenous inhibitor of NOS  
To further investigate the observed impairment in endothelium-dependent 
vasodilation in DIO aortas, the effect of high fat diet feeding on the endogenous 
inhibitor of NOS, ADMA, was determined. For this, ADMA levels were measured 
in plasma samples of DIO and control mice using liquid chromatography/ mass 
spectrometry. Plasma ADMA levels were not changed after 11 weeks of high fat 
diet (0.5365±0.1168 µM vs. 0.5161±0.1640 µM, p=ns, n=5 for each group). 
 
 
 
Figure 4.12: Plasma ADMA levels in DIO and control mice. 
Plasma ADMA levels were measured using liquid chromatograph/mass 
spectrometry in DIO and age-matched control mice. Data are expressed as 
mean±SD for n=5 animals per group. Data were analysed using Student’s t-test. 
ns, not significant. ADMA levels were provided by Dr James Leiper (MRC CSC 
Nitric Oxide Signalling Group). 
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4.3.4 Gene expression profiling in left ventricles of DIO mice 
4.3.4.1 Microarray analysis 
To identify gene expression changes associated with high fat diet-induced 
microvascular remodelling in the heart, cDNA microarray analysis was 
performed using mRNA isolated from left ventricles of 11 weeks DIO and age-
matched control mice.  
 
4.3.4.1.1 Quality assessment of RNA 
For microarray analysis high quality RNA is required. Quality of isolated RNA 
samples was assessed by measuring the absorbance ratio A260/280 on a 
nanodrop as well as running the samples on a Bioanalyser to obtain the RNA 
index number (RIN) which is proportional to RNA quality. All absorbance ratios 
were in the recommended range of 1.9 to 2.1 indicating pure RNA (see 
Appendix C – Microarray Quality Controls) and RIN of all samples run on the 
Bioanalyser were within the recommended range of 7 to 10, with 10 indicating 
high quality RNA (Appendix C – Microarry Quality Controls). To ensure 
consistently good quality at the end of each stage quality assessments were 
performed after rRNA reduction, first and second cycle cDNA synthesis as well 
as before and after fragmentation of cDNA (Appendix C – Microarry Quality 
Controls).  
 
4.3.4.1.2 Analysis of expression data 
Gene expression summary values of the Affymetrix Gene Chip data were 
generated using the robust multichip average (RMA) algorithm [172]. The quality 
of the expression replicates was then determined using principal-components 
analysis, hierarchical clustering and hybridisation control plot using GeneSpring 
software followed by a filtering step which included the removal of all values 
below the 20th percentile and the setting that 10 out of 10 samples should have 
probe values greater than the 20th percentile.   
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Ideally, all replicates of one condition are expected to group together and all 
replicates of the other condition to group together. However, principal 
component analysis showed that there was variation between replicates in both 
groups. This variability between samples resulted in no differentially expressed 
genes after multiple corrections and setting the false discovery rate at 5%. 
Therefore, the fold change (FC) was lowered to FC≥1.5 and a p value of p<0.01 
was considered to be significant. Using this setting, analysis of the transcriptome 
showed that 29 genes were differentially expressed in response to high fat diet 
feeding (1.5-fold or greater, p<0.01). Of these, 18 genes were down-regulated 
(Table 4.3) and 11 up-regulated (Table 4.4).  
 
The high fat diet-induced changes in expression included genes which are 
involved in a variety of biological processes. Annotation of genes resulted in 26 
genes being annotated and showed that the largest group of altered genes was 
associated with small molecule biochemistry, whereas lipid and carbohydrate 
metabolism were the next most commonly annotated groups. Using ingenuity 
system pathway analysis, we identified biologically relevant networks with top 
function in lipid metabolism associated with gene expression differences in 
response to high fat diet feeding (Figure 4.13 and Figure 4.14). At the individual 
gene level, genes involved in the biosynthesis of fatty acids (Scd4), oxidation of 
fatty acids (Ehhadh, Ucp3) as well as cholesterol biosynthesis (Fdft1) or the 
production of diacylglycerol (Rgs2) were down-regulated in response to high fat 
diet. Additionally, the gene encoding Pdk4, which plays an important role in 
glucose metabolism and whose expression is regulated by insulin was down-
regulated. Of the down-regulated genes four were found to be located in the 
mitochondria (Ucp3, Hmgcs2, Pdk4, Ehhadh). Furthermore, genes encoding 
proteins which are associated with hypertrophy and cardiac fibrosis like CTGF 
and LMCD1were down-regulated. On the other hand, Acta1, the gene encoding 
the major actin in postnatal skeletal muscle was increased. The other up-
regulated genes were found to play a role in phospholipase C signalling 
(Arhgef19), or G protein-coupled receptor mediated signalling (Gpr22).  
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Table 4.3: Down-regulated genes in left ventricles of DIO mice after 11 weeks of high fat diet 
Rank order by fold change (FC) 
Gene Symbol 
NCBI Entrez 
Gene ID FC p value 
Receptor (calcitonin) activity modifying protein 1 Ramp1 51801 -1.50 0.000816899 
3-hydroxy-3-methylglutaryl-Coenzyme A synthase 2 Hmgcs2 15360 -1.50 0.005196151 
Stearoyl-coenzyme A desaturase 4 Scd4 329065 -1.50 0.005372935 
Cold inducible RNA binding protein Cirbp 12696 -1.51 0.005479873 
Farnesyl diphosphate farnesyl transferase 1 Fdft1 14137 -1.56 8.30242E-05 
Enoyl-Coenzyme A, hydratase/3-hydroxyacyl Coenzyme 
A dehydrogenase 
Ehhadh 74147 -1.57 
 
0.007041528 
 
LIM and cysteine-rich domains 1 Lmcd1 30937 -1.58 0.002025513 
Gamma-aminobutyric acid (GABA(A)) receptor-
associated protein-like 1 
Gabarapl1 57436 -1.58 0.003706662 
 
Cyclin-dependent kinase-like 1 (CDC2-related kinase) Cdkl1 71091 -1.59 1.43557E-05 
Transmembrane protein 71 Tmem71 213068 -1.61 0.001730867 
T-complex 11 (mouse) like 2 Tcp11l2 216198 -1.63 0.000164171 
Pyruvate dehydrogenase kinase, isoenzyme 4 Pdk4 27273 -1.63 0.000503068 
Transmembrane and tetratricopeptide repeat containing 1 Tmtc1 387314 -1.66 0.000327137 
Uncoupling protein 3 (mitochondrial, proton carrier) Ucp3 22229 -1.74 0.003806227 
Regulator of G-protein signalling 2 Rgs2 19735 -1.76 0.005523294 
Histone cluster 1, H1c Hist1h1c 50708 -2.09 0.000474528 
Connective tissue growth factor Ctgf 14219 -2.13 0.000103499 
Metallothionein 2 Mt2 17750 -2.17 0.008681912 
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Table 4.4: Up-regulated genes in left ventricles of DIO mice after 11 weeks of high fat diet 
Gene Symbol 
NCBI Entrez 
Gene ID 
 
FC p value 
Nestin Nes 18008 1.52 0.001418669 
Soluble carrier family 6 (neurotransmitter transporter, 
creatine), member 8 
Slc6a8 102857 1.52 0.001909188 
 
G protein-coupled receptor 22 Gpr22 73010 1.53 0.008851907 
Amylase 1, salivary Amy1 11722 1.55 0.008093013 
Rho guanine nucleotide exchange factor (GEF) 19 Arhgef19 213649 1.56 0.000451041 
Transmembrane protein 204 Tmem204 407831 1.57 0.001733081 
Histidine rich calcium binding protein Hrc 15464 1.63 0.005019038 
Protein phosphatase 1, regulatory (inhibitor) subunit 3c Ppp1r3c 53412 1.63 0.005030717 
NF-κB inhibitor interacting Ras-like protein 1 Nkiras1 69721 1.72 0.000266726 
Actin, alpha 1, skeletal muscle Acta1 11459 1.80 0.001347989 
Transferrin receptor Tfrc 22042 2.06 0.007599853 
Rank order by fold change (FC) 
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Figure 4.13: Ingenuity analysis of genes differentially expressed by high 
fat diet.  
Functional annotation of 29 genes identified as being differentially expressed by 
high fat diet. The top ten groups are ranked according to p value significance, 
the threshold is indicated in yellow. 
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Figure 4.14: Regulatory network identified by Ingenuity network analysis. 
Example of regulatory network (lipid metabolism) from the probe sets identified 
as being differentially expressed by high fat diet. Interactions are defined from 
Ingenuity database and comprise referenced published protein-protein 
interactions and transcriptional regulation. Up-regulated genes are highlighted in 
red and down-regulated genes are highlighted in green. 
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4.3.4.2 Validation of microarray findings 
To validate the microarray findings, qRT-PCR was initially performed, followed 
by western blotting for a selection of differentially expressed genes and proteins. 
 
4.3.4.2.1 Validation of microarray findings using qRT-PCR 
To validate the microarray results, qRT-PCR was performed on differentially 
expressed genes. Primers were designed for the majority of annotated genes 
using GenScript Primer Design tool [170]. Gene expression levels were 
normalised to Cyclophilin A (Ppia), which has been shown not to change with 
diet [227, 228]. A comparison of gene expression levels measured by cDNA 
microarray and qRT-PCR demonstrated a good correlation in expression levels. 
Five of the nine up-regulated genes tested (Figure 4.15) and 12 of the 16 down-
regulated genes were confirmed by qRT-PCR (Figure 4.16). 
 
 
Figure 4.15: Validation of up-regulated genes using qRT-PCR.  
Validation of up-regulated genes from microarray experiment using qRT-PCR. 
Fold change relative to normal chow controls expressed as mean±SEM from 
three independent experiments normalised to Cyclophilin A. Dotted line 
indicates normal chow controls which was assigned as 1. Data were analysed 
using Student’s t-test. ** p<0.005 and *** p<0.0005. 
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Figure 4.16: Validation of down-regulated genes using qRT-PCR.  
Validation of down-regulated genes from microarray experiment using qRT-PCR. Fold change relative to normal 
chow controls expressed as mean±SEM from three independent experiments normalised to Cyclophilin A. Dotted 
line indicates normal chow controls which was assigned as 1. Data were analysed using Student’s t-test. * p<0.05, 
** p<0.005 and *** p<0.0005.
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4.3.4.2.2 Validation of microarray findings using protein expression 
analysis  
Protein expression analysis was used to determine whether the differential 
expression at the mRNA level has an effect on the protein levels of a subset of 
validated candidates. To determine whether these candidates play a role in the 
observed microvascular remodelling in DIO left ventricles, we mainly focussed 
on candidate genes which have been shown to be expressed in the vasculature. 
CTGF protein levels in whole heart extracts were studied due to its role in 
vascular smooth muscle cell proliferation and migration as well as its expression 
in atherosclerotic lesions [229, 230]. RGS2 levels were investigated because of 
its role in blood pressure regulation and vasoconstrictor signalling [231, 232] and 
MT2 due to its role in coronary arterial relaxation [233].  
 
Consistent to the microarray experiment, whole heart protein levels were 
investigated at baseline (without insulin stimulation). Left ventricles of age-
matched C57BL/6 mice were used as controls. After correcting for equal loading 
using glyceraldehyde 3-phosphate dehydrogenase (GAPDH), densitometric 
analysis of CTGF and MT2 protein bands showed no significant fold changes 
between control and DIO mice (0.9293±0.1145 vs. 1.000±0.02582, p=ns, n=6 
for CTGF and 0.7746±0.08105 vs. 0.9992±0.04543, p=ns, n=3 for MT2). 
However, a significant reduction of RGS2 protein expression was observed in 
DIO hearts compared to age-matched controls (0.5210±0.06619 vs. 
1.024±0.05538, p<0.005, n=4) (Figure 4.17).  
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Figure 4.17: Effects of high fat diet protein expression of selected 
microarray candidates.  
(A) Representative western blots of myocardial MT2, CTGF, RGS2 and GAPDH 
protein expression in control and DIO mice. (B-D) Densitometric analysis of 
western blots expressed as fold change after normalising to GAPDH to correct 
for loading differences. Data are expressed as mean±SD for n=3 for MT2, n=6 
for CTGF and n=4 for RGS2. Data were analysed using Student’s t-test. ns, not 
significant and ** p<0.005. 
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4.3.5 Myocardial insulin signalling 
The effects of high fat diet on myocardial insulin signalling was investigated in 
DIO animals after 11 weeks of high fat diet feeding at baseline and after insulin 
stimulation by looking at three members of the pathway, IRS1, Akt, and GLUT4.  
 
Total IRS1 and tyrosine phosphorylation of IRS1 was measured to determine 
the effect of high fat diet on the initiation of the PI3K-dependent branch of the 
insulin signalling pathway. Western blot analysis showed no significant 
differences in total IRS1 expression between control and DIO mice at baseline 
and after insulin stimulation (p=ns, n=3 for all groups) (Figure 4.18 A and C). For 
tyrosine phosphorylation similar baseline expression was observed in DIO and 
control hearts (1.042±0.05248 vs. 1.066±0.1712, p=ns, n=6). After insulin 
administration, tyrosine phosphorylation significantly increased by 59% in control 
hearts (p<0.05, n=4 for insulin stimulation and n=6 for baseline) whereas only by 
27% in DIO hearts (p=ns, n=3 or insulin stimulation and n=6 for baseline) 
(Figure 4.18 B and D).  
 
Furthermore, expression levels of the downstream target Akt and its 
phosphorylation at the serine 473 residue (P-Akt) was investigated in DIO hearts 
and compared to ob/ob and control heart lysates. No significant changes were 
observed in baseline P-Akt-to-Akt ratio between DIO and controls 
(0.3436±0.2486 vs. 0.1906±0.1346, p=ns, n=3). After in vivo insulin 
administration, a significant increase in P-Akt-to-Akt ratio was observed in both 
groups (1.343±0.2840 vs. 0.1906±0.1346, p<0.05 for CTRL + insulin vs. control; 
2.370±0.4877 vs. 0.3436±0.2486, p<0.0005 for DIO + insulin vs. DIO) (Figure 
4.19 A and C). When examining Akt expression in ob/ob mice, significantly 
higher baseline P-Akt-to-Akt ratio was observed compared to controls 
(0.6425±0.2647 vs. 0.06908±0.05993, p<0.05). After insulin administration, Akt 
phosphorylation significantly increased in control hearts (1.356±0.1436 vs. 
0.06908±0.05993, p<0.0005) but was blunted in ob/ob hearts (1.061±0.1449 vs. 
0.6425±0.2647, p=ns) (Figure 4.19 B and D).  
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Figure 4.18: Effects of high fat diet on total IRS1 levels and IRS1 tyrosine 
phosphorylation.  
(A) Representative western blot of total IRS1 (upper panel) and GAPDH (lower 
panel) expression at baseline and after insulin stimulation in DIO and control 
mice. (B) Representative western blot of IRS1 tyrosine phosphorylation (PY 
IRS1) at baseline and after insulin administration in DIO and control heart lysate. 
(C) Quantification of IRS1 expression normalised to GAPDH in DIO and control 
hearts. Data are expressed as mean±SD fold change relative to baseline control 
for n=3 animals per group. (D) Quantification of IRS1 tyrosine phosphorylation in 
DIO and control hearts. Data are expressed as mean±SD fold change relative to 
baseline control for n=6 animals in baseline groups and n=3-4 in insulin 
stimulated groups. Data were analysed using one-way ANOVA with Bonferroni’s 
multiple comparison. ns, not significant, * p<0.05. 
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Figure 4.19: Effects of high fat diet on myocardial Akt expression.  
(A) Representative western blot of myocardial phospho-Akt (top panel), total Akt 
(middle panel), and GAPDH (lower panel) in DIO and controls at baseline and 
after insulin stimulation. (B) Representative western blot of myocardial phospho-
Akt (top panel), total Akt (middle panel), and GAPDH (lower panel) in ob/ob and 
control mice at baseline and after insulin stimulation. (C and D) Densitometric 
analysis of Akt expression normalised to GAPDH in DIO, ob/ob and control 
hearts. Phospho-Akt-to-Akt ratio is expressed as mean±SD for n=3 animals per 
group. Data were analysed using one-way ANOVA with Bonferroni’s multiple 
comparison. ns, not significant; * p<0.05 and *** p<0.0005. 
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Moreover, the effect of high fat diet feeding on total GLUT4 content in the heart 
was investigated. Western blotting showed no significant changes in baseline 
expression of total GLUT4 in DIO whole heart lysates compared to age-matched 
controls (0.7593±0.07705 vs. 0.9705±0.05445, p=ns) (Figure 4.20). After insulin 
stimulation, GLUT4 content significantly increased in contols (1.983±0.5219 vs. 
0.9705±0.05445, p<0.005) but not in DIO hearts (1.282±0.2946 vs. 
0.7593±0.07705, p=ns) (Figure 4.20).  
 
Since GLUT4 content was determined in whole heart lysates we also 
determined GLUT4 expression specifically in cardiomyocytes using 
immunohistochemistry. GLUT4 immunohistochemistry showed strong and 
diffuse cytoplasmic staining of cardiomyocytes with membrane reinforcement in 
the controls at baseline. In the DIO hearts the expression was reduced, focal, 
and lacked membrane reinforcement (Figure 4.21 top panel). In contrast, after 
insulin stimulation GLUT4 expression increased in both groups with no obvious 
differences between them (Figure 4.21 bottom panel). 
 
 166 
 
 
 
Figure 4.20: Effects of high fat diet on myocardial GLUT4 expression.  
(A) Representative western blot of GLUT4 (upper panel) and GAPDH (lower 
panel) expression at baseline and after insulin administration in DIO and control 
heart lysate. (B) Densitometric analysis of GLUT4 expression in total heart 
lysate of DIO and control mice at baseline and after insulin stimulation 
normalised to GAPDH. Data are expressed as mean±SD fold change relative to 
baseline control for n=5 animals for baseline DIO and control mice and n=3 for 
insulin stimulated DIO and control mice. Data were analysed using one-way 
ANOVA with Bonferroni’s multiple comparison. ns, not significant; * p<0.05; ** 
p<0.005. 
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Figure 4.21: Effects of high fat diet on myocardial GLUT4 expression (IHC).  
Representative GLUT4 immunohistochemistry image at baseline and after 
insulin administration in DIO and control heart sections. Sections were incubated 
in peroxidase-streptavidin solution (brown) and counterstained using Meyer 
haematoxylin. Images are representative of 4 animals per group. 
Immunohistochemistry experiments were carried out by Dr Massimiliano 
Mancini, La Sapienza University, Rome.  
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4.4 Discussion 
In the first part of this chapter, our novel finding of coronary microvascular 
remodelling after high fat diet feeding was investigated. For this, the following 
questions were addressed: (1) Does coronary microvascular remodelling occur 
only after 14 weeks of high fat diet feeding or also at the two earlier time points 
investigated? (2) Is coronary microvascular remodelling associated with vascular 
functional changes as well as impairment of coronary flow? (3) Which 
genes/pathways might play a role in the development of coronary microvascular 
remodelling? Furthermore, in the second part of this chapter the effects of high 
fat diet feeding on members of the myocardial insulin signalling pathway were 
investigated.  
 
The main findings in this chapter are that coronary microvascular remodelling is 
already present after 8 weeks of high fat diet feeding but progresses with 
increasing feeding duration. Also, coronary microvascular remodelling is 
accompanied by coronary microvascular dysfunction and endothelial dysfunction 
in resistance arteries but independent of hypertension or cardiac hypertrophy. 
High fat diet feeding is associated with down-regulation of genes involved in 
myocardial lipid and glucose metabolism, the development of hypertrophy and 
fibrosis as well as vascular reactivity. Moreover, when looking at members of the 
PI3K-dependent branch of the insulin signalling pathway we show that high fat 
diet feeding leads to a blunted phosphorylation of IRS1, a significantly higher P-
Akt/Akt ratio, and no significant differences in GLUT4 expression in total heart 
lysates of DIO mice after insulin stimulation. When looking at cardiomyocytes of 
DIO mice, lower GLUT4 expression at baseline is observed compared to control 
mice. This is different to our findings in the myocardium of ob/ob mice, in which 
phosphorylation of Akt was attenuated and total GLUT4 unchanged at baseline. 
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4.4.1 Effects of high fat diet on coronary microvascular 
remodelling and metabolic markers 
The observed coronary microvascular remodelling, which has never been 
described in a diet-induced mouse model before, provides the possibility to 
directly study potential links between metabolic and coronary microvascular 
changes. To further characterise this finding the first question we addressed was 
whether coronary microvascular remodelling was not only present after 14 
weeks of high fat feeding but also after 8 and 11 weeks of high fat diet. We 
observed that thickening of the intimal layer was present after 8 weeks of high 
fat diet whereas the media-to-lumen ratio was not significantly increased. 
Concomitantly, fasting insulin and glucose were increased and glucose 
tolerance was mildly impaired after 8 weeks of high fat diet but not significantly 
changed. On the other hand, after 11 weeks of high fat diet both intimal layer 
thickening and media-to-lumen ratio as well as fasting insulin and glucose were 
significantly increased and glucose tolerance significantly impaired. Interestingly, 
in a study in female rats fed a 42% high fat diet for 8 weeks extensive 
perivascular fibrosis but no significant changes in the vessel wall or lumen area 
was observed in the hearts [234]. 
 
In addition to altered insulin and glucose levels we investigated leptin 
concentrations and FA concentrations in serum samples of DIO mice after 11 
weeks of high fat diet as additional markers of insulin resistance and T2DM. 
Serum leptin levels in DIO mice after 11 weeks of high fat diet were significantly 
increased and positively correlated with visceral fat mass. It has been shown 
that fat deposition and adipose endocrine function are affected by dietary fat 
intake [222]. Moreover, depending on the degree and duration of exposure leptin 
can have both harmful and cardioprotective effects on the heart [235-237]. 
Myocardial lipid accumulation and cardiac pathology has been described in 
leptin-deficient mice suggesting that hyperleptinaemia might be cardioprotective 
[202, 238]. Also, studies in human and rodent cardiomyocytes show that leptin 
can directly stimulate hypertrophy and increase ROS generation [239-242]. 
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Similar to the observations by Chess et al. we demonstrate in this study that 
high fat feeding significantly increases whole body adiposity and circulating 
leptin without obvious deleterious effects on the heart [222]. However, we 
cannot exclude that a combination of hyperinsulinaemia, hyperleptinaemia and 
hyperglycaemia contributes to the coronary microvascular remodelling we 
observed in DIO hearts. Besides increased leptin concentrations an increase of 
fatty acids in the blood of diabetic patients has been observed [50-52]. Several 
studies have shown that fatty acid levels were increased in genetic mouse 
models of T2DM due to the increased amount of lipolysis of stored triglycerides 
in adipose tissues [223, 243, 244]. However, publications on the effect of high 
fat diet on FA concentrations vary. In a study by Chess et al. a significant 
increase in plasma FFA was observed already after 6 weeks of high fat diet 
feeding (45% fat) [222] whereas Park et al. observed a significant increase in 
plasma FFA concentrations only after 15 weeks of high fat diet [75]. In our study 
FA concentrations in serum of 11 weeks DIO mice were slightly lower but not 
significantly changed compared to controls. Only in age-matched ob/ob mice a 
significant increase in serum FA concentrations was observed which is 
consistent with previous findings in ob/ob mice [243].  
 
  
 171 
 
4.4.2 Effects of high fat diet on coronary blood flow and 
vascular reactivity 
To determine whether hemodynamic load, i.e. blood pressure, contributed to the 
development of microvascular remodelling, MAP was investigated in DIO mice 
after 11 weeks of high fat diet and compared to age-matched controls. MAP did 
not differ between DIO mice and controls, indicating that hypertension did not 
contribute to changes observed in coronary vascular structure. Similarly, 
Roberts et al. have shown that hypertension in female Sprague Dawley rats 
developed only after 1 year of high fat, refined carbohydrate diet [245]. 
Additionally, we aimed to assess cardiac function of DIO hearts using 
echocardiography which is commonly used to investigate cardiac function in 
murine models [224-226]. Due to the increased amount of pericardial fat in DIO 
mice and the change in axial orientation of the heart we chose cardiac magnetic 
resonance imaging to investigate the effects of high fat diet on stroke volume 
and ejection fraction. Our results show no significant changes between DIO after 
11 weeks of high fat diet and age-matched control mice. In other diabetic mouse 
models impairment of cardiac function has been observed. Using cardiac MRI, 
Yu and co-workers demonstrated ventricular wall thinning, increased end-
systolic diameter and volume and diminished ejection fraction, stroke volume 
and cardiac output in STZ-induced T1DM mice at 12 weeks of age [246]. 
Additionally, increases in LV mass, wall thickness, and end-diastolic volume 
were observed in db/db mice between 5 and 13 weeks of age and decreased 
ejection fraction with no further changes at later stages [247]. Preliminary results 
by Wylezinska et al. in high fat diet fed mice show a trend to diminished ejection 
fraction which suggests that high fat diet may have implications on cardiac 
function [248]. Our results are in line with other studies that showed that short 
periods of high fat diet feeding does not affect baseline LV structure and function 
[166, 249]. However, the altered metabolic state due to the high fat diet was 
associated with increased LV remodelling and dysfunction after chronic pressure 
overload [166]. Park et al. showed that ventricular fractional shortening 
progressively declined after 10 to 15 weeks and was significantly reduced after 
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20 weeks of high fat diet feeding [75]. Accordingly, LV posterior wall thickness 
and heart weight increased only after 20 weeks [75]. Since cardiac function was 
not significantly blunted until after 20 weeks of high fat diet feeding, Park et al. 
suggested that cardiac insulin resistance per se does not mediate cardiac 
dysfunction in high fat-fed mice [75].  
 
Since the microcirculation is responsible for the control of myocardial blood flow 
the effects of coronary microvascular remodelling on microvascular function 
were investigated by assessing both myocardial blood flow and reactive 
hyperaemia. Reactive hyperaemia is defined as the transient increase in blood 
flow following a brief period of ischaemia [250]. The shortage of oxygen will lead 
to a build-up of vasodilator metabolites resulting in the dilation of arterioles, the 
reduction in vascular resistance and consequently to an increase in blood flow. 
By calculating the peak-to-baseline ratio it is possible to determine coronary flow 
reserve, an indirect measure of coronary microvascular dysfunction in humans 
[92]. Using Langendorff perfusion of isolated hearts no significant changes in 
peak-to-baseline ratio between DIO and control hearts were observed. However, 
a significant increase in total peak area as well as a significant increase in the 
time needed to return to baseline flow was observed in DIO mice. This suggests 
that despite no obvious differences in vasodilation after the ischaemic event, 
recovery was impaired. The fact that no differences were observed in the peak-
to-baseline ratio could be explained by the fact that the Langendorff set-up used 
is designed for the use of rat hearts and may thus be not sensitive enough to 
detect potential differences in mouse hearts.  
 
Changes in coronary flow can generally be ascribed to either changes in 
microvascular structure or to functional changes. Thus, we aimed to assess the 
effects of high fat diet on endothelial function. Impairment of endothelial function 
is well established in the micro- and macrocirculation of patients with T2DM and 
is an early manifestation of atherosclerotic vascular damage [251, 252]. It is 
characterised by reduced NO bioavailability resulting from ROS overproduction, 
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lipid peroxidation, and increased generation of adhesion molecules, increased 
expression of pro-inflammatory and pro-thrombotic factors as well as abnormal 
vasoreactivity [253, 254]. In both clinical settings and animal models of diabetes 
like the db/db mouse reduced endothelium-dependent vasodilations are 
commonly observed [166, 245, 255, 256]. Additionally, leptin has been shown to 
contribute to endothelial dysfunction or damage with high concentrations of 
leptin leading to an impairment of acetylcholine-induced NO-dependent 
vasorelaxation both in vitro and in vivo [257]. Since previous studies in high fat 
diet fed animals reported endothelial dysfunction [166, 245, 255, 256] we 
investigated endothelial function in vivo by administering the vasodilator ACh 
and measuring the effect of this challenge on MAP as well as time required to 
return to baseline MAP. We hypothesised that the bigger the drop in MAP the 
higher the vasodilatory effect in response to ACh. Thus, in wild type mice we 
expected that MAP would drop upon ACh administration and slowly return back 
to baseline. On the other hand we hypothesised that high fat diet feeding would 
attenuate the response to ACh. Our results showed a significantly blunted drop 
in MAP after ACh administration in DIO mice and significantly reduced recovery 
time compared to age-matched controls which suggests an impaired 
vasodilation and greater resistance in DIO mice and thus indicates impairment 
of vascular reactivity and endothelial function in DIO mice in vivo. This result 
was further strengthened by ex vivo assessment of vascular reactivity in vessels 
of DIO mice. Wire tension myography on aortic rings of DIO and control animals 
showed that high fat diet consumption for 11 weeks induces endothelial 
dysfunction before the onset of hypertension and that endothelium-independent 
relaxation is not impaired in DIO mice. ACh was used to assess the effects of 
high fat diet on endothelium-dependent vasodilation. Our results are in line with 
previous publications demonstrating impaired endothelium-dependent 
vasodilation to ACh in aorta of mice fed a high fat diet for 15 and 30 weeks [258, 
259], and in aorta of rats after 8 weeks [234, 260], or 7 month [245] of high fat 
diet treatment. To assess the effects of high fat diet on vascular smooth muscle 
function SNP was used. SNP-induced relaxation was similar in both DIO and 
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control mice, which is consistent with previous publications in aorta of mice and 
rats fed a high fat diet [245, 258]. This indicates that the ability of vascular 
smooth muscle to relax in response to exogenous NO was not impaired in DIO 
mice and that diet selectively impaired endothelium-dependent vasodilation.  
 
To further investigate the observed endothelial dysfunction we looked at a 
possible underlying cause, an impairment of NO bioavailability. Impaired NO 
bioavailability could be due to an imbalance of NO production and/or increased 
NO inactivation [261-263]. As described in Chapter 1, NO is produced in 
vascular endothelium by activation of eNOS which catalyses the conversion of 
the substrate L-arginine to NO and L-citrulline [36]. Possible mechanisms for NO 
deficiency are reduced eNOS activity and/or reduced NO synthesis caused by 
asymmetrically methylated arginines (NG monomethyl-L-arginine [L-NMMA] and 
asymmetric dimethylarginine [ADMA]) or production of ROS that inhibit NOS 
activity [36, 264, 265] (Figure 4.22). L-NMMA is the prototype inhibitor of NOS 
and is widely used as a pharmacological tool in cells and animal models [265]. 
ADMA exists normally in the body and has been found to be elevated to levels 
that can significantly inhibit NOS activity in individuals with 
hypercholesterolaemia, hypertension, tobacco exposure, and hyperglycaemia 
[168, 266, 267]. In DIO mice after 11 weeks of high fat diet no changes were 
observed in plasma ADMA levels compared to age-matched control mice which 
suggests that the observed endothelial dysfunction was not caused by increased 
NO inhibition by ADMA. However, it still needs to be determined whether L-
NMMA, ROS generation or NOS activity are affected by high fat diet and thus 
are a potential underlying mechanism of impaired endothelium-dependent 
vasodilation observed in DIO mice.  
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Figure 4.22: Simplified model for the regulation of NO synthesis. 
L-arginine is metabolised to NO and L-citrulline by NOS. Free intracellular L-
NMMA and ADMA inhibit the production of NO catalysed by NOS. ADMA, 
asymmetric dimethylarginine; NO, nitric oxide; NOS, nitric oxide synthase; -ve, 
negative. Adapted from [265]. 
 
 
Interestingly, a high variation in the ACh-induced endothelium-dependent 
vasodilation was observed in DIO aortic ring segments. In this context, it is 
important to note that the type of vessel as well as the origin of ring segment 
used plays an important role in the assessment of vascular reactivity. With 
regards to the origin of ring segments, a reason for variation in vascular 
reactivity could be the exposure of the vasculature to different blood flow 
patterns on the endothelial layer at distinct sites [252, 268]. It has been shown 
that the effect of blood flow contributes to the distinct physiological 
characteristics of the arterial wall which in some regions promote an anti-
inflammatory, anti-thrombotic, anti-coagulative, profibrinolytic and anti-
hypertrophic state [252, 268]. In contrast, other regions such as branches and 
arches of the arterial tree are susceptible to the development of atherosclerosis 
[252]. In our experiments ring segments were chosen randomly and thus we 
cannot exclude the possibility that both of the described regions were used and 
thereby might explain in part the high variation between samples.  
 
L-arginine NO
L-citrulline
ADMA
NOS
-ve
L-NMMA
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Additionally, spontaneous contractions to ACh were observed in aortic ring 
segments which might have influenced the results. Studies in rat peripheral 
arteries have observed endothelium-dependent contraction to ACh under 
pathological conditions like hypertension and diabetes [269-271]. Faraci et al. 
demonstrated that ACh caused contraction in the carotid artery of eNOS 
knockout mice [272]. Since ACh has been shown to cause endothelium-
independent contraction by activating muscarinic receptors located on VSMC in 
some vessels [273, 274] it is possible that the contraction was either mediated 
by an endothelial or smooth muscle action of ACh. Recently, Zhou et al. 
demonstrated for the first time that ACh causes endothelium-dependent 
contraction in wild-type and eNOS knockout mouse arteries [275]. They suggest 
that ACh initiates two competing responses in mouse arteries (endothelium-
dependent relaxation mediated predominantly by NO and endothelium-
dependent contraction mediated most likely by thromboxane A2) and that 
contraction to ACh appears to be a normal physiological response of the blood 
vessels [275]. Although contraction of vessels in response to ACh occurs in 
pathological conditions in rats, the modulation of endothelium-dependent 
contraction still remains to be determined in mouse vascular pathologies [275]. 
Thus, it could be possible that the observed contractions in DIO ring segments 
may be due to a combinatory effect of the diet and high age of the animals since 
spontaneous contractions of aortic rings in older animals have been observed 
before [269]; unpublished observations by Dr Sujkovic). 
 
Taken together, our results show that coronary microvascular remodelling in 
DIO mice is independent of hypertension and cardiac hypertrophy. Additionally, 
we observed an association between the development of muscular inward 
remodelling and the progressive worsening of metabolic parameters like insulin, 
glucose or leptin. The fact that no overt changes were observed in myocardial 
blood flow and cardiac function suggests that microvascular changes precede 
the impairment of cardiac function. Furthermore, high fat diet feeding impaired 
endothelium-dependent vasodilation in aortic rings.   
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4.4.3 Effect of high fat diet on myocardial gene expression and 
a potential role in vascular remodelling 
To investigate which genes/pathways in the heart are affected by high fat diet 
feeding and which of those might play a role in the development of vascular 
remodelling, microarray analysis of left ventricles was chosen. This mixed 
tissues approach was chosen due to sample and technical limitations. 
Generally, laser capture microdissection of transmural arterioles with 
subsequent RNA isolation and microarray analysis would have been the 
preferred choice. However, due to the small size of the murine heart a large 
number of animals would have been necessary to obtain the required quantity of 
RNA.  
 
Genes which were differentially expressed with high fat diet were divided into 
three groups depending on their function: (1) lipid metabolism, (2) hypertrophy 
and fibrosis and (3) vascular reactivity.  
 
In our DIO mouse model, the majority of genes involved in lipid metabolism were 
down-regulated. Genes involved in lipid metabolism and their functions are listed 
in Table 4.5. Fatty acids play an important role in the healthy myocardium due to 
their role as fuels, mediators of signal transduction, or ligands for nuclear 
transcription factors like peroxisome proliferator-activated receptor α (PPARα), a 
key player in transcriptional control of FA metabolism [276]. Generally, in lipid 
metabolism, FFA can enter the circulation and muscle fibres by diffusion once 
they are freed from glycerol. Beta-oxidation in mitochondria eventually splits 
long carbon-chains of FA into acetyl CoA, which can eventually enter the citric 
acid cycle. In T2DM elevation of plasma FFA levels leads to the activation of the 
transcription factor PPARα which induces the expression of PPARα-regulated 
genes like Pdk4 and Ucp3 [277]. Both Pdk4 and Ucp3 were down-regulated in 
DIO hearts. PDK4 is located in the matrix of mitochondria and contributes to the 
regulation of glucose metabolism by inhibiting the mitochondrial pyruvate 
dehydrogenase complex [278]. Its expression is regulated by insulin and studies 
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have shown that it is up-regulated in hearts of STZ-induced animal models of 
diabetes and down-regulated in animal models of hypertrophy (pressure 
overload-induced) [277]. In female albino Wistar rats fed a 43% high fat diet for 
4 weeks PDK4 protein expression was significantly increased compared to 
controls on a low fat/high carbohydrate diet [279]. In transgenic mice with 
cardiac-specific overexpression of PDK4, hearts show low myocardial glucose 
oxidation and increased fatty acid oxidation (a fuel shift that has been shown to 
sensitise the heart to ischaemic insult and ventricular dysfunction) as well as 
protection against high fat diet-induced myocyte lipid accumulation [278]. UCP3 
facilitates transfer of anions from the inner to outer mitochondrial membrane and 
the return transfer from outer to inner membrane and therefore regulates 
mitochondrial membrane potential. Like PDK4, UCP3 has been found to be up-
regulated in diabetes and down-regulated in hypertrophy [277, 280]. This was 
confirmed in another study in FVB mice fed a 45% high fat diet for 20 weeks. 
Both PPARα-regulated genes, PDK4 and UCP3, were upregulated in the hearts 
of animals fed the high fat diet [281]. Intriguingly, Schrauwen et al. have shown 
that UCP3 protein content was significantly lower in muscle biopsies of pre-
diabetic subjects with impaired glucose tolerance as well as diabetic patients 
compared to healthy controls [282]. Additionally, UPC3 expression was found to 
be reduced following myocardial infarction in wild-type mice [148] and Young et 
al. have shown that progression of diabetes is associated with a dramatic 
decrease of PPARα expression and the PPARα-regulated UCP3 in the adult rat 
heart [280]. In DIO myocardium UCP3 mRNA levels were significantly lower 
expressed compared to controls, which is in line with the latter findings in 
diabetic rat hearts and muscle of diabetic patients and suggests that FA 
oxidation in DIO hearts is impaired. 
 
Furthermore, the expression of Ehhadh, Hmgcs2, and Scd4 were significantly 
reduced in DIO hearts. Scd4 plays a role in the biosynthesis of 
monounsaturated FA. It is exclusively expressed in the heart and is induced by 
high carbohydrate diet [283]. In hearts of ob/ob mice Scd4 mRNA was increased 
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by 5-fold compared to wild type controls and decreased with leptin-treatment of 
ob/ob mice. Miyazaki et al. concluded that down-regulation of Scd4 expression 
by leptin may be one of the mechanisms by which leptin depletes lipid from the 
heart and exerts its anti-lipotoxic effects [283].  
 
Ehhadh is a member of the peroxisomal enzymes of the classical peroxisomal 
β-oxidation cycle, which plays an essential role in the shortening of very long 
chain FA prior to complete oxidation in mitochondria [284] but little is known 
about its role in the diabetic heart. The lower expression of Ehhadh in DIO 
hearts suggests that peroxisomal β-oxidation cycle might be attenuated and 
thus potentially inducing accumulation of very long chain FA in the myocardium.  
 
HMGCS2 is a mitochondrial enzyme that catalyses a rate-limiting reaction in 
ketogenesis, a mitochondrial process by which acetyl-CoA is converted into 
ketone bodies in states such as starvation, poorly controlled diabetes or low 
carbohydrate feeding [285]. Its transcription is induced by fatty acids both in vivo 
and in vitro and transcriptional activation seems to be mediated by PPAR [286]. 
In adult rat liver, a 40% saturated fat diet produces a 3-fold increase in 
mitochondrial Hmgcs2 mRNA and protein levels [287, 288] which is mediated by 
PPAR. Additionally, rats in which diabetes has been induced by STZ show 
increased mitochondrial Hmgcs2 mRNA levels compared to normal controls 
[288]. In the liver, insulin suppresses the expression of Hmgcs2 [289] and Wentz 
et al. have shown that in cultured cardiomyocytes Hmgcs2 induction is 
dependent on PPARα and inhibited by insulin [285]. This would suggest that 
hyperinsulinaemia present in DIO animals might lead to the lower expression of 
Hmgcs2 at the transcriptional level. 
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Table 4.5: Genes involved in lipid metabolism and their protein function 
 
Gene encoding for Protein function 
Stearoyl-coenzyme A desaturase 4 
(Scd4) 
Biosynthesis of monounsaturated FA 
Enoyl-CoA hydratase/3-hydroxyacyl 
Coenzyme A dehydrogenase 
(Ehhadh) 
 
Peroxisomal β-oxidation  
 
3-hydroxy-3-methylglutaryl-Coenzyme 
A synthase 2 (Hmgcs2) 
 
Catalysation of ketogenesis 
Farnesyl diphosphate farnesyl 
transferase 1 (Fdft1) 
Cholesterol biosynthesis 
Uncoupling protein 3 (Ucp3) Regulator of mitochondrial membrane 
potential 
Pyruvate dehydrogenase kinase 4 
(Pdk4) 
Phosphorylation and inhibition of pyruvate 
dehydrogenase 
 
 
Besides lipid metabolism, differentially expressed genes involved in the 
development of hypertrophy and fibrosis were identified. Genes encoding 
connective tissue growth factor (Ctgf) and the protein LIM and cysteine-rich 
domains 1 (Lmcd1) were significantly lower expressed in DIO hearts compared 
to age-matched controls. LIM domain proteins interact with transcriptional 
regulators, kinases, and structural proteins, and have therefore been assigned 
roles in cell growth, differentiation, and cytoskeletal remodelling [290]. LMCD1 is 
expressed in most tissues but particularly high in skeletal and cardiac muscle 
[291]. Bian et al. have shown in primary cardiomyocytes and cardiac-specific 
Lmcd1 transgenic mice after a hypertrophic stimulus (transverse aortic 
constriction) that Lmcd1 overexpression increases the hypertrophic and fibrotic 
response via activation of the calcineurin/nuclear factor of activated T cells 
signalling pathway whereas in the absence of this stimulus overexpression 
alone does not induce cardiac hypertrophy [292]. Additionally, they have shown 
that hypertrophy can be blocked by inhibiting Lmcd1. One downstream target 
gene of Lmcd1, the cardiac hypertrophy marker Ctgf, was also significantly 
down-regulated in DIO myocardium at the transcriptional level. Ctgf is rapidly 
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up-regulated in cardiomyocytes exposed to prohypertrophic stimuli [292] and 
mediates high glucose and palmitate induced hypertrophy and apoptosis in 
cardiomyocytes of STZ-treated rats [293]. Similarly, in VSMC, overexpression 
promotes expression of more extracellular matrix protein collagen I and 
fibronectin, and is a mediator of angiotensin II-induced fibrosis in vitro [229]. 
Despite its lower mRNA expression in DIO hearts, protein expression was not 
significantly changed compared to control hearts. 
 
Finally, differentially expressed genes encoding metallothionein 2 (Mt2), G 
protein-coupled receptor 22 (Gpr22) and regulator of G protein signalling 2 
(Rgs2) were grouped together due to their role in vascular reactivity. Gpr22 is 
termed as an orphan G protein-coupled receptor due to the fact that its natural 
ligands have not been identified. Gpr22 mRNA and protein are highly expressed 
in cardiomyocytes and coronary arteries and Gpr22 knockout mice show 
increased susceptibility to heart failure under conditions of hemodynamic stress 
[294]. The enriched expression in coronary vascular cells suggests a possible 
role for this receptor in the regulation of coronary blood flow [294]. In contrast to 
these findings, Gpr22 mRNA expression was significantly up-regulated in DIO 
hearts compared to age-matched controls.   
 
Another differentially expressed gene, Metallothionein 2 (Mt2), was significantly 
down-regulated in DIO hearts. Mt2 is an intracellular metal-binding and cystein-
rich protein, which mainly act as regulator of matrix metalloproteinases [233, 
295]. It is a potent antioxidant and adaptive (or stress) protein to protect cells 
and tissues from oxidative stress [295]. It has been shown that enhanced Mt2 
expression in heart and kidney provided significant protection from diabetes-
induced organ dysfunction such as cardiomyopathy and nephrophathy [295, 
296]. Interestingly, both gene and protein expression was significantly lower in 
aortic tissue and cultured aortic smooth muscle cells form bicuspid aortic valve 
patients [233] which suggests a role of metallothionein in regulating extracellular 
matrix homoestasis within the media of the ascending aorta. The lower 
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expression of Mt2 mRNA in DIO hearts was accompanied by a reduction of MT2 
protein expression of about 20%. However, due to the high variability between 
samples no statistical significance was observed. Despite this, the data suggest 
a possible impairment of the antioxidant action of MT2 in DIO hearts which may 
promote the development of oxidative stress induced cellular changes in 
myocardium or vascular tissue.  
 
The gene encoding regulator of G protein signalling 2 (Rgs2) is another gene 
identified by microarray analysis which was differentially regulated by high fat 
diet. Regulators of G protein signalling accelerate the deactivation and inhibit 
signalling by acting as GTPase-accelerating proteins at active Gα protein 
subunits [297]. RGS2 shows regulatory selectivity for the Gαq subclass of G 
proteins which is involved in signalling of many important cardiovascular 
hormones such as endothelin-1, angiotensin-II or norepinephrine [231]. 
Additionally, expression of RGS2 has been described in tissues that are 
important for blood pressure regulation like the kidney, vascular smooth muscle 
cells and the central nervous system [231]. Polymorphisms in Rgs2 have been 
observed in a Japanese hypertensive cohort [298] whereas hypotensive patients 
have increased expression of RGS2 at the RNA and protein level [299]. 
Moreover, animal studies have shown that homo- and heterozygous knockout 
mice exhibit a hypertensive phenotype [297]. In DIO hearts not only Rgs2 mRNA 
expression was significantly lower but also protein expression was significantly 
reduced by ~50% compared to control hearts. The in vivo role of RGS2 in 
regulating cardiac function and blood pressure together with the significant 
findings at both RNA and protein level after high fat diet feeding lead us to 
suggest that reduced expression of RGS2 could be of considerable 
pathophysiological significance and therefore might be a potential candidate 
involved in the development of microvascular remodelling in DIO hearts. 
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4.4.4 Effects of high fat diet on the myocardial insulin signalling 
pathway 
Cellular insulin resistance involves a combination of factors and disruption of 
more than one signalling component [300, 301]. Despite the fact that the heart is 
only a minor site of whole body glucose disposal [13], a reduction in glucose 
uptake and utilisation as well as insulin resistance has been observed in the 
diabetic heart [45, 70]. Since insulin action on glucose transport in the heart 
appears to be primarily mediated by the PI3K-dependent branch [302], we 
focused on three members of this branch to investigate the effects of high fat 
diet feeding on insulin-mediated glucose uptake.  
 
IRS1 is a critical point for the control of glucose uptake in heart and skeletal 
muscle and a deficit in IRS1 tyrosine phosphorylation has been observed in 
skeletal muscle of diabetic patients [300, 303]. After 11 weeks of high fat diet, no 
significant differences were observed in total IRS1 content between DIO and 
control mice at both baseline and after insulin stimulation. Moreover, similar 
baseline tyrosine phosphorylation levels of IRS1 were observed in DIO and 
control hearts. After insulin stimulation, phosphorylation significantly increased in 
control mice but not in DIO hearts. Similarly, no differences in baseline 
phosphorylation of Akt were observed between DIO and control hearts. When 
stimulated with insulin, phosphorylation significantly increased in both groups. In 
ob/ob mouse hearts, baseline P-Akt levels were significantly increased 
compared to controls and only in control hearts a significant increase in P-Akt 
after insulin stimulation was observed. Similarly to the results in ob/ob hearts, 
the observed results suggest that high fat diet feeding and the resulting 
compensatory hyperinsulinaemia activates the insulin receptor leading to 
tyrosine phosphorylation of IRS1. Although IRS1 phosphotyrosine levels are 
lower in DIO hearts it appears to be sufficient to activate the PI3K-dependent 
branch of the insulin signalling pathway resulting in a significant increase in 
phosphorylation of Akt. Akt is regarded as an important signalling node in the 
insulin signalling pathway. Activation of Akt results in modulation of various 
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downstream targets like eNOS activity, GLUT4 translocation, GSK1 or the 
transcription factor FOXO (described in Chapter 1). In contrast to our 
observations in high fat diet fed animals, Park et al. reported a reduction of 
insulin-stimulated Akt phosphorylation by 40% after 10 days of feeding a 55% 
high fat diet [75]. Similarly, no differences in basal P-Akt levels but a decrease in 
P-Akt after insulin stimulation was reported in ob/ob mice [73]. The differences in 
Akt phosphorylation between our study and the publication by Park and co-
workers [75] could, in part, be explained by the differences in fat content of the 
diet (45% vs. 55%), the age of the animals as well as the feeding duration (11 
weeks vs. 10 days and 3 weeks). It is possible that short-term high fat diet 
feeding results in a reduction of Akt activity whereas long-term feeding together 
with compensatory factors might have a different effect on Akt protein 
expression. Also, the possibility of cross talk between different signalling 
pathways should not be excluded. For example, up-regulation of the 
sympathetic nervous system has been described to play an important role in the 
pathogenesis of insulin resistance. Morisco et al. have observed interaction 
between beta-adrenergic and insulin receptors in neonatal cardiomyocytes [29]. 
Moreover, insulin and leptin signalling pathways are known to share certain 
downstream molecules such as IRS, PI3K, Akt, and MAPK [304] and in vitro 
data in skeletal muscle provide evidence that high leptin levels lead to the 
hallmarks of insulin resistance including inhibition of insulin-stimulated glucose 
uptake [305].  
 
Reduced insulin-stimulated glucose uptake has been observed in different 
mouse models of insulin resistance and T2DM [73-75]. Wright et al. observed 
that a short duration of high-fat feeding (2 and 5 weeks of 45% high fat diet) 
causes an early reduction in glucose utilisation on the basis of reduced GLUT4 
content and translocation [74]. Similarly, Park and co-workers demonstrate a 
reduction in total GLUT4 content in animals fed a high fat diet for 10 days as 
well as 3 weeks and conclude that diet-induced cardiac insulin resistance 
develops before alterations in whole-body glucose homeostasis and secondary 
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to defects in Akt-mediated insulin signalling and GLUT4 expression [75]. In 
contrast, we observed a slightly lower but not significant GLUT4 protein content 
in DIO mouse total heart lysates at baseline. When looking specifically at 
GLUT4 content in cardiomyocytes lower basal GLUT4 expression was clearly 
observed. Interestingly, insulin stimulation resulted in an increased expression of 
GLUT4 in control hearts but no significant differences were observed in DIO 
mice. Similarly, no changes in total GLUT4 content after insulin stimulation have 
also been observed in the leptin-deficient ob/ob mouse hearts whereas the 
ability of insulin to stimulate glucose uptake was completely blunted [73]. Since 
insulin-responsive glucose uptake in the heart is facilitated by the translocation 
of GLUT4 from intracellular storage vesicles to the sarcolemma [48] it is likely 
that blunted glucose uptake represents a defect in GLUT4 translocation to the 
sarcolemma. To determine whether a defect in GLUT4 translocation exists in 
DIO hearts after insulin stimulation we tried to investigate GLUT4 localisation at 
the sarcolemma as well as the major proteins involved in GLUT4 trafficking and 
docking like AS160, Syntaxin4, VAMP2/3, or Munc18c [306]. However, due to 
technical constraints we were unable to obtain the data and thus we cannot 
properly address this particular question. 
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Chapter Five: Evaluating the role of 
RGS2 in coronary microvascular 
remodelling and blood pressure control 
in DIO  
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5.1 Introduction 
Coronary microvascular remodelling is associated with functional changes as 
well as structural alterations in vessel morphology and has been observed in 
patients with hypertension, T2DM, or HCM [92]. As described in the previous 
chapters we have demonstrated the development of blood pressure-
independent coronary microvascular remodelling in our DIO mouse model. 
Moreover, microarray analysis on DIO hearts resulted in differentially expressed 
genes involved in lipid metabolism, fibrosis and hypertrophy as well as 
regulation of cardiovascular function and disease (Chapter 4). Among the genes 
which were differentially expressed in DIO mice, we here focus on Rgs2, which 
was decreased at both RNA and protein level, and might play a significant role 
in the development of microvascular remodelling in DIO hearts.  
 
5.1.1 Physiological role of RGS2 
RGS2 expression has been described in tissues that are important for blood 
pressure regulation and vascular function like the kidney, VSMC and the central 
nervous system [231, 307]. Both clinical and basic studies have demonstrated 
that deregulation of RGS2 contributes to the pathogenesis of CVD [308, 309]. 
For example, studies have shown that RGS2 mRNA and protein levels are 
reduced in hypertensive patients [310, 311]. Yang et al. have identified two rare 
mutation of RGS2 in a Japanese hypertensive cohort (RGS2-Q2L and RGS2-
Q2R) which were reported to affect protein stability [312]. In contrast to these 
results, in 2007 Bodenstein and co-workers showed that only RGS2-Q2L results 
in strong proteasomal degradation and lower expression in HEK293 cells [297]. 
Further studies have shown that another mutation, RGS2-R44H, disrupts the 
amphipathic α-helix which is crucial for proper plasma-membrane targeting and 
function [313] whereas the RGS2- C1114G variant has been shown to associate 
with hypertension and higher than normal body mass index which suggests a 
link between RGS2 and obesity and the metabolic syndrome [314]. Animal 
studies have further underlined the essential role of RGS2 in the regulation of 
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vascular tone. RGS2 knockout mice exhibit modest systemic hypertension and 
strikingly elevated mean arterial pressure [315, 316]. Additionally, Tang et al. 
have shown increased contraction and impaired cGMP-mediated relaxation in 
aortic rings from RGS2 knockout mice [315] and Sun et al. provided the first 
evidence indicating that RGS2 mediates the action of the NO-cGMP pathway on 
blood pressure by promoting relaxation of the resistance vasculature through its 
ability to attenuate vasoconstrictor-induced Ca2+ signalling [232]. Interestingly, a 
recently published study by Gurley et al. demonstrated that RGS2 expression in 
the kidney but not in other tissues including the central nervous system and 
peripheral vasculature is critical for the regulation of blood pressure [317]. 
Moreover, down-regulation of RGS2 has been described in animal models of 
hypertrophy [318] and occurs even before the onset of hypertrophy. Following 
pressure overload, RGS2 deficient mice display a marked dilation accompanied 
with significantly increased end diastolic and end systolic dimensions and 
decline in fractional shortening as well as impaired relaxation [319]. 
Furthermore, Zhang et al. have demonstrated that overexpression of RGS2 
inhibits Gαq/11-mediated cardiomyocyte hypertrophy [318]. 
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5.1.2 G protein signalling regulation by RGS2 
RGS2 is a member of more than 30 RGS domain-containing proteins that 
regulate G protein-coupled receptor (GPCR) signalling [232, 297, 317]. GPCRs 
like the angiotensin II type 1 (AT1) receptor are transmembrane receptors that 
are associated with heterotrimeric G proteins (consisting of an α, β, and γ 
subunit), which mediate a wide array of signalling processes [231, 297] (Figure 
5.1 A). Binding of a hormone results in the activation of GPCRs, a 
conformational change of the receptor and thus in the activation of G proteins. G 
proteins exchange guanosine 5’-diphosphate (GDP) for GTP on the Gα subunit 
leading to the dissociation of the Gβγ dimer from Gα [309, 320]. This 
dissociation will activate other proteins further downstream in the signal 
transduction pathway leading for example to vasoconstriction and VSMC 
proliferation (Figure 5.1 B). G protein signalling is further regulated by proteins 
like RGS2. RGS2 accelerates the hydrolysis of Gα-bound GTP to GDP and thus 
terminates the Gα-effector interactions leading to the inhibition of 
vasoconstriction and VSMC proliferation in the example of the AT1 receptor 
[231, 297] (Figure 5.1 C). RGS2 shows regulatory selectivity for the Gαq/11 
subclass of G proteins where many important cardiovascular hormones such as 
ET-1, angiotensin II or norepinephrine activated receptors couple to [231].  
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     AT1 receptor 
 
 
Figure 5.1: G protein signalling regulation by RGS2.  
(A-C) Regulation of G protein signalling by RGS2 on the example of the AT1 
receptor. (A) In the basal state the AT1 receptor is associated with a 
heterotrimeric G protein. (B) Binding of angiotensin II activates the G protein-
coupled AT1 receptor, causing a conformational change and exchange of GDP 
for GTP on Gαq. The Gαq-GTP and Gβγ subunits dissociate leading to the 
activation of downstream proteins, which eventually results in physiological 
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actions such as vasoconstriction and VSMC hypertrophy. (C) In the presence of 
RGS2 the Gαq-catalysed hydrolysis of GTP to GDP is accelerated leading to a 
termination of the Gα-effector interactions. GDP, guanosine 5’-diphosphate; 
GTP, guanosine 5’-triphosphate, VSMC, vascular smooth muscle cells. Adapted 
from [231]. Figure was produced using Servier Medical Art (www.servier.com). 
 
 
5.2 Aims 
We wanted to investigate the role of RGS2 in the development of coronary 
microvascular remodelling in DIO mice.  
Furthermore, we aimed to assess the effects of a non-pharmacological lifestyle 
change due to a shift in diet from high fat back to normal rodent chow on 
coronary vascular remodelling and RGS2 expression in DIO mice. 
 
To assess these questions the following aims were addressed: 
 
1. Investigate the expression of RGS2 in VSMC and the kidney of DIO mice 
 
2. Investigate effects of diet shift on metabolic parameters 
 
3. Investigate effects of diet shift on RGS2 expression and vascular 
remodelling 
 
 
 192 
 
5.3 Results 
5.3.1 Evaluation of RGS2 expression in DIO 
As described in Chapter 4, RGS2 mRNA and protein expression was 
significantly reduced in total heart lysates of DIO mice compared to control 
animals. To investigate the potential role of RGS2 in coronary microvascular 
remodelling RGS2 expression was measured in vascular smooth muscle cells of 
DIO and control mice. Heart sections of DIO and control mice were stained for 
RGS2 using immunohistochemistry. To assess RGS2 expression specifically in 
VSMC, they were detected using specific staining against α-smooth muscle 
actin. RGS2 expression was measured in vessels with a diameter smaller than 
120 µm using digital morphometric analysis. Our results show a strong 
cytoplasmic expression of RGS2 in smooth muscle cells in control animals 
whereas mean RGS2 intensity in DIO mice was significantly reduced compared 
to controls (1.721±0.8178 vs. 14.11±2.193 for DIO vs. controls, p<0.005, n=4) 
(Figure 5.2). 
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Figure 5.2: Effects of high fat diet on RGS2 expression in VSMC.  
(A) Representative images of RGS2 expression in VSMC of control (left) and 
DIO (right) mice. RGS2 expression was detected by immunofluorescence 
staining using anti-RGS2 antibody and Alexa Fluor 488-conjugated secondary 
antibody (green). Identification of VSMC was achieved by staining with anti-
vascular smooth muscle actin antibody and Alexa Fluor 568-conjugated 
secondary antibody (red). Nuclei were detected by TO-PRO3 staining (purple). 
Images were taken by confocal microscopy (Zeiss LSM 510) (40x 
magnification). White scale bars indicate 20 µm. (B) Quantification of RGS2 
expression measuring mean fluorescence intensity (MFI) around multiple 
vessels (>10). Data are expressed as mean±SEM with 5 animals per group. 
Data were analysed using Student’s t-test. ** p<0.005. 
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A study by Gurley and co-workers showed that the development of hypertension 
is solely determined by a reduced expression of RGS2 in the kidneys [317]. 
Since we did not observe hypertension in DIO mice we wanted to investigate 
whether RGS2 is differentially expressed in DIO kidneys compared to age-
matched controls. For this, protein expression analysis using western blotting on 
total kidney lysates of DIO and control mice was performed. Mean protein 
expression of RGS2 in kidneys of DIO mice did not change compared to control 
animals (0.7733±0.08388 vs. 0.8645±0.09015 for DIO vs. controls, p=ns, n=3) 
(Figure 5.3). 
 
 
 
Figure 5.3: Effects of high fat diet on expression of RGS2 in kidneys.  
(A) Representative western blot showing RGS2 (top) and GAPDH (bottom) 
expression in total kidney lysate in DIO and control animals (n=3). (B) 
Quantification of mean intensity of RGS2 protein expression after correcting for 
loading differences using GAPDH. Fold change is expressed as mean±SD for 3 
animals per group. Data were analysed using Student’s t-test. ns, not significant.  
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5.3.2 Effects of diet shift on body composition and metabolic 
markers in DIO mice 
In the previous chapter we have demonstrated that exposure to high fat diet 
leads to coronary microvascular remodelling. Therefore, we determined whether 
the observed microvascular remodelling is reversible in DIO mice animals. For 
this, animals were put back on the normal rodent chow for three weeks and the 
effects on body composition, metabolic markers, RGS2 expression in vascular 
smooth muscle cells, and coronary microvascular remodelling were investigated.  
 
5.3.2.1 Whole body composition 
Interestingly, after three weeks of normal rodent chow, body weight decreased 
in DIO mice back to the same weight as the age-matched controls (30.03±1.915 
g vs. 29.74±2.349 g, p=ns, n=10). These mice were labelled ‘DIO-weight loss’ 
(DIO-WL). This was also confirmed when correcting end body weight for 
differences in animal size using the tibia length. There was a significant 
difference body weight-to-tibia ratio between DIO mice and DIO-WL mice but not 
between DIO-WL and control mice (2.412±0.09426 mg/mm vs. 1.719±0.3729 
mg/mm, p<0.0001, n=10 for DIO vs. DIO-WL and 1.719±0.3729 mg/mm vs. 
1.714±0.1070 mg/mm, p=ns, n=10 for DIO-WL vs. controls) (Figure 5.4 A).  
 
Additionally, both fat weight-to-tibia ratio and liver weight-to-tibia ratio of DIO-WL 
animals went back to almost the same levels as in control animals (53.60±20.78 
mg/mm vs. 39.70±14.76 mg/mm, p=ns, n=10 fat weight-to-tibia ratio and 
84.08±14.04 mg/mm vs. 68.39±7.384 mg/mm, p=ns, n=10 for liver weight-to-
tibia ratio) (Figure 5.4 B and E). No significant changes were observed in heart 
weight-to-tibia ratio and kidney weight-to-tibia ratio in DIO, DIO-WL and control 
mice. However, before correcting for tibia length, DIO mice showed a significant 
increase in kidney weight compared to control mice (177.0±5.448 mg/mm vs. 
150.1±5.380 mg/mm, p<0.05, n=10) (Figure 5.4 C and D). Interestingly, after 
putting the mice back on the normal rodent chow the kidney weight in DIO-WL 
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mice did not go back to control levels but stayed similar to DIO levels 
(178.0±7.688 mg/mm vs. 177.0±5.448 mg/mm, p=ns, n=10 for DIO-WL vs. DIO). 
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Figure 5.4: Effects of high fat diet and a shift in diet on body composition.  
(A) End body weight normalised to tibia length in g/mm. (B) Fat weight 
normalised to tibia length in mg/mm. (C) Heart weight-to-tibia ratio in mg/mm. 
(D) Kidney weight-to-tibia ratio in mg/mm and (E) liver weight-to-tibia ratio in 
mg/mm. Data are expressed as mean±SD for 10 animals in each group. Data 
were analysed using one-way ANOVA with Bonferroni’s multiple comparison. 
ns, not significant; ** p<0.005 and *** p<0.0005.  
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5.3.2.2 Metabolic parameters 
Concomitantly to the whole body weight loss, fasting serum insulin levels in DIO-
WL mice improved and did not significantly differ from control levels 
(1.854±0.5660 ng/mL vs. 0.5564±0.08629 ng/mL, p=ns, n=10) (Figure 5.5). 
Similar to serum insulin levels, baseline fasting glucose levels improved with no 
significant differences between DIO-WL and control mice (9.950±1.542 mmol/L 
vs. 9.900±0.7000 mmol/L, p=ns, n=4) (Figure 5.6 A). After an oral glucose 
challenge, blood glucose levels peaked after 15 minutes in control mice and 
after 30 minutes in DIO and DIO-WL mice and returned back to baseline after 
120 minutes in DIO-WL but not DIO mice (Figure 5.6 A). As described in 
Chapter 3, DIO mice had a significant increase in the AUC of 99% (p<0.0001) 
whereas only an increase of 8% in AUC was observed in DIO-WL mice 
compared to controls (p=ns) (Figure 5.6 B). 
 
 
 
Figure 5.5: Fasting serum insulin levels in control, DIO and DIO-WL mice.  
Serum insulin levels in DIO-WL after 3 weeks of normal rodent chow compared 
to control and DIO mice using an insulin ELISA. Insulin levels of each animal 
were analysed in duplicates. Data are expressed as mean±SEM with n=5 for 
controls, n=8 for DIO and n=4 for DIO-WL mice. Data were analysed using one-
way ANOVA with Bonferroni’s multiple comparison. ns, not significant; ** 
p<0.005.  
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Figure 5.6: Oral glucose tolerance test (OGTT) in DIO-WL animals, age-
matched DIO and control mice.  
(A) OGTT in DIO-WL and age-matched DIO and control animals. Blood glucose 
levels at baseline, 30, 60 and 120 min after an oral glucose load. (B) AUC 
analysis of OGTT. Data are expressed as mean±SEM with n=4 for control and 
DIO-WL mice and n=6 for DIO mice. Data were analysed using one-way 
ANOVA with Bonferroni’s multiple comparison. ns, not significant; ** p<0.005. 
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5.3.2.3 Effects of diet shift on coronary microvascular remodelling 
and RGS2 expression in vascular smooth muscle cells  
To investigate whether the shift in diet has an effect on coronary microvascular 
remodelling, histomorphometrical analysis was performed. Three weeks of 
normal rodent chow resulted in a decrease in medial area (1845±177.1 µm2 vs. 
2687±207.3 µm2, p=ns for DIO-WL vs. DIO) (Figure 5.7 A and B) and a 
significant decrease in media-to-lumen ratio (1.702±0.2634 vs. 2.791±0.2530, 
p<0.05 for DIO-WL vs. DIO) in vessels smaller than 150 µm in the DIO-WL mice 
compared to DIO mice, returning to values similar to control mice (1.702±0.2634 
vs. 1.617±0.1648, p=ns for DIO-WL vs. controls) (Figure 5.7 A and C).  
 
In parallel to the reversal of coronary microvascular remodelling, mean intensity 
of RGS2 expression in vascular smooth muscle cells went back up to baseline 
control levels after 3 weeks of normal rodent chow (14.35±2.742 vs. 
14.11±2.193 for DIO-WL vs. control, p=ns) (Figure 5.8). 
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Figure 5.7: Effect of shift in diet on coronary microvascular remodelling.  
(A) Histological sections of small arterioles (circled by dashed line) in left 
ventricles of control, DIO and DIO-WL mice. Sections were stained with 
haematoxylin and eosin. Nuclei are stained in dark blue whereas eosinophilic 
structures like cytoplasm, intra- and extracellular proteins or red blood cells are 
stained in shades of red. Images were taken using 40x magnification. Black 
scale bars indicate 25 µm. (B) Quantification of medial area of transmural 
vessels in DIO, DIO-WL and age-matched controls. (C) Quantification of media-
to-lumen ratio of transmural vessels in DIO, DIO-WL and age-matched controls. 
Data are expressed as mean±SEM for n=4 for control and DIO-WL mice and 
n=10 for DIO mice and at least 6 vessels per heart. Data were analysed using 
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one-way ANOVA with Bonferroni’s multiple comparison. ns, not significant; * 
p<0.05 and ** p<0.005. Histomorphometrical analysis was carried out by Dr 
Massimiliano Mancini, La Sapienza University, Rome. Data analysis was 
performed by Christina Kleinert. 
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Figure 5.8: Effects of shift in diet on RGS2 expression in VSMC.  
(A) Representative images of RGS2 expression in VSMC of control (top left), 
DIO (top right) and DIO-WL mice (bottom left). RGS2 expression was detected 
by immunofluorescence staining using anti-RGS2 antibody and Alexa Fluor 488-
conjugated secondary antibody (green). Identification of VSMC was achieved by 
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staining with anti-vascular smooth muscle actin antibody and Alexa Fluor 568-
conjugated secondary antibody (red). Nuclei were detected by TO-PRO3 
staining (purple). Images were taken by confocal microscopy using a 40x 
magnification. White scale bars indicate 20 µm. (B) Quantification of RGS2 
expression measuring mean fluorescence intensity (MFI) around multiple 
vessels (>10). Data are expressed as mean±SEM with n=5 for control and DIO 
mice and n=3 for DIO-WL mice. Data were analysed using one-way ANOVA 
with Bonferroni’s multiple comparison. ** p<0.005. 
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5.4 Discussion 
5.4.1 Effect of high fat diet on RGS2 expression in VSMC and 
kidney  
In the previous chapter we have shown that high fat diet feeding is associated 
with alterations in metabolic markers, vascular structure and function as well as 
cardiac gene expression. In an attempt to identify a potential candidate involved 
in the observed microvascular remodelling in DIO hearts one differentially 
expressed gene, Rgs2, was of particular interest due to its role in blood pressure 
control, cardiac hypertrophy, vasoconstriction and VSMC proliferation [231, 309, 
315]. We hypothesised that RGS2 protein levels are not only reduced in total 
hearts of DIO mice but also in VSMC and thus might contribute to the 
development of coronary microvascular remodelling in left ventricles of DIO 
mice. Our results show that RGS2 expression was significantly reduced in 
VSMC of DIO mice after 11 weeks of high fat diet feeding. The reduced 
expression of RGS2 in DIO hearts suggests that the inhibitory effect of RGS2 on 
G protein-coupled receptor signalling transduction is attenuated and thus may 
potentiate vasoconstriction in response to vasoconstrictors such as endothelin 
or angiotensin II [316], and lead to proliferation and hypertrophy of VSMC.  
 
RGS2 expression and regulation has been extensively studied in hypertension. 
Down-regulation of RGS2 has been observed in cultured fibroblasts of 
hypertensive patients [310] as well as in animal models of hypertension [321]. It 
has been shown that RGS2 expression was reduced in saphenous arteries of 
SHR and adrenocorticotropic hormone-induced hypertensive rats, in which 
vascular remodelling occurs [321]. A study by Sun et al. showed that RGS2 
mediates the action of the NO-cGMP pathway on blood pressure and 
vasoconstrictor signalling in smooth muscle cells by promoting relaxation of the 
resistance vasculature through its ability to attenuate vasoconstrictor-induced 
Ca2+ signalling [232]. This was supported by an observation showing that RGS2 
mRNA expression is down-regulated in aortic smooth muscle in a NG-nitro-L-
arginine methyl ester (L-NAME)-induced hypertension rat model which suggests 
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that decreased eNOS function may play a role in the down-regulation of RGS2 
[322]. In the context of DIO mice it would be interesting to determine whether 
reduced eNOS function (possibly due to impaired insulin signalling transduction 
in VSMC or endothelial cells) may also be involved in down-regulation of RGS2 
in DIO mice before the onset of hypertension. 
 
Besides RGS2 expression in VSMC of DIO mice, we also investigated its 
expression in DIO kidneys after 11 weeks of high fat diet as a study by Gurley 
and co-workers showed that the development of hypertension is solely 
determined by a reduced expression of RGS2 in the kidneys [317]. As described 
in the previous chapter we did not observe any effects of high fat diet on mean 
arterial pressure (Figure 4.7). Concomitantly, no changes were observed in 
renal RGS2 expression after high fat diet feeding. This suggests that the reason 
why we did not observe hypertension in DIO mice might be due to the lack of 
differential/reduced expression of RGS2 in the kidneys. 
 
 
5.4.2 Effects of shift in diet on whole body composition and 
vascular remodelling 
Structural changes in the heart and vasculature can be attributed to the diabetic 
milieu of hyperglycaemia, hyperinsulinaemia, increased cellular FA uptake or 
hyperglycaemia-induced oxidative stress [13, 124]. It has been suggested that 
insulin or other related substances such as insulin-like growth factors may have 
a role in promoting vascular cell growth and thus promoting vascular remodelling 
[100, 323]. Additionally, high glucose concentrations can promote vascular 
complications by activating transcription factors that regulate pro-inflammatory 
and pro-atherosclerotic genes in endothelial cells and VSMC, stimulating 
oxidative stress, or VSMC proliferation, migration, and altered reactivity [94]. To 
the best of our knowledge no information is available about the regulation of 
RGS2 and its role in vascular remodelling in diabetes. To test whether RGS2 
expression and coronary vascular remodelling is modulated by glycaemic and 
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insulinaemic control, we used a non-pharmacological approach. We 
hypothesised that a shift in diet from high fat back to normal rodent chow would 
beneficially influence RGS2 expression in DIO mice. Additionally, we 
hypothesised that improvement of insulin sensitivity and blood glucose levels 
would promote reverse remodelling in coronary small vessels. It has been 
shown that non-pharmacological lifestyle interventions such as diet, weight loss, 
or physical activity all increase insulin sensitivity, adiponectin levels and reduce 
endothelial dysfunction [12]. Our results show that a shift in diet back to normal 
rodent chow (11 weeks 35% carbohydrate and 45% lard-based high fat diet, 
then shift to 11.5% fat and 61.2% carbohydrates for three weeks) resulted in a 
significant reduction of body weight, fat weight and liver weight. In our study, 
food intake was not measured. Although a shift to a low fat/high carbohydrate 
diet resulted in body weight reduction, it is important to note that this could have 
been caused not only by the shift in diet but also by other factors like stress-
dependent reduction in food intake.  
 
Furthermore, glucose and insulin levels were positively affected by the shift in 
diet as well as insulin sensitivity. These results are in contrast with recently 
published work by Lee and co-workers in which they showed that a shift in diet 
from high fat to high carbohydrate (45% high fat diet for 9 weeks then shift to 
70% carbohydrates for 3 weeks) in male C57BL/6 mice did not affect glucose 
and insulin levels as well as insulin sensitivity [324]. They concluded that a three 
weeks duration might not be sufficient to improve blood glucose and blood 
insulin levels even though body weight and body fat decreased significantly 
[324].  
 
Concomitantly to the improvement of metabolic markers after the shift in diet, 
coronary vascular remodelling as well as RGS2 expression in VSMC was 
significantly improved. This suggests that a shift in diet and the resulting 
glycaemic and/or insulinaemic control was efficient enough to reverse coronary 
microvascular remodelling in DIO hearts and improve RGS2 expression 
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returning back to baseline control levels. Studies in T1DM and T2DM have 
shown that hyperglycaemia plays a key role in the pathogenesis of vascular 
dysfunction in diabetes [92]. A study in the spontaneously diabetic (T2DM), 
nonobese, and normotensive GK rat, Sachidanandam et al. investigated the 
effects of hyperglycaemia in mediating vascular complications [93]. They 
observed that glycaemic control with Metformin, which improves insulin 
sensitivity and endothelium-dependent vasodilation [12] shortly after the onset of 
diabetes can prevent activation of growth-promoting and pro-fibrotic vasoactive 
factors and thus prevent vascular remodelling and dysfunction in mesenteric 
arteries [93]. However, they did not investigate whether an intervention strategy 
with Metformin results in reverse remodelling or whether glucose regulation in 
established diabetes can prevent and/or reverse vascular remodelling and 
dysfunction [93]. Similarly, at this stage it is impossible to give a conclusive 
explanation as to whether the observed reverse remodelling observed in our 
study was due to the improvement of an individual factor (i.e. hyperglycaemia or 
insulin-resistance) or a synergistic effect. In other disease settings such as 
hypertension, non-pharmacological lifestyle interventions might not be sufficient 
to improve coronary microvascular remodelling. Therapies aimed at improving 
for example insulin resistance, inflammation, oxidative stress, or endothelial 
dysfunction are predicted to have simultaneous beneficial effects on both 
metabolic and cardiovascular function [12]. Work in our group has shown that 
pharmacological treatment with the ACE inhibitor Ramipril and/or the NO-
independent soluble guanylate cyclase activator HMR1766 in SHR not only 
leads to a reduction in blood pressure but also to reverse remodelling of the 
coronary microcirculation and therefore also to functional improvement [325]. 
 
In addition to the improvement of metabolic markers, the shift in diet from a high 
fat to a high carbohydrate diet might also have contributed to a reversal of 
dietary fatty acid-induced changes in gene expression and therefore positively 
influenced RGS2 gene expression and regulation. Also, it has been shown that 
calorie restriction not only increases insulin sensitivity but also improves NO-
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dependent vasodilation in obese or hypertensive individuals [326, 327]. 
Restoration of normal RGS2 expression levels in VSMC might have influenced 
vasoconstrictor signalling in smooth muscle cells and thus promotes relaxation 
of the resistance vasculature.  
 
In summary, our results identify a previously unrecognised role of RGS2 in diet-
induced coronary vascular remodelling before the onset of hypertension. A shift 
in diet from high fat to high carbohydrate diet resulted in significant reduction of 
body, fat, and liver weight but also in a substantial improvement of insulin 
sensitivity and blood glucose levels. Importantly, this diet shift was sufficient to 
reverse the observed coronary microvascular remodelling and restore RGS2 
expression levels in VSMC.  
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Chapter Six: General Discussion 
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6.1 Summary of main study findings 
Listed below is a summary of the main findings of this study: 
 
1. The 11 weeks high fat diet-induced obese C57BL/6 mouse is a more 
appropriate model to study insulin resistance and T2DM than the ob/ob 
mouse model. 
 
2. Coronary microvascular remodelling characterised by thickening of the 
media was present in DIO mice as early as 8 weeks of high fat diet but 
absent in both normoglycaemic and hyperglycaemic ob/ob mice. 
 
3. Coronary microvascular remodelling in DIO mice was independent of 
hypertension and overt changes of the myocardium. A shift in diet from 
high fat to high carbohydrate diet resulted in reverse remodelling of the 
coronary microvasculature. 
 
4. High fat diet feeding was not associated with overt changes in coronary 
blood flow but an impairment of endothelium-dependent vasodilation in 
the aorta.  
 
5. Microarray analysis of the left ventricle revealed diet-induced changes in 
mRNA expression of genes involved in lipid metabolism, hypertrophy and 
fibrosis, and vascular reactivity. Moreover, high fat diet feeding was 
associated with diet-induced changes in protein expression levels of 
members of the insulin signalling pathway. 
 
6. RGS2, a protein involved in blood pressure control and vasoconstrictor 
signalling, was differentially expressed in DIO mice. This effect was 
reversible by a dietary shift from high fat to normal rodent chow. 
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6.2 General discussion 
One of the aims of this project was to generate a high fat diet induced mouse 
model of insulin resistance and T2DM and determine which of the different 
feeding periods studied would make the most suitable model to investigate the 
molecular and genetic mechanisms of myocardial insulin resistance. The results 
described in Chapter 3 show that high fat diet feeding gradually alters the 
characteristic risk factors contributing to the development of insulin resistance 
and eventually T2DM leading to macroscopic and microscopic changes in the 
liver, kidney, and heart. Our results together with numerous previous studies on 
diet-induced metabolic and pathological changes [74, 75, 166, 176, 198] 
underline the suitability of the high fat diet fed C57BL/6 mouse as a model of 
environmentally induced T2DM and obesity [160].  
 
This thesis describes for the first time the progressive development of inward 
muscular remodelling of coronary arterioles in DIO mice which is not present in 
the heart of leptin-deficient ob/ob mice (Figure 6.1; Chapter 4). Microvascular 
remodelling and dysfunction has been studied in patients with hypertension 
[104, 328], diabetes [100, 206] or HCM [92, 102] and represents a predisposing 
factor for myocardial ischaemia in HCM [329, 330]. However, only few animal 
models of coronary microvascular remodelling exist [214]. We could 
demonstrate that the observed coronary microvascular remodelling in DIO mice 
is independent of hypertension or cardiac hypertrophy and that it is 
accompanied by mild coronary microvascular dysfunction and endothelial 
dysfunction. Moreover, a dietary shift from the high fat to a high carbohydrate 
diet lead to significant improvement of the metabolic markers of insulin 
resistance as well as to reverse remodelling of coronary arterioles (Figure 6.1). 
Although the observed remodelling is diet-induced, our work provides the first 
murine model that phenotypically mimics the microvascular remodelling 
observed in patients with HCM.  
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A key aim of this thesis was to identify gene expression changes associated with 
high fat diet-induced coronary microvascular remodelling. Microarray analysis 
identified several genes involved in myocardial lipid and glucose metabolism, 
the development of hypertrophy and fibrosis as well as vascular reactivity which 
were differentially expressed in left ventricles of DIO mice compared to age-
matched controls (Chapter 4). Further analysis revealed one very interesting 
gene which might play a significant role in the development of microvascular 
remodelling in DIO hearts. RGS2, a member of the regulators of G protein 
signalling family, was differentially expressed at both the RNA and protein level 
in left ventricles and VSMC of DIO mice. Specifically, we demonstrated that 
RGS2 is down-regulated in VSMC of transmural arterioles in DIO hearts 
(Chapter 5). Expression of RGS2 has been described in tissues that are 
important for blood pressure regulation, vascular function, and vasoconstriction 
like the kidney, VSMC and the central nervous system [231, 307]. Previous 
clinical and basic studies have demonstrated that deregulation of RGS2 
contributes to the pathogenesis of CVD [308, 309, 331]. Our work suggests a 
novel unrecognised role of RGS2 in diet-induced coronary vascular remodelling 
before the onset of hypertension. Moreover, the dietary shift back to a normal 
rodent chow (high carbohydrate diet) was sufficient to not only reverse the 
observed coronary microvascular remodelling but also restore RGS2 expression 
levels in VSMC (Figure 6.1).  
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Figure 6.1: Effects of diet on coronary microvascular remodelling.  
 
High fat diet feeding was associated with a significant increase in blood insulin 
and glucose levels, the development of coronary microvascular remodelling and 
down-regulation of RGS2 in VSMC. A shift in diet from high fat to a normal 
rodent chow (high carbohydrate diet) lead to reverse remodelling of coronary 
arterioles and the return of metabolic markers and RGS2 expression to baseline. 
In contrast, the spontaneously diabetic, leptin-deficient ob/ob mouse heart did 
not show any signs of coronary microvascular remodelling despite elevated 
blood glucose and insulin levels. WT, wild type; DIO, diet-induced obese; DIO-
WL, diet-induced obese weight loss; RGS2, regulator of G protein signalling 2; ↑ 
increase; ↔ unchanged; ? unknown. 
 
 
Furthermore, impairment of the PI3K-dependent branch of the insulin signalling 
transduction pathway has been observed in different mouse models of insulin 
resistance and T2DM [73-75]. We show that high fat diet feeding was associated 
with differential expression and activity of Akt, a down-stream target of the 
insulin signalling pathway as well as lower basal expression of GLUT4 in DIO 
cardiomyocytes but no significant differences in GLUT4 expression between 
WT DIO DIO-WL ob/ob
Insulin
Glucose
Insulin
Glucose
Insulin
Glucose
RGS2 RGS2 RGS2?
??
High fat 
diet
High carb
diet
Spontaneously 
diabetic
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baseline and insulin-stimulated DIO hearts (see Chapter 4). Previous work from 
our group on human myocardial biopsy samples of diabetic patients has shown 
that impaired insulin signalling was associated with increased myocardial IRS1-
PI3K activity, unchanged total GLUT4 content and a reduction of basal 
sarcolemmal GLUT4 [72]. Moreover, these results in human myocardium were 
confirmed in comparative studies in the leptin-deficient ob/ob mouse heart [72]. 
 
 
6.3 Future work 
Our observations have opened up several new lines of enquiry which should 
now be addressed experimentally in future studies.  
 
Firstly, it would be interesting to further study the phenomenon of why some 
animals did not respond to the high fat diet with significant body weight gain. 
Generally, only mice with the highest weight gain are used for further studies. 
However, on average 30% of the mice in this study did not increase their body 
weight when fed the high fat diet and were thus classified as diet-induced 
resistant. It has been suggested that a significantly lower initial body weight and 
lower calorie intake after 5 weeks of high fat diet [167] might be the reason for 
their diet resistance. Moreover, Burcelin and co-workers have started to classify 
high fat diet fed mice into lean non-diabetic, lean diabetic, obese diabetic, and 
intermediate phenotype and observed that the first three phenotypes are insulin 
resistant [332]. Nevertheless, it would be interesting to further investigate 
phenotypical and cellular differences between the diet-resistant and diet-induced 
obese mice and therefore gain further insight into the mechanisms involved in 
insulin resistance.  
 
Secondly, with regards to the DIO mice further characterisation of metabolic 
changes in DIO mice might give a better insight into the pathophysiological 
changes associated with high fat diet feeding. The increase in adipose tissue 
due to the high fat diet will stimulate pro-inflammatory cytokine and adipokine 
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production [61] and suppress anti-inflammatory adipokines [62] and therefore 
promote a pro-inflammatory and pro-thrombotic state. It would be interesting to 
study inflammatory markers like TNFα or IL-6 as well as circulating levels of 
adiponectin, an anti-inflammatory adipokine, but also cholesterol and triglyceride 
levels, which might also be modulated by high fat diet feeding. Moreover, 
increased ROS production and oxidative stress have been implicated in the 
development of cardiovascular changes leading to endothelial dysfunction and 
the development of atherosclerosis [13]. Due to practical constraints, the effects 
of high fat diet on ROS production, protein oxidation or the free-radical 
scavenging capacity of DIO mice was not determined. Thus, it would be 
desirable to measure plasma hydrogen peroxide as an indicator for ROS 
generation, protein oxidation by protein carbonyl determination or the plasma 
antioxidant power to test the free-radical scavenging capacity [245].  
 
Given our observations that high fat diet promotes impairment of endothelium-
dependent vasodilation in the aorta we attempted to further investigate this. We 
demonstrated that high fat diet did not affected plasma levels of an endogenous 
inhibitor of eNOS, ADMA, which has been associated with a range of 
cardiovascular disease states [168, 266, 267]. To further investigate endothelial 
dysfunction and the underlying mechanisms in future experiments several 
approaches are possible. Firstly, NO availability could be evaluated by an ACh 
concentration-response curve after pre-incubation with the NOS inhibitor L-
NAME. Secondly, to determine whether oxidative stress contributed to a 
decrease in NO bioavailability and thereby promoted endothelial dysfunction, 
ROS production could be evaluated by pre-incubating vessels with the 
antioxidant and .O2- dismutase mimetic Tempol and then constructing an ACh 
concentration-response curve similar to a report by Marchesi et al. [333] or by 
measuring ROS generation within the aorta in situ using dihydroethidium 
fluorescence [260]. Thirdly, eNOS activity in the vasculature could be 
investigated by measuring its expression, phosphorylation, and eNOS protein 
dimer formation which is necessary for eNOS activity [334] using western 
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blotting. Finally, proteins like Akt, Caveolin-1, soluble guanylate cyclase, or 
AMPK which have been shown to play vital roles in the regulation of NO 
production and activity [37, 334] could be investigated in the vasculature of DIO 
mice at baseline and after insulin stimulation to determine whether decreased 
insulin signalling was responsible for impaired NO release and vasodilation.  
 
One of the key findings of this thesis was the presence of coronary 
microvascular remodelling in DIO hearts which we could not observe in the 
leptin-deficient ob/ob mouse heart. To further dissect which trigger might be 
responsible for the development of coronary microvascular remodelling, it would 
be desirable to investigate the earliest time point of high fat diet feeding after 
which coronary microvascular remodelling occurs. Moreover, due to time 
limitations the exact mechanism by which this remodelling occurs has not been 
fully studied. Our observations suggest a potential novel role of RGS2 in the 
development of coronary microvascular remodelling before the onset of 
hypertension due to its differential expression in coronary VSMC. To the best of 
our knowledge, no studies have investigated RGS2 expression and regulation in 
the context of diabetes. RGS2 expression has been shown to be regulated in a 
G protein-dependent and –independent way in the context of hypertension [309, 
335]. It has been suggested that prolonged GPCR stimulation in response to 
chronic elevated catecholamines may induce down-regulation of RGS2 and thus 
contribute to the pathogenesis of CVD including hypertension and myocardial 
hypertrophy [309, 318]. Furthermore, phosphorylation of RGS2 has been shown 
to be regulated in a protein kinase G (PKG)-dependent way [309]. Mice lacking 
RGS2 have an impaired cGMP-mediated inhibition of Ca2+ transients elicited by 
vasoconstrictors [232, 316], and display decreased cGMP-mediated relaxation 
[232, 315]. Moreover, reduced eNOS-NO signalling is expected to cause a 
defect of the PKG-mediated RGS2 regulation, thus leading to an exacerbated 
Gαq signalling and contributing to the pathogenesis of CVD [309].  
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In our study it is important to mention that we cannot conclude that the 
differential expression of RGS2 promotes the observed remodelling or that the 
differential expression is a result of the remodelling. It would be very interesting 
to investigate whether the diet-resistant mice develop coronary microvascular 
remodelling and analyse the expression of RGS2 in VSMC of these mice. 
Moreover, further experiments are needed to investigate the function and 
regulation of RGS2 in VSMC of DIO mice. Since we only investigated RGS2 
expression in the coronary microvasculature it would be important to determine 
whether RGS2 is generally differentially regulated in the DIO vasculature. If this 
is the case, further analysis of the regulation of RGS2 expression and activity 
could be performed. The involvement of the above mentioned signalling 
pathways should be further assessed in the context of vascular remodelling in 
DIO mice. For this, isolation of VSMC of DIO vessels with subsequent 
measurement of intracellular Ca2+ transients using a fluo-4 AM Ca2+ 
fluorescence assay [297] or ex vivo analysis of vascular remodelling in carotid 
arteries using adenoviral overexpression [336] or siRNA knock-down studies 
could be employed. Moreover, we only focussed on the effects of a shift in diet 
on RGS2 expression in VSMC using immunohistochemistry in DIO-WL hearts. 
However, we did not look at RGS2 RNA expression and protein content in whole 
hearts of DIO-WL mice which should be investigated in future experiments 
similar to the results described in Chapter 4. 
 
The observed lower expression of RGS2 at the mRNA level could be due to 
epigenetic impairment by various factors such as dietary fatty acids, exposure of 
VSMC to hyperglycamia or angiotensin II with possible effects on chromatin 
domains, transcription factors, RNA transport, or mRNA degradation. It has 
been shown that the promoter region, introns and untranslated regions of RGS2 
contain several single nucleotide polymorphisms and insertion/deletion 
polymorphisms [311, 313], with one resulting in enhanced calcium mobilisation 
in fibroblasts in response to angiotensin II [310], and another being linked to an 
increased risk of the metabolic syndrome in white Caucasian Europeans [337]. 
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Additionally, it has been shown that the promoter region of RGS2 contains 
regulatory binding sites for transcription factors like STAT5, c-Jun, JunB, 
PPARγ1, or PPARγ2 [338, 339]. In this context, Yue et al. have shown that 
RGS2 is also a target gene of STAT3 in hearts of AT1 receptor transgenic mice 
[338]. Moreover, they have shown that regulation of RGS2 by AT1 receptor is 
critically dependent on the availability of higher levels of STAT3 and that binding 
of STAT3 to the promoter is essential for expression of RGS2. In an initial 
experiment we eliminated the possibility of pre-existing genetic differences in the 
RGS2 gene between DIO and control animals by looking at the RGS2 coding 
region in both DIO and control animals (Appendix D – RGS2 coding region). 
However, future experiments are needed to investigate the possibility of 
epigenetic changes leading to differential expression of RGS2. For example, 
methylation-specific PCR analysis and bisulphite sequencing could be used to 
further investigate whether methylation of the CpG island in the RGS2 promoter 
correlates with RGS2 expression [340]. Furthermore, the effects of high fat diet 
on the binding of transcription factors such as STAT3 to the RGS2 promoter 
should be investigated using chromatin immunoprecipitation assays [338].  
 
With regards to the effects of high fat diet feeding on myocardial insulin 
signalling, further experiments are necessary to determine whether insulin-
stimulated myocardial glucose uptake is impaired. Basal and insulin-stimulated 
glucose uptake could be measured in vitro in isolated cardiomyocytes using 
radioactively-labelled 2-deoxyglucose as described by Mazumder and co-
workers [73] but also in vivo using positron-emission tomography with 18F-
labelled fluorodeoxyglucose. Furthermore, GLUT4 translocation to the 
sarcolemma and the major proteins involved in GLUT4 trafficking and docking 
like AS160, Syntaxin4, VAMP2/3, or Munc18c should be further investigated [44, 
341-344]. For this, preparation of membranes from myocardial tissue by 
fractionation and sucrose-gradient centrifugation or isolation of cardiomyocytes 
and subsequent fluorescent imaging of proteins involved could be performed. 
Finally, only the PI3K-dependent branch of the insulin signalling pathway has 
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been investigated in this study. Further experiments are also needed to 
determine whether the MAPK-dependent branch is affected by high fat diet 
feeding.  
 
 
6.4 Concluding remarks and relevance to human 
disease 
The results described in this thesis provide the first direct evidence of coronary 
microvascular remodelling before the onset of hypertension or cardiomyopathy 
in a diet-induced mouse model of insulin resistance and T2DM. Moreover, our 
results suggest a potential role of a regulator of G protein signalling, RGS2, in 
microvascular remodelling. These findings support the use of a diet-induced 
mouse model to study the molecular and genetic mechanisms of myocardial 
insulin resistance in humans and mice. Understanding the pathophysiology and 
molecular mechanisms of coronary microvascular remodelling and how RGS2 
can turn off maladaptive signals should lead to new insights into pathogenesis 
and reveal novel therapeutic approaches to treat microvascular disease and 
improve the structure and function of the vasculature which eventually may 
improve T2DM outcomes and reduce a large burden of disease.  
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APPENDICES 
 
Appendix A – Buffers and stock solutions  
 
Krebs-Henseleit Buffer  13.8 g NaCl, 0.70 g KCl, 0.44 g CaCl 
2H2O, 0.32 g MgSO4 H2O, 4.18 g 
NaHCO3, 0.32 g KH2PO4, 4.02 g 
Glucose in 2 L H2O, filtered prior to 
use. 
 
BSA Bovine serum albumin to 10 mg/mL in 
H2O, stored at -20 °C. 
 
10% APS 1g Ammonium persulfate in 10 mL 
H2O, stored at -20 °C. 
 
10% SDS  100 g Sodium dodecyl sulphate in 1 L 
H2O. 
 
1 M Tris-HCl, pH 6.8  121.14 g Tris base in 900 mL H2O, pH 
to 6.8 with HCl, made up to 1 L with 
H2O. 
  
1 M Tris-HCl, pH 8.8 121.14 g Tris base in 900 mL H2O, pH 
to 8.8 with HCl, made up to 1 L with 
H2O. 
 
Acrylamide 30% Acrylamide/0.8% Bis-acrylamide 
in H2O (UltraPure Protogel, Fisher 
Scientific) 
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Protein Lysis Buffer 10 mL 10x Cell Lysis Buffer (Cell 
Signaling Technology) made up to 100 
mL with H2O, stored at 4 °C. 1 mM 
PMSF and 1 mM Protease inhibitor 
cocktail prior to use. 
 
Running Buffer 100 mL 10x Tris/Glycine/SDS Buffer 
(BioRad Laboratories) made up to 1 L 
with H2O. 
 
Loading Dye 4x NuPage® LDS Sample Buffer 
(Invitrogen) 
 
Transfer Buffer 100 mL 10x Tris/Glycine/SDS Buffer 
(BioRad Laboratories), 200 mL 
methanol, made up to 1 L with H2O. 
 
TBS 100 mL 10x Tris-buffered saline 
(BioRad Laboratories) made up to 1 L 
with H2O. 
 
TBST 100 mL 10x Tris-buffered Saline 
(BioRad Laboratories), 10 mL 10% 
Tween20 Solution (BioRad 
Laboratories) made up to 1 L with H2O. 
 
RIPA Buffer 50 mM Tris-HCl, 150 mM NaCl, 0.1% 
SDS, 0.5% Na Deoxycholate, 1% 
Triton® X-100 in H2O, stored at 4 °C. 1 
mM PMSF and 1 mM protease inhibitor 
cocktail prior to use. 
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Protease inhibitor cocktail 4-(2-Aminoethyl)benzenesulfonyl 
fluoride hydrochloride, Aprotinin, 
Bestatin hydrochloride, N-(trans-
Epoxysuccinyl)-L-leucine 4-
guanidinobutylamide, Leupeptin 
hemisulfate salt, Pepstatin A, stored at  
-20 °C. 
 
PMSF (200 mM stock) Phenylmethylsulfonyl fluoride to 
35mg/mL in anhydrous isopropanol 
with heating, stored at -20 °C. 
 
PBS 8 g NaCl, 0.2 g KCl, 1,44 g Na2HPO4 . 
2H2O, 0.24 g KH2PO4, made up to 1 L 
with H2O, pH 7.4 
 
PBST 10 mL 10% Tween20 Solution (BioRad 
Laboratories) made up to 1 L with PBS. 
 
Citric Buffer pH 6.0  0.35 g Citric Acid and 2.40 g Sodium 
Citrate tribase in 900 mL H2O, pH to 
6.0 with HCl, made up to 1 L with H2O, 
stored at 4 °C. 
 
dNTP mix 10 µL of 100 mM dATP, dCTP, dGTP 
and dTTP were mixed with 210 µL H2O, 
stored at -20 °C. 
  
Orange G 2.5 g Ficoll 400, 0.25 g Orange G made 
up to 10 mL in H2O. 
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Appendix B – Kidney Histology  
 
 
Figure B.1: Histological changes in kidney after 14 weeks of high fat diet 
feeding.  
Histological sections of kidneys from control animals and DIO. (A and B) 
Haematoxylin and eosin staining of control and DIO kidney sections. Nuclei are 
stained in dark blue whereas eosinophilic structures like cytoplasm or intra- and 
extracellular proteins are stained in shades of red. (C and D) Picro-sirius red 
staining of collagen (red) on a pale yellow background (kidney parenchyma). 
Images were taken at 10x magnification and are representative for n=4 in each 
group. Black scale bars indicate 100 µm. Histological analysis was carried out 
by Dr Massimiliano Mancini, La Sapienza University, Rome. 
A B
C D
CTRL DIO
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Appendix C – Microarray Quality Controls  
 
Table C.1: QC1 – Concentrations and ODs of total and reduced RNA 
 
Sample ID total RNA 
(ng/µg) 
OD  
(260/280 nm) 
rRNA reduced 
(ng/µg) 
OD  
(260/280 nm) 
Control 1 357.0 2.01 45.6 2.01 
Control 2 297.8 2.02 44.7 1.92 
Control 3 404.4 2.10 37.5 2.07 
Control 4 673.5 2.04 29.0 1.90 
Control 5 415.4 2.09 49.0 1.96 
DIO 1 343.1 2.11 33.6 1.95 
DIO 2 668.9 2.04 32.9 2.10 
DIO 3 510.5 2.10 42.7 2.05 
DIO 4 358.3 2.08 33.9 1.98 
DIO 5 495.8 2.02 28.1 2.02 
OD: optical density 
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Figure C.1: QC1 - Bioanalyser trace of total RNA 
Electropherogram of total RNA (1 µg) from control and DIO myocardium. Red 
trace indicates total RNA with peaks for the marker, 18S and 28S ribosomal 
RNA. Samples were run at the MRC Genomics Laboratory. 
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Figure C.2: QC1 - Bioanalyser trace of reduced RNA 
Electropherogram of reduced RNA from control and DIO myocardium. Red trace 
indicates reduced RNA with peaks for the marker, 18S and 28S ribosomal RNA. 
Samples were run at the MRC Genomics Laboratory. 
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Table C.2: QC2 – Concentrations, OD values and yield  
 
Sample ID cRNA (ng/µg) OD (260/280 nm) Volume (µL) Yield (µg) 
Control 1 2747.8 2.05 13 35.721 
Control 2 3266.6 2.08 14 45.732 
Control 3 3037.8 2.10 16 48.605 
Control 4 3256.8 2.08 17 55.366 
Control 5 3189.1 2.09 19 60.593 
DIO 1 3152.6 2.10 15 47.289 
DIO 2 3185.4 2.11 18 57.337 
DIO 3 2330.1 2.05 15 43.952 
DIO 4 3044.3 2.03 19 57.842 
DIO 5 1807.1 2.09 13 23.492 
OD: optical density 
 
 
 
Table C.3: QC3 – Concentrations, OD values and yield  
 
Sample ID cDNA (ng/µg) OD (260/280 nm) Volume (µL) Yield (µg) 
Control 1 284.0 2.03 26 7.384 
Control 2 288.5 2.03 24 6.924 
Control 3 297.4 2.04 25 7.435 
Control 4 305.7 2.02 27 8.254 
Control 5 311.3 2.01 22 6.849 
DIO 1 290.1 2.02 24 6.962 
DIO 2 349.6 2.02 20 6.992 
DIO 3 277.9 2.03 24 6.670 
DIO 4 289.1 2.01 25 7.228 
DIO 5 391.8 2.02 24 9.403 
OD: optical density 
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Figure C.3: QC4 – Bioanalyser trace before and after fragmentation 
Electropherogram of single-stranded cDNA before fragementation 
(unfragmented) and after fragmentation (fragmented) from control and DIO 
myocardium. Samples were run at the MRC Genomics Laboratory. 
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Appendix D – RGS2 coding region  
 
 
Figure D.1: RGS2 coding region in DIO and control mice. 
First 300 bases of RGS2 coding region of DIO and control mice. No differences 
were observed over the entire RGS2 coding region between DIO and control 
mice. Sequences were analysed using the Bioedit programme [173].  
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